<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2026"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:jspr="http://jaspertx.com/20260930"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="jspr-20260930.xsd" xlink:type="simple"/>
    <context id="cref_425078768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1858178790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2026-09-30</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_508417479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_251733876">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_670918599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-30</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_784097639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-09-30</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_695164559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_412907873">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_958635761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:KiraProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_496941438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:KiraProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1899411762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:JasperLegacyProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_179629139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:JasperLegacyProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1363313740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:JasperLegacyProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_1014094683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:JasperLegacyProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_95503200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CMOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_670150753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CMOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_250823479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CMOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_1036589198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CMOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1158453148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_831143890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1408331276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1983631772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_1022455718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1949907198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_720969816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_783867749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_1525021411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_715971754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_1915775068">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_2041185935">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_1219709907">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1363913454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">jspr:SharesIssuableUponExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_2055775269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">jspr:SharesIssuableUponExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_113149684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_800311341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_2074272259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_219886843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1322910456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_104973327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1737323973">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_348542625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_550033926">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_1286531519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_672740131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_115941406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_467222934">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_917246047">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_2133907001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_693960815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_2064740571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_417554493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfESPPSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_1893202121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfESPPSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_842698381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_525949808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1197670068">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_953568589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_30173999">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1726680811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1933079880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_448202803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_14848088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_615715924">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_633509554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1420393742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_550751598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_993582515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_345633811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_559150147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_1132710420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_1518962523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1802387595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_679251772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1700925523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_1162832620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_911663582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_1317305563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1539927539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jspr:IncomeStatementAxis">jspr:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_2086284145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jspr:IncomeStatementAxis">jspr:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_2001091885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jspr:IncomeStatementAxis">jspr:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_1353539073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jspr:IncomeStatementAxis">jspr:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1780130885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jspr:IncomeStatementAxis">jspr:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_728870186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jspr:IncomeStatementAxis">jspr:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_314860208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jspr:IncomeStatementAxis">jspr:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_181449592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceShareUnitsPSUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="jspr:IncomeStatementAxis">jspr:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_516925813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_596601295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_715354114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="cref_1562358810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="cref_264924557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1441139425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1965311085">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_703287044">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_643612063">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-31</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_864588011">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceBasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1624526096">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_742412452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockOptionActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_568691185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockOptionActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_477524601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:StockOptionActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_791341145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:StockOptionActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1482373684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:StockOptionActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_1856018927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_2064041890">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_717715067">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-31</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_190705790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_727048804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:KirasTwoThousandSeventeenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-16</startDate>
            <endDate>2026-07-16</endDate>
        </period>
    </context>
    <context id="cref_1369093598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:KirasTwoThousandSeventeenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-16</instant>
        </period>
    </context>
    <context id="cref_2143834460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:Pre-CombinationServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:KirasTwoThousandSeventeenStockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-16</startDate>
            <endDate>2026-07-16</endDate>
        </period>
    </context>
    <context id="cref_392200963">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:KirasTwoThousandSeventeenStockPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">jspr:KiraPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-16</startDate>
            <endDate>2026-07-16</endDate>
        </period>
    </context>
    <context id="cref_1533801715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">jspr:KiraPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-16</startDate>
            <endDate>2026-07-16</endDate>
        </period>
    </context>
    <context id="cref_2015256046">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2026-07-16</startDate>
            <endDate>2026-07-16</endDate>
        </period>
    </context>
    <context id="cref_282179714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:KirasTwoThousandSeventeenStockPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-16</instant>
        </period>
    </context>
    <context id="cref_603642347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoZeroTwoFourESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_570178122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoZeroTwoTwoInducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1678542402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoZeroTwoFourESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_366835540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoZeroOneNinePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_783103872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:TwoThousandTwentyFourPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_2103363847">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">jspr:UnderwrittenOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_254503131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">jspr:UnderwrittenOfferingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-18</startDate>
            <endDate>2025-09-18</endDate>
        </period>
    </context>
    <context id="cref_1004196278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1339959004">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2025-03-26</startDate>
            <endDate>2025-03-26</endDate>
        </period>
    </context>
    <context id="cref_927708732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1406249857">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:PublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_831031631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1785065301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1144305534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1525217165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnder2022InducementEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1695691226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_517669350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnderEmployeeStockPurchasePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_559681780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnderEquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1601700699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesAvailableForGrantUnderEquityIncentivePlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1045102301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1108093153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfPreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_747199849">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_460567013">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfCommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1412025843">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_2018067789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_261132654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_2019022675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1080596398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedNon-VotingRedeemableConvertiblePreferredStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1052254435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedCommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_2055620455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedCommonStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_2116292910">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedSharesOfNon-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1387491772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_610464657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_65068980">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertibleCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_137967644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1663002504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="cref_447920408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2025-12-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1033720489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:CommonWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-10-07</startDate>
            <endDate>2026-10-07</endDate>
        </period>
    </context>
    <context id="cref_1061460467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-10-07</instant>
        </period>
    </context>
    <context id="cref_125041417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-10-07</startDate>
            <endDate>2026-10-07</endDate>
        </period>
    </context>
    <context id="cref_183127202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1588263218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_885096443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1946265291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_941820053">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_546811629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:CommonWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="cref_1181131728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="cref_1018411722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:September2025OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_486113179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:TwentyTwentyFourStanfordLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_388220087">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:TwentyTwentyFourStanfordLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1899529043">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:TwentyTwentyOneStanfordLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_1037550575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:TwentyTwentyOneStanfordLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1820753273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:TwentyTwentyOneStanfordLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1715336576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:UPennLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1473213167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:MiradorLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1369165700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-07-31</endDate>
        </period>
    </context>
    <context id="cref_1220081959">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1678293840">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1024002468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:CaliforniaInstituteForRegenerativeMedicineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_618204288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="cref_313204812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_771486823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1446456635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_2015909371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_944162999">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1307131979">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1202149676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_175017037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1004583299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_2091543422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_371832694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1177742945">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1552244561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_252467714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_370614834">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_2117277377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1540488194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1855552252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1672252480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_399747609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_433218626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_706617466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_902515789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_429255704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_765934275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_531380622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_269678243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_611839070">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1523632232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_470969475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1423913122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1762904961">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_515151336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1459298868">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1113287897">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1486452983">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1259657621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">jspr:PresentValueFactorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-16</instant>
        </period>
    </context>
    <context id="cref_2052244175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">jspr:EstimatedProbabilityOfReceivingPriorityReviewVoucherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-16</instant>
        </period>
    </context>
    <context id="cref_1479479981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">jspr:EstimatedMilestoneTermInYearsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-16</instant>
        </period>
    </context>
    <context id="cref_612342829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:CVRAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-16</instant>
        </period>
    </context>
    <context id="cref_1247387906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:MiradorLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1005082927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:MiradorLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1129386989">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:MiradorLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-16</instant>
        </period>
    </context>
    <context id="cref_923253358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:MiradorLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_207786416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1635995546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1441946775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-16</instant>
        </period>
    </context>
    <context id="cref_533209010">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-16</startDate>
            <endDate>2026-07-16</endDate>
        </period>
    </context>
    <context id="cref_1148231922">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-16</instant>
        </period>
    </context>
    <context id="cref_874463771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-16</startDate>
            <endDate>2026-07-16</endDate>
        </period>
    </context>
    <context id="cref_624338329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-16</instant>
        </period>
    </context>
    <context id="cref_462183075">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-16</startDate>
            <endDate>2026-07-16</endDate>
        </period>
    </context>
    <context id="cref_1263862735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-07-16</instant>
        </period>
    </context>
    <context id="cref_1276532786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-16</startDate>
            <endDate>2026-07-16</endDate>
        </period>
    </context>
    <context id="cref_2083879426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1739629765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:PurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-16</startDate>
            <endDate>2026-07-16</endDate>
        </period>
    </context>
    <context id="cref_1780751148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:SimpleAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-16</startDate>
            <endDate>2026-07-16</endDate>
        </period>
    </context>
    <context id="cref_1787096341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:VotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-16</startDate>
            <endDate>2026-07-16</endDate>
        </period>
    </context>
    <context id="cref_512327195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-16</startDate>
            <endDate>2026-07-16</endDate>
        </period>
    </context>
    <context id="cref_1310868310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jspr:KiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:VotingCommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">jspr:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-16</startDate>
            <endDate>2026-07-16</endDate>
        </period>
    </context>
    <context id="cref_1564344885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:AU</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_2054649991">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_231442692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_927560703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-11-06</startDate>
            <endDate>2026-11-06</endDate>
        </period>
    </context>
    <context id="cref_201511992">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <instant>2026-07-16</instant>
        </period>
    </context>
    <context id="cref_299745704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_407357311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="cref_1948172915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="cref_768091885">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="cref_1158731033">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_2115684516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_149810593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_761505966">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_989769482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_2011411420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_1009714356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1997348204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1551775696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1000513054">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">jspr:OptionsForNon-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_204240691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1287141415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1785317663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_632984971">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">jspr:OptionsForNon-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_10375207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_2045309124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1269286801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_557089658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1267445350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1488673319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_161897712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_642932012">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_956536289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1345562415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1327130334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_447373007">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_847846390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1369684380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_569188311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">jspr:OptionsForNon-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_480045159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_2058778082">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1831308950">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_326139870">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1426140614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_460056060">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1703679386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_926539682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:OptionsForNon-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_878634835">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1889250434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
        </entity>
        <period>
            <instant>2026-11-10</instant>
        </period>
    </context>
    <context id="cref_1053105136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">jspr:PreFundedWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1135442090">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonvotingCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1815721878">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_452837838">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_57092141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_716601487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">jspr:OptionsForNon-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1780687701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_44617186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">jspr:OptionsForNon-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_2085834406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:PerformanceRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-01-31</endDate>
        </period>
    </context>
    <context id="cref_146200286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_310841094">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_2024905596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:BlackScholesMertonModelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_607498816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:ValuationOfESPPSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_789684937">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:KiraProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_412084137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jspr:KiraProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_1764515244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1522608553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_801368141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_451150944">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_43420443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_20060263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:NonredeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_2125509794">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockOptionActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1075624723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jspr:Non-VotingRedeemableConvertiblePreferredStockOptionActivityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-12-31</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_2058416657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jspr:SingleReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_165816062">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">jspr:SharesIssuableUponExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-07-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1889385037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">jspr:SharesIssuableUponExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-09-30</endDate>
        </period>
    </context>
    <context id="cref_1692841711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jspr:OptionsForNon-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1278649306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="cref_2117742345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedSharesOfNon-VotingRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_344846042">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedNon-VotingRedeemableConvertiblePreferredStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1051121782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_1194750343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_544678935">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_610462204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_440997632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_142531149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1287142805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_372230478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1570879240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1562155616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">jspr:WarrantLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1215539598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:OutstandingAndIssuedPerformancebasedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <context id="cref_161023939">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001788028</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jspr:SharesIssuableUponExerciseOfPublicWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-09-30</instant>
        </period>
    </context>
    <unit id="uref_1858178790">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="uref_501881879">
        <measure>shares</measure>
    </unit>
    <unit id="uref_672740131">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="uref_417554493">
        <measure>pure</measure>
    </unit>
    <unit id="uref_2058416657">
        <measure>jspr:Segment</measure>
    </unit>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_610464657"
      id="fc_1200041397"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_610464657"
      id="fc_869020569"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="cref_1053105136"
      id="fc_1053105136"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="cref_183127202"
      id="fc_1976852577"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_1135442090"
      id="fc_1135442090"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_610464657"
      id="fc_1958742004"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="cref_695164559"
      id="fc_1017018388"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="cref_695164559"
      id="fc_2117802916"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssued1
      contextRef="cref_695164559"
      id="fc_642154428"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:Non-VotingRedeemablePreferredStockIssuedInConnectionWithAcquisition
      contextRef="cref_695164559"
      id="fc_2016926362"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:WarrantLiabilityRecognizedInConnectionWithUnderwrittenOffering
      contextRef="cref_508417479"
      id="fc_1087483127"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:UnpaidOfferingCosts
      contextRef="cref_508417479"
      id="fc_471454730"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="cref_412907873"
      id="fc_899800172"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:CostOfDrugSuppliesAndCompounds
      contextRef="cref_695164559"
      id="fc_1447409526"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:AcquiredIn-ProcessResearchAndDevelopment
      contextRef="cref_412907873"
      id="fc_41975742"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_1815721878"
      id="fc_1815721878"
      unitRef="uref_672740131"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_452837838"
      id="fc_452837838"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_452837838"
      id="fc_495372498"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_1815721878"
      id="fc_1441914854"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_2058778082"
      id="fc_214336223"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_847846390"
      id="fc_1343786023"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_1287141415"
      id="fc_831664227"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_569188311"
      id="fc_1714568797"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_2058778082"
      id="fc_2124962502"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_1369684380"
      id="fc_1037721136"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_847846390"
      id="fc_101559598"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_1785317663"
      id="fc_2124224943"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_1287141415"
      id="fc_737628680"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_508417479"
      id="fc_1595665871"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="cref_2045309124"
      id="fc_1513183715"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="cref_10375207"
      id="fc_805001230"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="cref_1287141415"
      id="fc_1576385065"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="cref_149810593"
      id="fc_57092316"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="cref_2045309124"
      id="fc_1713620398"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="cref_632984971"
      id="fc_101972921"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="cref_149810593"
      id="fc_1421670482"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="cref_2115684516"
      id="fc_1152580747"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="cref_1158731033"
      id="fc_1988953284"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="cref_695164559"
      id="fc_1615709730"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="cref_847846390"
      id="fc_1614884939"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="cref_2045309124"
      id="fc_506491989"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="cref_2045309124"
      id="fc_1920061274"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="cref_632984971"
      id="fc_2128591551"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_2058778082"
      id="fc_219368426"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_1488673319"
      id="fc_1958171275"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_2045309124"
      id="fc_913598413"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_149810593"
      id="fc_1550154705"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_1158731033"
      id="fc_839302155"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_149810593"
      id="fc_1666667363"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1785317663"
      id="fc_1612363885"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_642932012"
      id="fc_1374951568"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1369684380"
      id="fc_1164291926"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_1158731033"
      id="fc_442012719"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="cref_57092141"
      id="fc_57092141"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_716601487"
      id="fc_716601487"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_1780687701"
      id="fc_1780687701"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_44617186"
      id="fc_44617186"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition
      contextRef="cref_480045159"
      id="fc_643335517"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition
      contextRef="cref_2058778082"
      id="fc_1200026791"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition
      contextRef="cref_2045309124"
      id="fc_1169530862"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition
      contextRef="cref_10375207"
      id="fc_1673292669"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:StockIssuedDuringPeriodValueATMOfferingNetOfCommissionsAndIssuanceCosts
      contextRef="cref_1158731033"
      id="fc_345137093"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:StockIssuedDuringPeriodSharesPurchaseStockInExchangeForAssumedOptionsWithTheAcquisition
      contextRef="cref_480045159"
      id="fc_809773495"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <jspr:StockIssuedDuringPeriodSharesPurchaseStockInExchangeForAssumedOptionsWithTheAcquisition
      contextRef="cref_2058778082"
      id="fc_1566858563"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <jspr:GainOnRreversalOfCIRMGrantLiability
      contextRef="cref_695164559"
      id="fc_1851196792"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="cref_695164559"
      id="fc_1994094601"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock
      contextRef="cref_695164559"
      id="fc_1512317185"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:ProceedsFromIssuanceOfCommonStockAndWarrantsThroughUnderwrittenOfferingNet
      contextRef="cref_508417479"
      id="fc_375385590"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:OptionsAssumedInTheConnectionWithTheAcquisition
      contextRef="cref_695164559"
      id="fc_1387615083"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:DistributionOfContingentValueRightDistribution
      contextRef="cref_695164559"
      id="fc_1562321474"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="cref_508417479"
      id="fc_2109349735"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="cref_695164559"
      id="fc_1957789876"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:CostOfDrugSuppliesAndCompounds
      contextRef="cref_412907873"
      id="fc_139221253"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:AcquiredIn-ProcessResearchAndDevelopment
      contextRef="cref_695164559"
      id="fc_609569724"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_452837838"
      id="fc_557499052"
      unitRef="uref_672740131"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_1815721878"
      id="fc_507207436"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_452837838"
      id="fc_1121896333"
      unitRef="uref_672740131"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_1815721878"
      id="fc_1919546101"
      unitRef="uref_672740131"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_569188311"
      id="fc_1674065863"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_632984971"
      id="fc_1889859883"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_10375207"
      id="fc_784261229"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="cref_2058778082"
      id="fc_18204298"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="cref_10375207"
      id="fc_1101633194"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_425078768"
      id="fc_2122117829"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_632984971"
      id="fc_1494950587"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_10375207"
      id="fc_1704090861"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="cref_2045309124"
      id="fc_791003068"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="cref_632984971"
      id="fc_1943577858"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="cref_1158731033"
      id="fc_1265176335"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="cref_2045309124"
      id="fc_419531849"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="cref_10375207"
      id="fc_1839544440"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="cref_1785317663"
      id="fc_714065472"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="cref_1287141415"
      id="fc_1029338716"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="cref_508417479"
      id="fc_1911155035"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="cref_480045159"
      id="fc_1636169009"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="cref_569188311"
      id="fc_1425934996"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="cref_2058778082"
      id="fc_1220352032"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="cref_10375207"
      id="fc_2103478937"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="cref_10375207"
      id="fc_1201956952"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="cref_1287141415"
      id="fc_455583569"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_847846390"
      id="fc_1588256713"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_642932012"
      id="fc_22804749"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_10375207"
      id="fc_1029126308"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_1287141415"
      id="fc_808357131"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_2115684516"
      id="fc_301196183"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_10375207"
      id="fc_86028790"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_161897712"
      id="fc_903481005"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_2058778082"
      id="fc_1027193915"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_1488673319"
      id="fc_1170881834"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:StockIssuedDuringPeriodValueATMOfferingNetOfCommissionsAndIssuanceCosts
      contextRef="cref_642932012"
      id="fc_295645327"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:StockIssuedDuringPeriodValueATMOfferingNetOfCommissionsAndIssuanceCosts
      contextRef="cref_1488673319"
      id="fc_978504833"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="cref_1780687701"
      id="fc_1831157071"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="cref_57092141"
      id="fc_398064506"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition
      contextRef="cref_847846390"
      id="fc_1118694519"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition
      contextRef="cref_1287141415"
      id="fc_2055061430"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:StockIssuedDuringPeriodValueATMOfferingNetOfCommissionsAndIssuanceCosts
      contextRef="cref_149810593"
      id="fc_520674769"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:StockIssuedDuringPeriodSharesPurchaseStockInExchangeForAssumedOptionsWithTheAcquisition
      contextRef="cref_2045309124"
      id="fc_754931986"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <jspr:StockIssuedDuringPeriodSharesPurchaseStockInExchangeForAssumedOptionsWithTheAcquisition
      contextRef="cref_10375207"
      id="fc_548504351"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <jspr:AcquiredIn-ProcessResearchAndDevelopment
      contextRef="cref_695164559"
      id="fc_486635086"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:OfferingCostsRecognizedInOtherExpenseNet
      contextRef="cref_508417479"
      id="fc_311504077"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="cref_695164559"
      id="fc_1354362639"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_508417479"
      id="fc_756467789"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="cref_508417479"
      id="fc_278197360"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:UnpaidFinancingCosts
      contextRef="cref_695164559"
      id="fc_1265349057"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="cref_703287044"
      id="fc_806152820"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="cref_703287044"
      id="fc_1727881323"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="cref_672740131"
      id="fc_810636039"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashCurrent
      contextRef="cref_1785065301"
      id="fc_26421649"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="cref_425078768"
      id="fc_1389371738"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="cref_508417479"
      id="fc_1849020020"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="cref_412907873"
      id="fc_1841360430"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="cref_695164559"
      id="fc_1394114044"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_190705790"
      id="fc_818916274"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_864588011"
      id="fc_233473549"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_703287044"
      id="fc_1387955129"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="cref_425078768"
      id="fc_2089850336"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="cref_508417479"
      id="fc_1162855172"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_2085834406"
      id="fc_2085834406"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_146200286"
      id="fc_146200286"
      unitRef="uref_417554493"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_1420393742"
      id="fc_866586732"
      unitRef="uref_417554493"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_310841094"
      id="fc_310841094"
      unitRef="uref_417554493"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_2024905596"
      id="fc_2024905596"
      unitRef="uref_417554493"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_607498816"
      id="fc_607498816"
      unitRef="uref_417554493"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="cref_412907873"
      id="fc_1899066660"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:Revenues
      contextRef="cref_695164559"
      id="fc_1275356602"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:CostOfDrugSuppliesAndCompounds
      contextRef="cref_412907873"
      id="fc_27895422"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:CostOfDrugSuppliesAndCompounds
      contextRef="cref_695164559"
      id="fc_694187185"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="cref_789684937"
      id="fc_789684937"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:CostOfRevenue
      contextRef="cref_412084137"
      id="fc_412084137"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration contextRef="cref_508417479" id="fc_1986956982">http://fasb.org/srt/2026#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_1764515244"
      id="fc_1764515244"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1522608553"
      id="fc_1522608553"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="cref_672740131"
      id="fc_1309884966"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="cref_672740131"
      id="fc_1996480958"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="cref_1785065301"
      id="fc_836782775"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="cref_672740131"
      id="fc_1414921488"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="cref_1785065301"
      id="fc_1562189913"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_801368141"
      id="fc_801368141"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_451150944"
      id="fc_451150944"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_43420443"
      id="fc_43420443"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_20060263"
      id="fc_20060263"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_20060263"
      id="fc_1229535605"
      unitRef="uref_672740131"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="cref_451150944"
      id="fc_104311661"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_2125509794"
      id="fc_2125509794"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_2125509794"
      id="fc_1700199582"
      unitRef="uref_672740131"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="cref_1075624723"
      id="fc_1075624723"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_2125509794"
      id="fc_114941406"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_525949808"
      id="fc_1144374733"
      unitRef="uref_417554493"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_842698381"
      id="fc_1870289881"
      unitRef="uref_417554493"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_451150944"
      id="fc_496555976"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_451150944"
      id="fc_210306356"
      unitRef="uref_672740131"
      xsi:nil="true"/>
    <jspr:ContingentValueRightLiabilityNoncurrent
      contextRef="cref_1785065301"
      id="fc_1398351397"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="cref_878634835"
      id="fc_222368914"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:NumberOfReportableSegments
      contextRef="cref_2058416657"
      decimals="0"
      id="fc_2058416657"
      unitRef="uref_2058416657">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="cref_508417479"
      decimals="0"
      id="fc_947699899"
      unitRef="uref_2058416657">1</us-gaap:NumberOfOperatingSegments>
    <jspr:AcquiredIn-ProcessResearchAndDevelopment
      contextRef="cref_412907873"
      id="fc_796581455"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <jspr:AcquiredIn-ProcessResearchAndDevelopment
      contextRef="cref_695164559"
      id="fc_277937578"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_165816062"
      id="fc_165816062"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="cref_1785065301"
      id="fc_1975213467"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashCurrent
      contextRef="cref_1785065301"
      id="fc_169415604"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="cref_672740131"
      id="fc_2046568827"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesIssued
      contextRef="cref_1785065301"
      id="fc_1470885562"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1889385037"
      id="fc_1889385037"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="cref_672740131"
      id="fc_1117172317"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="cref_1785065301"
      id="fc_694749955"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="cref_878634835"
      id="fc_1207433192"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="cref_1692841711"
      id="fc_1692841711"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="cref_878634835"
      id="fc_84898202"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="cref_878634835"
      id="fc_182002543"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_20060263"
      id="fc_1722163284"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1278649306"
      id="fc_1278649306"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="cref_20060263"
      id="fc_890442523"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_20060263"
      id="fc_847985134"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_20060263"
      id="fc_452590843"
      unitRef="uref_672740131"
      xsi:nil="true"/>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_451150944"
      id="fc_69411533"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_451150944"
      id="fc_2030684856"
      unitRef="uref_672740131"
      xsi:nil="true"/>
    <jspr:AccruedFinancingCosts
      contextRef="cref_1785065301"
      id="fc_773892869"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_2117742345"
      id="fc_2117742345"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_344846042"
      id="fc_344846042"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:ShortTermLeaseCost
      contextRef="cref_508417479"
      id="fc_1689173779"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:RoyaltyExpense
      contextRef="cref_508417479"
      id="fc_1717637872"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:LossContingencyAccrualAtCarryingValue
      contextRef="cref_672740131"
      id="fc_664243033"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:LossContingencyLossInPeriod
      contextRef="cref_425078768"
      id="fc_1845022880"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1051121782"
      id="fc_1051121782"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1194750343"
      id="fc_1194750343"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_544678935"
      id="fc_544678935"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1423913122"
      id="fc_1820792883"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_610462204"
      id="fc_610462204"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_440997632"
      id="fc_440997632"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_1459298868"
      id="fc_1162495712"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_544678935"
      id="fc_310659570"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_142531149"
      id="fc_142531149"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1287142805"
      id="fc_1287142805"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_372230478"
      id="fc_372230478"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_429255704"
      id="fc_780334193"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_1570879240"
      id="fc_1570879240"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_1562155616"
      id="fc_1562155616"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_269678243"
      id="fc_775168835"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_372230478"
      id="fc_706986998"
      unitRef="uref_1858178790"
      xsi:nil="true"/>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1215539598"
      id="fc_1215539598"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_161023939"
      id="fc_161023939"
      unitRef="uref_501881879"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="cref_508417479" id="ixv-11550">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="cref_508417479" id="ixv-11551">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="cref_508417479" id="ixv-11552">0001788028</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="cref_508417479" id="ixv-11553">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType contextRef="cref_508417479" id="ixv-14063">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="cref_508417479" id="ixv-14064">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="cref_508417479" id="ixv-14065">2026-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="cref_508417479" id="ixv-14066">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="cref_508417479" id="ixv-14067">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="cref_508417479" id="ixv-14068">001-39138</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="cref_508417479" id="ixv-14069">JASPER THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="cref_508417479" id="ixv-14070">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="cref_508417479" id="ixv-14071">84-2984849</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="cref_508417479" id="ixv-14072">2200 Bridge Pkwy</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="cref_508417479" id="ixv-14073">Suite #102</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="cref_508417479" id="ixv-14074">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="cref_508417479" id="ixv-14075">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="cref_508417479" id="ixv-14076">94065</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="cref_508417479" id="ixv-14077">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="cref_508417479" id="ixv-14078">549-1400</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="cref_508417479" id="ixv-14079">Voting Common Stock, par     value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="cref_508417479" id="ixv-14080">JSPR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="cref_508417479" id="ixv-14081">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="cref_508417479" id="ixv-14082">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="cref_508417479" id="ixv-14083">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="cref_508417479" id="ixv-14084">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="cref_508417479" id="ixv-14085">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="cref_508417479" id="ixv-14086">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="cref_508417479" id="ixv-14087">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="cref_1889250434"
      decimals="0"
      id="ixv-14088"
      unitRef="uref_501881879">1109133</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14089"
      unitRef="uref_1858178790">135349000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14090"
      unitRef="uref_1858178790">28692000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14091"
      unitRef="uref_1858178790">417000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14092"
      unitRef="uref_1858178790">8000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14093"
      unitRef="uref_1858178790">3508000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14094"
      unitRef="uref_1858178790">5953000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14095"
      unitRef="uref_1858178790">147274000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14096"
      unitRef="uref_1858178790">34645000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14097"
      unitRef="uref_1858178790">57000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14098"
      unitRef="uref_1858178790">102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14099"
      unitRef="uref_1858178790">67000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14100"
      unitRef="uref_1858178790">502000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14101"
      unitRef="uref_1858178790">417000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14102"
      unitRef="uref_1858178790">18000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14103"
      unitRef="uref_1858178790">113000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14104"
      unitRef="uref_1858178790">147416000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14105"
      unitRef="uref_1858178790">35779000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14106"
      unitRef="uref_1858178790">3759000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14107"
      unitRef="uref_1858178790">6220000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14108"
      unitRef="uref_1858178790">69000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14109"
      unitRef="uref_1858178790">1235000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14110"
      unitRef="uref_1858178790">10084000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14111"
      unitRef="uref_1858178790">5745000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14112"
      unitRef="uref_1858178790">13912000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14113"
      unitRef="uref_1858178790">13200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14114"
      unitRef="uref_1858178790">3784000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14115"
      unitRef="uref_1858178790">16164000</us-gaap:WarrantsAndRightsOutstanding>
    <jspr:ContingentValueRightLiabilityNoncurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14116"
      unitRef="uref_1858178790">1900000</jspr:ContingentValueRightLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14117"
      unitRef="uref_1858178790">1298000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14118"
      unitRef="uref_1858178790">2264000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14119"
      unitRef="uref_1858178790">20894000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14120"
      unitRef="uref_1858178790">31628000</us-gaap:Liabilities>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="cref_137967644"
      decimals="4"
      id="ixv-14121"
      unitRef="uref_672740131">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="cref_878634835"
      decimals="4"
      id="ixv-14122"
      unitRef="uref_672740131">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="cref_137967644"
      decimals="0"
      id="ixv-14123"
      unitRef="uref_501881879">9906591</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="cref_137967644"
      decimals="0"
      id="ixv-14124"
      unitRef="uref_501881879">9555390</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="cref_137967644"
      decimals="0"
      id="ixv-14125"
      unitRef="uref_501881879">9555390</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="cref_137967644"
      decimals="-3"
      id="ixv-14126"
      unitRef="uref_1858178790">263502000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="cref_926539682"
      decimals="-3"
      id="ixv-14127"
      unitRef="uref_1858178790">3267000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="cref_672740131"
      decimals="4"
      id="ixv-14128"
      unitRef="uref_672740131">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="cref_1785065301"
      decimals="4"
      id="ixv-14129"
      unitRef="uref_672740131">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="cref_672740131"
      decimals="0"
      id="ixv-14130"
      unitRef="uref_501881879">93409</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="cref_1785065301"
      decimals="0"
      id="ixv-14131"
      unitRef="uref_501881879">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_672740131"
      decimals="4"
      id="ixv-14132"
      unitRef="uref_672740131">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1785065301"
      decimals="4"
      id="ixv-14133"
      unitRef="uref_672740131">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_672740131"
      decimals="0"
      id="ixv-14134"
      unitRef="uref_501881879">492000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1785065301"
      decimals="0"
      id="ixv-14135"
      unitRef="uref_501881879">492000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_672740131"
      decimals="0"
      id="ixv-14136"
      unitRef="uref_501881879">1109133</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_672740131"
      decimals="0"
      id="ixv-14137"
      unitRef="uref_501881879">1109133</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1785065301"
      decimals="0"
      id="ixv-14138"
      unitRef="uref_501881879">933242</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_1785065301"
      decimals="0"
      id="ixv-14139"
      unitRef="uref_501881879">933242</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14140"
      unitRef="uref_1858178790">3000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14141"
      unitRef="uref_1858178790">3000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14142"
      unitRef="uref_1858178790">324809000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14143"
      unitRef="uref_1858178790">320818000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14144"
      unitRef="uref_1858178790">-465059000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14145"
      unitRef="uref_1858178790">-316670000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14146"
      unitRef="uref_1858178790">-140247000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14147"
      unitRef="uref_1858178790">4151000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14148"
      unitRef="uref_1858178790">147416000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14149"
      unitRef="uref_1858178790">35779000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14150"
      unitRef="uref_1858178790">8000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14151"
      unitRef="uref_1858178790">8000000</us-gaap:Revenues>
    <jspr:CostOfDrugSuppliesAndCompounds
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14152"
      unitRef="uref_1858178790">7993000</jspr:CostOfDrugSuppliesAndCompounds>
    <jspr:CostOfDrugSuppliesAndCompounds
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14153"
      unitRef="uref_1858178790">7993000</jspr:CostOfDrugSuppliesAndCompounds>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14154"
      unitRef="uref_1858178790">8327000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14155"
      unitRef="uref_1858178790">14391000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14156"
      unitRef="uref_1858178790">19276000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14157"
      unitRef="uref_1858178790">51744000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14158"
      unitRef="uref_1858178790">6359000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14159"
      unitRef="uref_1858178790">4775000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14160"
      unitRef="uref_1858178790">15569000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14161"
      unitRef="uref_1858178790">16300000</us-gaap:GeneralAndAdministrativeExpense>
    <jspr:AcquiredIn-ProcessResearchAndDevelopment
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14162"
      unitRef="uref_1858178790">129494000</jspr:AcquiredIn-ProcessResearchAndDevelopment>
    <jspr:AcquiredIn-ProcessResearchAndDevelopment
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14163"
      unitRef="uref_1858178790">129494000</jspr:AcquiredIn-ProcessResearchAndDevelopment>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14164"
      unitRef="uref_1858178790">152173000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14165"
      unitRef="uref_1858178790">19166000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14166"
      unitRef="uref_1858178790">172332000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14167"
      unitRef="uref_1858178790">68044000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14168"
      unitRef="uref_1858178790">-144173000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14169"
      unitRef="uref_1858178790">-19166000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14170"
      unitRef="uref_1858178790">-164332000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14171"
      unitRef="uref_1858178790">-68044000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14172"
      unitRef="uref_1858178790">999000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14173"
      unitRef="uref_1858178790">342000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14174"
      unitRef="uref_1858178790">1245000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14175"
      unitRef="uref_1858178790">1403000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14176"
      unitRef="uref_1858178790">1240000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14177"
      unitRef="uref_1858178790">-2099000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14178"
      unitRef="uref_1858178790">-12380000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14179"
      unitRef="uref_1858178790">-2099000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14180"
      unitRef="uref_1858178790">-41000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14181"
      unitRef="uref_1858178790">-2011000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14182"
      unitRef="uref_1858178790">2318000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14183"
      unitRef="uref_1858178790">-2158000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14184"
      unitRef="uref_1858178790">-282000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14185"
      unitRef="uref_1858178790">430000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14186"
      unitRef="uref_1858178790">15943000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14187"
      unitRef="uref_1858178790">1344000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="cref_425078768"
      decimals="-3"
      id="fc_126167226"
      unitRef="uref_1858178790">-144455000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_412907873"
      decimals="-3"
      id="fc_1008649589"
      unitRef="uref_1858178790">-18736000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_508417479"
      decimals="-3"
      id="fc_251689952"
      unitRef="uref_1858178790">-148389000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_695164559"
      decimals="-3"
      id="fc_1435099224"
      unitRef="uref_1858178790">-66700000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_425078768"
      decimals="2"
      id="ixv-14192"
      unitRef="uref_672740131">-10.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_425078768"
      decimals="2"
      id="ixv-14193"
      unitRef="uref_672740131">-10.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_412907873"
      decimals="2"
      id="ixv-14194"
      unitRef="uref_672740131">-32.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_412907873"
      decimals="2"
      id="ixv-14195"
      unitRef="uref_672740131">-32.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_508417479"
      decimals="2"
      id="ixv-14196"
      unitRef="uref_672740131">-14.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_508417479"
      decimals="2"
      id="ixv-14197"
      unitRef="uref_672740131">-14.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_695164559"
      decimals="2"
      id="ixv-14198"
      unitRef="uref_672740131">-125.3</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_695164559"
      decimals="2"
      id="ixv-14199"
      unitRef="uref_672740131">-125.3</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_425078768"
      decimals="0"
      id="ixv-14200"
      unitRef="uref_501881879">1075259</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_425078768"
      decimals="0"
      id="ixv-14201"
      unitRef="uref_501881879">1075259</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_412907873"
      decimals="0"
      id="ixv-14202"
      unitRef="uref_501881879">584056</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_412907873"
      decimals="0"
      id="ixv-14203"
      unitRef="uref_501881879">584056</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_508417479"
      decimals="0"
      id="ixv-14204"
      unitRef="uref_501881879">1040513</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_508417479"
      decimals="0"
      id="ixv-14205"
      unitRef="uref_501881879">1040513</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_695164559"
      decimals="0"
      id="ixv-14206"
      unitRef="uref_501881879">532312</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_695164559"
      decimals="0"
      id="ixv-14207"
      unitRef="uref_501881879">532312</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_1703679386"
      decimals="2"
      id="ixv-14208"
      unitRef="uref_672740131">-13.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_1703679386"
      decimals="2"
      id="ixv-14209"
      unitRef="uref_672740131">-13.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_231442692"
      decimals="2"
      id="ixv-14210"
      unitRef="uref_672740131">-13.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_231442692"
      decimals="2"
      id="ixv-14211"
      unitRef="uref_672740131">-13.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_1703679386"
      decimals="0"
      id="ixv-14212"
      unitRef="uref_501881879">9555390</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_1703679386"
      decimals="0"
      id="ixv-14213"
      unitRef="uref_501881879">9555390</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_231442692"
      decimals="0"
      id="ixv-14214"
      unitRef="uref_501881879">9555390</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_231442692"
      decimals="0"
      id="ixv-14215"
      unitRef="uref_501881879">9555390</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="cref_460056060"
      decimals="0"
      id="ixv-14216"
      unitRef="uref_501881879">935992</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_460056060"
      decimals="-3"
      id="ixv-14217"
      unitRef="uref_1858178790">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1426140614"
      decimals="-3"
      id="ixv-14218"
      unitRef="uref_1858178790">322014000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_326139870"
      decimals="-3"
      id="ixv-14219"
      unitRef="uref_1858178790">-320604000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1831308950"
      decimals="-3"
      id="ixv-14220"
      unitRef="uref_1858178790">1413000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="cref_480045159"
      decimals="0"
      id="ixv-14221"
      unitRef="uref_501881879">4899439</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_480045159"
      decimals="-3"
      id="ixv-14222"
      unitRef="uref_1858178790">138913000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="cref_2058778082"
      decimals="0"
      id="ixv-14223"
      unitRef="uref_501881879">173149</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_1369684380"
      decimals="-3"
      id="ixv-14224"
      unitRef="uref_1858178790">4021000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14225"
      unitRef="uref_1858178790">4021000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <jspr:StockIssuedDuringPeriodValueStockInConnectionWithTheFinancingNetOfIssuanceCosts
      contextRef="cref_425078768"
      decimals="-3"
      id="fc_995771739"
      unitRef="uref_1858178790">7411000</jspr:StockIssuedDuringPeriodValueStockInConnectionWithTheFinancingNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="cref_480045159"
      decimals="0"
      id="ixv-14227"
      unitRef="uref_501881879">4655951</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_480045159"
      decimals="-3"
      id="ixv-14228"
      unitRef="uref_1858178790">124589000</us-gaap:StockIssuedDuringPeriodValueOther>
    <jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition
      contextRef="cref_569188311"
      decimals="-3"
      id="fc_2105308113"
      unitRef="uref_1858178790">2640000</jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition>
    <jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition
      contextRef="cref_1369684380"
      decimals="-3"
      id="fc_546901396"
      unitRef="uref_1858178790">82000</jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition>
    <jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition
      contextRef="cref_425078768"
      decimals="-3"
      id="fc_252829212"
      unitRef="uref_1858178790">82000</jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="cref_1369684380"
      decimals="-3"
      id="ixv-14232"
      unitRef="uref_1858178790">-1900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14233"
      unitRef="uref_1858178790">-1900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_569188311"
      decimals="-3"
      id="ixv-14234"
      unitRef="uref_1858178790">627000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_1369684380"
      decimals="-3"
      id="ixv-14235"
      unitRef="uref_1858178790">592000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14236"
      unitRef="uref_1858178790">592000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="cref_847846390"
      decimals="-3"
      id="ixv-14237"
      unitRef="uref_1858178790">-144455000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14238"
      unitRef="uref_1858178790">-144455000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="cref_204240691"
      decimals="0"
      id="ixv-14239"
      unitRef="uref_501881879">9555390</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_204240691"
      decimals="-3"
      id="ixv-14240"
      unitRef="uref_1858178790">263502000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1000513054"
      decimals="-3"
      id="ixv-14241"
      unitRef="uref_1858178790">3267000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="cref_1551775696"
      decimals="0"
      id="ixv-14242"
      unitRef="uref_501881879">1109133</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_1551775696"
      decimals="-3"
      id="ixv-14243"
      unitRef="uref_1858178790">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1997348204"
      decimals="-3"
      id="ixv-14244"
      unitRef="uref_1858178790">324809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1009714356"
      decimals="-3"
      id="ixv-14245"
      unitRef="uref_1858178790">-465059000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14246"
      unitRef="uref_1858178790">-140247000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="cref_447373007"
      decimals="0"
      id="ixv-14247"
      unitRef="uref_501881879">540662</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_447373007"
      decimals="-3"
      id="ixv-14248"
      unitRef="uref_1858178790">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1327130334"
      decimals="-3"
      id="ixv-14249"
      unitRef="uref_1858178790">312332000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1345562415"
      decimals="-3"
      id="ixv-14250"
      unitRef="uref_1858178790">-288833000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_956536289"
      decimals="-3"
      id="ixv-14251"
      unitRef="uref_1858178790">23501000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="cref_412907873"
      decimals="-5"
      id="ixv-14252"
      unitRef="uref_1858178790">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_642932012"
      decimals="0"
      id="ixv-14253"
      unitRef="uref_501881879">389023</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_642932012"
      decimals="-3"
      id="ixv-14254"
      unitRef="uref_1858178790">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_161897712"
      decimals="-3"
      id="ixv-14255"
      unitRef="uref_1858178790">4867000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14256"
      unitRef="uref_1858178790">4868000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <jspr:StockIssuedDuringPeriodValueNetOfDiscountsAndCommissionsAndIssuanceCost
      contextRef="cref_412907873"
      decimals="-5"
      id="fc_673684543"
      unitRef="uref_1858178790">100000</jspr:StockIssuedDuringPeriodValueNetOfDiscountsAndCommissionsAndIssuanceCost>
    <jspr:StockIssuedDuringPeriodSharesOfATMOffering
      contextRef="cref_642932012"
      decimals="0"
      id="fc_642932012"
      unitRef="uref_501881879">3136</jspr:StockIssuedDuringPeriodSharesOfATMOffering>
    <jspr:StockIssuedDuringPeriodValueATMOfferingNetOfCommissionsAndIssuanceCosts
      contextRef="cref_161897712"
      decimals="-3"
      id="fc_32388504"
      unitRef="uref_1858178790">514000</jspr:StockIssuedDuringPeriodValueATMOfferingNetOfCommissionsAndIssuanceCosts>
    <jspr:StockIssuedDuringPeriodValueATMOfferingNetOfCommissionsAndIssuanceCosts
      contextRef="cref_412907873"
      decimals="-3"
      id="fc_1678953546"
      unitRef="uref_1858178790">514000</jspr:StockIssuedDuringPeriodValueATMOfferingNetOfCommissionsAndIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_161897712"
      decimals="-3"
      id="ixv-14261"
      unitRef="uref_1858178790">1424000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14262"
      unitRef="uref_1858178790">1424000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1488673319"
      decimals="-3"
      id="ixv-14263"
      unitRef="uref_1858178790">-18736000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14264"
      unitRef="uref_1858178790">-18736000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="cref_768091885"
      decimals="0"
      id="ixv-14265"
      unitRef="uref_501881879">932821</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_768091885"
      decimals="-3"
      id="ixv-14266"
      unitRef="uref_1858178790">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1948172915"
      decimals="-3"
      id="ixv-14267"
      unitRef="uref_1858178790">319137000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_407357311"
      decimals="-3"
      id="ixv-14268"
      unitRef="uref_1858178790">-307569000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1663002504"
      decimals="-3"
      id="ixv-14269"
      unitRef="uref_1858178790">11571000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="cref_1267445350"
      decimals="0"
      id="ixv-14270"
      unitRef="uref_501881879">933242</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_1267445350"
      decimals="-3"
      id="ixv-14271"
      unitRef="uref_1858178790">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_557089658"
      decimals="-3"
      id="ixv-14272"
      unitRef="uref_1858178790">320818000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1269286801"
      decimals="-3"
      id="ixv-14273"
      unitRef="uref_1858178790">-316670000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14274"
      unitRef="uref_1858178790">4151000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="cref_2045309124"
      decimals="0"
      id="ixv-14275"
      unitRef="uref_501881879">4899439</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_2045309124"
      decimals="-3"
      id="ixv-14276"
      unitRef="uref_1858178790">138913000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="cref_10375207"
      decimals="0"
      id="ixv-14277"
      unitRef="uref_501881879">173149</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_1785317663"
      decimals="-3"
      id="ixv-14278"
      unitRef="uref_1858178790">4021000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <us-gaap:StockIssuedDuringPeriodValueAcquisitions
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14279"
      unitRef="uref_1858178790">4021000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
    <jspr:StockIssuedDuringPeriodValueStockInConnectionWithTheFinancingNetOfIssuanceCosts
      contextRef="cref_508417479"
      decimals="-3"
      id="fc_485844937"
      unitRef="uref_1858178790">7411000</jspr:StockIssuedDuringPeriodValueStockInConnectionWithTheFinancingNetOfIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="cref_2045309124"
      decimals="0"
      id="ixv-14281"
      unitRef="uref_501881879">4655951</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="cref_2045309124"
      decimals="-3"
      id="ixv-14282"
      unitRef="uref_1858178790">124589000</us-gaap:StockIssuedDuringPeriodValueOther>
    <jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition
      contextRef="cref_632984971"
      decimals="-3"
      id="fc_626365858"
      unitRef="uref_1858178790">2640000</jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition>
    <jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition
      contextRef="cref_1785317663"
      decimals="-3"
      id="fc_1623281576"
      unitRef="uref_1858178790">82000</jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition>
    <jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition
      contextRef="cref_508417479"
      decimals="-3"
      id="fc_979926056"
      unitRef="uref_1858178790">82000</jspr:StockIssuedDuringPeriodValuePurchaseStockInExchangeForAssumedOptionsWithTheAcquisition>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="cref_10375207"
      decimals="0"
      id="ixv-14286"
      unitRef="uref_501881879">428</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="cref_1785317663"
      decimals="-3"
      id="ixv-14287"
      unitRef="uref_1858178790">9000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14288"
      unitRef="uref_1858178790">9000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="cref_10375207"
      decimals="0"
      id="ixv-14289"
      unitRef="uref_501881879">2322</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="cref_1785317663"
      decimals="-3"
      id="ixv-14290"
      unitRef="uref_1858178790">-1900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14291"
      unitRef="uref_1858178790">-1900000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_632984971"
      decimals="-3"
      id="ixv-14292"
      unitRef="uref_1858178790">627000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_1785317663"
      decimals="-3"
      id="ixv-14293"
      unitRef="uref_1858178790">1779000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14294"
      unitRef="uref_1858178790">1779000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1287141415"
      decimals="-3"
      id="ixv-14295"
      unitRef="uref_1858178790">-148389000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14296"
      unitRef="uref_1858178790">-148389000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="cref_204240691"
      decimals="0"
      id="ixv-14297"
      unitRef="uref_501881879">9555390</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_204240691"
      decimals="-3"
      id="ixv-14298"
      unitRef="uref_1858178790">263502000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1000513054"
      decimals="-3"
      id="ixv-14299"
      unitRef="uref_1858178790">3267000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="cref_1551775696"
      decimals="0"
      id="ixv-14300"
      unitRef="uref_501881879">1109133</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_1551775696"
      decimals="-3"
      id="ixv-14301"
      unitRef="uref_1858178790">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1997348204"
      decimals="-3"
      id="ixv-14302"
      unitRef="uref_1858178790">324809000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1009714356"
      decimals="-3"
      id="ixv-14303"
      unitRef="uref_1858178790">-465059000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14304"
      unitRef="uref_1858178790">-140247000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="cref_2011411420"
      decimals="0"
      id="ixv-14305"
      unitRef="uref_501881879">500791</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_2011411420"
      decimals="-3"
      id="ixv-14306"
      unitRef="uref_1858178790">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_989769482"
      decimals="-3"
      id="ixv-14307"
      unitRef="uref_1858178790">302541000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_761505966"
      decimals="-3"
      id="ixv-14308"
      unitRef="uref_1858178790">-240869000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_299745704"
      decimals="-3"
      id="ixv-14309"
      unitRef="uref_1858178790">61674000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="cref_695164559"
      decimals="-5"
      id="ixv-14310"
      unitRef="uref_1858178790">400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_149810593"
      decimals="0"
      id="ixv-14311"
      unitRef="uref_501881879">389023</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_149810593"
      decimals="-3"
      id="ixv-14312"
      unitRef="uref_1858178790">1000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_2115684516"
      decimals="-3"
      id="ixv-14313"
      unitRef="uref_1858178790">4867000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14314"
      unitRef="uref_1858178790">4868000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <jspr:StockIssuedDuringPeriodValueNetOfDiscountsAndCommissionsAndIssuanceCost
      contextRef="cref_695164559"
      decimals="-5"
      id="ixv-14315"
      unitRef="uref_1858178790">300000</jspr:StockIssuedDuringPeriodValueNetOfDiscountsAndCommissionsAndIssuanceCost>
    <jspr:StockIssuedDuringPeriodSharesOfATMOffering
      contextRef="cref_149810593"
      decimals="0"
      id="ixv-14316"
      unitRef="uref_501881879">41035</jspr:StockIssuedDuringPeriodSharesOfATMOffering>
    <jspr:StockIssuedDuringPeriodValueATMOfferingNetOfCommissionsAndIssuanceCosts
      contextRef="cref_2115684516"
      decimals="-3"
      id="ixv-14317"
      unitRef="uref_1858178790">6454000</jspr:StockIssuedDuringPeriodValueATMOfferingNetOfCommissionsAndIssuanceCosts>
    <jspr:StockIssuedDuringPeriodValueATMOfferingNetOfCommissionsAndIssuanceCosts
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14318"
      unitRef="uref_1858178790">6454000</jspr:StockIssuedDuringPeriodValueATMOfferingNetOfCommissionsAndIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="cref_149810593"
      decimals="0"
      id="ixv-14319"
      unitRef="uref_501881879">400</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="cref_149810593"
      decimals="0"
      id="ixv-14320"
      unitRef="uref_501881879">1572</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="cref_2115684516"
      decimals="-3"
      id="ixv-14321"
      unitRef="uref_1858178790">223000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14322"
      unitRef="uref_1858178790">223000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_2115684516"
      decimals="-3"
      id="ixv-14323"
      unitRef="uref_1858178790">5052000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14324"
      unitRef="uref_1858178790">5052000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1158731033"
      decimals="-3"
      id="ixv-14325"
      unitRef="uref_1858178790">-66700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14326"
      unitRef="uref_1858178790">-66700000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="cref_768091885"
      decimals="0"
      id="ixv-14327"
      unitRef="uref_501881879">932821</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="cref_768091885"
      decimals="-3"
      id="ixv-14328"
      unitRef="uref_1858178790">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1948172915"
      decimals="-3"
      id="ixv-14329"
      unitRef="uref_1858178790">319137000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_407357311"
      decimals="-3"
      id="ixv-14330"
      unitRef="uref_1858178790">-307569000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_1663002504"
      decimals="-3"
      id="ixv-14331"
      unitRef="uref_1858178790">11571000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14332"
      unitRef="uref_1858178790">-148389000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14333"
      unitRef="uref_1858178790">-66700000</us-gaap:NetIncomeLoss>
    <jspr:AcquiredIn-ProcessResearchAndDevelopment
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14334"
      unitRef="uref_1858178790">129494000</jspr:AcquiredIn-ProcessResearchAndDevelopment>
    <us-gaap:DepreciationAndAmortization
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14335"
      unitRef="uref_1858178790">59000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14336"
      unitRef="uref_1858178790">766000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherNoncashExpense
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14337"
      unitRef="uref_1858178790">458000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14338"
      unitRef="uref_1858178790">834000</us-gaap:OtherNoncashExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14339"
      unitRef="uref_1858178790">2406000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14340"
      unitRef="uref_1858178790">5052000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14341"
      unitRef="uref_1858178790">-12380000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14342"
      unitRef="uref_1858178790">-2099000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14343"
      unitRef="uref_1858178790">105000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <jspr:GainOnRreversalOfCIRMGrantLiability
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14344"
      unitRef="uref_1858178790">2264000</jspr:GainOnRreversalOfCIRMGrantLiability>
    <jspr:OfferingCostsRecognizedInOtherExpenseNet
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14345"
      unitRef="uref_1858178790">2046000</jspr:OfferingCostsRecognizedInOtherExpenseNet>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14346"
      unitRef="uref_1858178790">-4000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14347"
      unitRef="uref_1858178790">-11437000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14348"
      unitRef="uref_1858178790">-509000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14349"
      unitRef="uref_1858178790">-143000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14350"
      unitRef="uref_1858178790">-670000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14351"
      unitRef="uref_1858178790">-6217000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14352"
      unitRef="uref_1858178790">5139000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14353"
      unitRef="uref_1858178790">-4415000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14354"
      unitRef="uref_1858178790">-309000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14355"
      unitRef="uref_1858178790">-1191000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14356"
      unitRef="uref_1858178790">-1202000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14357"
      unitRef="uref_1858178790">-26964000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14358"
      unitRef="uref_1858178790">-55294000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14359"
      unitRef="uref_1858178790">-7678000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14360"
      unitRef="uref_1858178790">7000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14361"
      unitRef="uref_1858178790">105000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14362"
      unitRef="uref_1858178790">12000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14363"
      unitRef="uref_1858178790">7783000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14364"
      unitRef="uref_1858178790">5000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14365"
      unitRef="uref_1858178790">132000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14366"
      unitRef="uref_1858178790">6171000</us-gaap:PaymentsForRepurchaseOfRedeemableConvertiblePreferredStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14367"
      unitRef="uref_1858178790">6454000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <jspr:ProceedsFromIssuanceOfCommonStockAndWarrantsThroughUnderwrittenOfferingNet
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14368"
      unitRef="uref_1858178790">27874000</jspr:ProceedsFromIssuanceOfCommonStockAndWarrantsThroughUnderwrittenOfferingNet>
    <us-gaap:ProceedsFromStockPlans
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14369"
      unitRef="uref_1858178790">9000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14370"
      unitRef="uref_1858178790">223000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14371"
      unitRef="uref_1858178790">125838000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14372"
      unitRef="uref_1858178790">34551000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14373"
      unitRef="uref_1858178790">106657000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14374"
      unitRef="uref_1858178790">-20738000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14375"
      unitRef="uref_1858178790">29109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_299745704"
      decimals="-3"
      id="ixv-14376"
      unitRef="uref_1858178790">72054000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14377"
      unitRef="uref_1858178790">135766000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1663002504"
      decimals="-3"
      id="ixv-14378"
      unitRef="uref_1858178790">51316000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:StockIssued1
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14379"
      unitRef="uref_1858178790">4021000</us-gaap:StockIssued1>
    <jspr:Non-VotingRedeemablePreferredStockIssuedInConnectionWithAcquisition
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14380"
      unitRef="uref_1858178790">138913000</jspr:Non-VotingRedeemablePreferredStockIssuedInConnectionWithAcquisition>
    <jspr:OptionsAssumedInTheConnectionWithTheAcquisition
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14381"
      unitRef="uref_1858178790">2722000</jspr:OptionsAssumedInTheConnectionWithTheAcquisition>
    <jspr:DistributionOfContingentValueRightDistribution
      contextRef="cref_508417479"
      decimals="-3"
      id="fc_276820995"
      unitRef="uref_1858178790">1900000</jspr:DistributionOfContingentValueRightDistribution>
    <jspr:UnpaidFinancingCosts
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14383"
      unitRef="uref_1858178790">1240000</jspr:UnpaidFinancingCosts>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14384"
      unitRef="uref_1858178790">1092000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <jspr:WarrantLiabilityRecognizedInConnectionWithUnderwrittenOffering
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14385"
      unitRef="uref_1858178790">24692000</jspr:WarrantLiabilityRecognizedInConnectionWithUnderwrittenOffering>
    <jspr:UnpaidOfferingCosts
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14386"
      unitRef="uref_1858178790">360000</jspr:UnpaidOfferingCosts>
    <us-gaap:NatureOfOperations contextRef="cref_508417479" id="ixv-3270">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 1. ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Description of Business &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Jasper Therapeutics, Inc., together with its consolidated subsidiaries (collectively, &#x201c;Jasper&#x201d; or the &#x201c;Company&#x201d;), was incorporated in the State of Delaware in March 2018. Jasper is a clinical-stage biotechnology company advancing a pipeline of biologic agents designed to improve outcomes in patients with immunologically-driven disorders. The Company&#x2019;s headquarters are located in Redwood City, California. In September 2021, the Company completed a merger with Amplitude Healthcare Acquisition Corporation and became a public company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; On July 16, 2026, Jasper acquired Kira Pharmaceuticals (&#x201c;Kira&#x201d;), a Cayman Islands exempted company, in accordance with the terms of the Agreement and Plan of Merger (the &#x201c;Merger Agreement&#x201d;), by and among the Company, Kira Holdco Inc., a Delaware corporation and a wholly owned subsidiary of Jasper (the &#x201c;Merger Sub&#x201d;), and Kira (the &#x201c;Acquisition&#x201d;). Pursuant to the Merger Agreement, Kira merged with and into Merger Sub, with Merger Sub continuing as the surviving corporation and a wholly owned subsidiary of the Company. Kira operates in the United States, People&#x2019;s Republic of China (&#x201c;PRC&#x201d;) and Australia, through its wholly-owned subsidiaries: Kira Pharmaceuticals (Hong Kong) Limited (&#x201c;Kira Hong Kong&#x201d;), Kira Pharmaceuticals (Suzhou) Limited (&#x201c;Kira Suzhou&#x201d;), Kira Pharmaceuticals (Shanghai) Limited (&#x201c;Kira Shanghai&#x201d;); Kira Pharmaceuticals (US) LLC and Kira Pharmaceuticals (Australia) PTY LTD. Concurrently with the execution of the Merger Agreement, the Company entered into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) pursuant to which the Company issued 4,655,951 shares of non-voting redeemable convertible preferred stock for an aggregate purchase price of approximately $132.0 million (the &#x201c;Financing&#x201d;). The Financing closed on July 20, 2026. Concurrently with the closing of the Acquisition, the Company also entered into a contingent value rights agreement (the &#x201c;CVR Agreement&#x201d;), pursuant to which holders of the Company&#x2019;s common stock immediately prior to the Acquisition received one contingent value right (&#x201c;CVR&#x201d;) for each share held. The CVRs entitle the holders to receive, on a pro rata basis, up to $30.0 million upon achievement of the applicable milestone (the &#x201c;CVR liability&#x201d;). See Note 3 for additional details. &lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="cref_2015256046"
      decimals="0"
      id="ixv-14387"
      unitRef="uref_501881879">4655951</us-gaap:StockIssuedDuringPeriodSharesOther>
    <jspr:SharsePurchasePrice
      contextRef="cref_2015256046"
      decimals="-5"
      id="ixv-14388"
      unitRef="uref_1858178790">132000000</jspr:SharsePurchasePrice>
    <us-gaap:OtherReceivables
      contextRef="cref_201511992"
      decimals="-5"
      id="ixv-14389"
      unitRef="uref_1858178790">30000000</us-gaap:OtherReceivables>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="cref_508417479" id="ixv-3284">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Basis of Presentation &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The condensed consolidated financial statements and accompanying notes are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) for financial reporting.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The accompanying condensed financial statements are consolidated and include the accounts of Jasper Therapeutics, Inc. and its wholly-owned subsidiaries. The results of operations of Kira and its subsidiaries are included from July 16, 2026, the acquisition date. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Certain information and footnote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2025 included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 30, 2026. There were no changes to the Company&#x2019;s significant accounting policies as described in the Annual Report on Form 10-K, except those disclosed below. The information as of December 31, 2025, included in the condensed consolidated balance sheets was derived from the Company&#x2019;s audited consolidated financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Company&#x2019;s consolidated financial statements. The results of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026 or for any other interim period or for any other future year.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; On November 6, 2026, the Company effected a 1-for-30 reverse stock split of the Company&#x2019;s outstanding common stock (the &#x201c;Reverse Stock Split&#x201d;). The number of authorized shares and par value per share were not adjusted as a result of the Reverse Stock Split. All references to shares, common stock, restricted stock units (&#x201c;RSUs&#x201d;), options to purchase common stock, warrants to purchase common stock, the conversion ratio of non-voting redeemable convertible preferred stock, share data, per share data, and related information contained in the condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Going Concern&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 205-40, Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of the Company&#x2019;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, the Company evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about its ability to continue as a going concern. The mitigating effect of the Company&#x2019;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. In performing this analysis, the Company excluded certain elements of its operating plan that cannot be considered probable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The Company has incurred significant losses and negative cash flows from operations since its inception. During the three and nine months ended September 30, 2026, the Company incurred net losses of $144.5&#160;million and $148.4&#160;million, respectively. During the three and nine months ended September 30, 2025, the Company incurred net losses of $18.7&#160;million and $66.7&#160;million, respectively. During the nine months ended September 30, 2026 and 2025, the Company had negative cash flows from operations of $27.0 million and $55.3&#160;million, respectively. As of September 30, 2026, the Company had an accumulated deficit of $465.1&#160;million.&#160;The Company expects to continue to incur substantial losses, and its ability to achieve and sustain profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support the Company&#x2019;s cost structure. As of September 30, 2026, the Company had cash and cash equivalents of $135.3 million. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; Each share of non-voting redeemable convertible preferred stock is automatically convertible into 2.03 shares of voting common stock on the third business day following the Stockholder Approval (as defined below in Note 3). At any time following the earlier of the Stockholder Approval or 12 months after the initial issuance of the non-voting redeemable convertible preferred stock, if a holder submits a notice of conversion and the Company fails to deliver the applicable shares of voting common stock by the third trading day after the applicable share delivery date, the holder may require the Company to pay cash equal to the fair value of the undelivered shares. The Company has agreed to hold a stockholders&#x2019; meeting to submit the approval of conversion of non-voting redeemable convertible preferred stock to voting common stock to its stockholders for their consideration. In connection with this, the Company filed with the SEC a definitive proxy statement and other relevant materials. On November 13, 2026, the Company convened and then adjourned, without conducting any business, the special meeting of stockholders because a quorum was not present. The adjourned special meeting will reconvene on December 1, 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company&#x2019;s ability to satisfy these potential cash settlement obligations is not entirely within its control, as it is contingent on, among other things, the Company&#x2019;s ability to obtain the Stockholder Approval and to deliver shares of its voting common stock upon conversion within the set timeframe. If the Company is unable to obtain the Stockholder Approval in a timely manner, or is otherwise unable to timely deliver shares of voting common stock upon conversion, holders who submit conversion notices after the applicable trigger date could require the Company to make significant cash payments that could substantially reduce the Company&#x2019;s available cash resources.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;After evaluating the conditions described above in the aggregate, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The accompanying unaudited interim condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. These unaudited interim condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The preparation of condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates, assumptions and judgements that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions made in the condensed consolidated financial statements include, but are not limited to, the determination of the accrued research and development expenses, the measurement of stock-based compensation expense, the valuation of warrant liability, the valuation of consideration transferred and assets acquired and liabilities assumed in the Acquisition, valuation of CVR liability (see Note 3) and realizability of deferred tax assets. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total amount shown in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;September 30,&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;December&#160;31,&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;2026&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;2025&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;135,349&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;28,692&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Restricted cash, current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;417&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_26421649;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Restricted cash, non-current&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_810636039;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;417&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;135,766&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;29,109&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Cash and cash equivalents consist of cash held in operating accounts and investments in money market funds. Restricted cash relates to the letter of credit secured in conjunction with the operating lease (Note 9) and was included in current assets in the condensed consolidated balance sheet as of September 30, 2026. Restricted cash was non-current in the condensed consolidated balance sheet as of December 31, 2025.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The Company&#x2019;s cash and cash equivalents are maintained with financial institutions in the United&#160;States of America (&#x201c;U.S.&#x201d;), PRC and Australia. The balances held at financial institutions in U.S. may exceed federally insured limits. As of September 30, 2026, the Company had cash on deposit with financial institutions in PRC and Australia of $1.0 million and less than $0.1 million, respectively. To date, the Company has not experienced any losses on its cash and cash equivalents balances and periodically evaluates the creditworthiness of its financial institutions. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company is subject to risks common to companies in the development stage, including, but not limited to, development and regulatory approval of new product candidates, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product development plans. To achieve profitable operations, the Company must successfully develop and obtain requisite regulatory approvals for, manufacture, and market its product candidates. There can be no assurance that any such product candidate can be developed and approved or manufactured at an acceptable cost and with appropriate performance characteristics, or that such product will be successfully marketed. These factors could have a material adverse effect on the Company&#x2019;s future financial results.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Products developed by the Company require approval from the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company&#x2019;s future products will receive the necessary clearances. If the Company were denied such clearances or such clearances were delayed, it could have a materially adverse impact on the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Asset Acquisitions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in;"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an asset acquisition. If the screen test is not met, further determination is required as to whether the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. The cost to acquire is allocated to the identifiable assets acquired and liabilities assumed based on their relative fair values as of the acquisition date. Goodwill is not recognized in an asset acquisition. In an asset acquisition, the cost allocated to the acquired in-process research and development assets with no alternative future use is charged to research and development expense at the acquisition date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;CVR Liability&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The contingent value rights distributed by the Company pursuant to the terms of the CVR Agreement (see Note 3) represent a distribution to the Company&#x2019;s common stockholders that are initially recognized at their estimated fair value on the date of issuance of $1.9 million, with a corresponding CVR liability. Subsequent to initial recognition, the Company accounts for the CVR liability in accordance with ASC 450, &lt;i&gt;Contingencies&lt;/i&gt;. The liability is evaluated at each reporting date based on changes in facts and circumstances related to the underlying payment obligation. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company&#x2019;s revenue relates to the license agreement with Mirador Therapeutics, Inc. (&#x201c;Mirador&#x201d;), which the Company assumed the contractual rights and obligations in connection with the Acquisition. Consideration under the agreement includes an upfront license payment, a payment for delivery of drug supplies and compounds, potential development, regulatory and commercial milestone payments, and royalties on future net sales. See Note 7 for additional information.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company recognizes revenue when or as control of promised goods or services transfers to the customer, in an amount that reflects the consideration it expects to receive. The Company follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations and (v) recognize revenue when (or as) the customer obtains control of the product or service.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;A promised good or service is accounted for as a separate performance obligation when the customer can benefit from it on its own or together with readily available resources and the promise is separately identifiable from other promises in the arrangement. The transaction price is allocated to separate performance obligations based on their relative standalone selling prices, except when the criteria for allocating variable consideration to a specific performance obligation are met. When standalone selling prices are not directly observable, the Company estimates them using available information concerning the goods or services and relevant market conditions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Transaction price allocated to a distinct license that provides a right to use intellectual property is recognized when Mirador can use and benefit from the license. The license was transferred to Mirador before the Acquisition, and the related license revenue was recognized by Kira prior to the closing of the Acquisition (see Note 7). Transaction price allocated to drug supplies and compounds is recognized when control transfers to Mirador in accordance with the contractual delivery and acceptance provisions. Accordingly, no revenue associated with the upfront license payment was recognized by the Company following the Acquisition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Development and regulatory milestone payments are included in the transaction price only when it is probable that a significant reversal of cumulative revenue will not occur upon resolution of the related uncertainty. The Company reassesses variable consideration at each reporting date. Sales-based milestones and royalties attributable to licenses of intellectual property are recognized at the later of the occurrence of the underlying sales or satisfaction of the related performance obligation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Accounts Receivable and Contract Balances&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company records amounts as accounts receivable when the right to consideration is deemed unconditional, for which only the passage of time is required before payment is due. Accounts receivable are presented net of an allowance for expected credit losses. The allowance for credit losses is based on the Company&#x2019;s assessment of collectability. Accounts receivable deemed uncollectible are charged against the allowance for credit losses. There was no allowance for credit losses activity for the periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Contract assets represent rights to consideration that remain conditional on factors other than the passage of time. Amounts received or due before the related performance obligations are satisfied are recorded as contract liabilities. A contract liability is an obligation to transfer goods or services for which the Company has received consideration, or for which an amount of consideration is due from the customer. Contract liabilities consist of deferred revenue and relate to amounts invoiced to, or advance consideration received from the customer that precede the Company&#x2019;s satisfaction of the associated performance obligations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; As of September 30, 2026, the accounts receivable and deferred revenue balances were $8.0 million and zero, respectively. The accounts receivable related to delivered drug supplies and compounds under the Mirador license agreement. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Foreign Currency Transaction Gains and Losses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The Company&#x2019;s reporting currency and the functional currency of all of its subsidiaries is the U.S. dollar. Monetary assets and liabilities denominated in such currencies are remeasured at exchange rates in effect at the balance sheet date. Nonmonetary assets and liabilities are remeasured at historical exchange rates. Revenues and expenses are remeasured using average exchange rates prevailing during the period, unless historical rates are required. Transactions denominated in currencies other than an entity&#x2019;s functional currency are recorded at exchange rates in effect on the transaction dates. Resulting foreign currency transaction gains and losses are recognized in other income (expense), net, in the condensed consolidated statements of operations and comprehensive loss. Net foreign currency transaction loss was $0.1 million for the three and nine months ended September 30, 2026. Net foreign currency transaction loss was $0.1 million and less than $0.1 million for the three and nine months ended September 30, 2025, respectively. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Non-Voting Redeemable Convertible Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company classifies its non-voting redeemable convertible preferred stock as temporary equity, outside of stockholders&#x2019; equity, because it contains contingent redemption provisions that are not solely within the Company&#x2019;s control. As of September 30, 2026, the shares were not currently redeemable, and the Company concluded that it was not probable that they would become redeemable. Accordingly, no adjustment to their carrying amount was recognized.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Comprehensive Loss&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; Comprehensive loss represents all changes in stockholders&#x2019; equity except those resulting from distributions to stockholders. There have been &lt;span style="-sec-ix-hidden:fc_1389371738;"&gt;&lt;span style="-sec-ix-hidden:fc_1394114044;"&gt;&lt;span style="-sec-ix-hidden:fc_1841360430;"&gt;&lt;span style="-sec-ix-hidden:fc_1849020020;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; items qualifying as other comprehensive income (loss) during the three and nine months ended September 30, 2026 and 2025. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Net Loss per Share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company calculates basic and diluted net loss per share using the two-class method for multiple classes of common stock and participating securities. Under the two-class method, earnings and losses are allocated based on dividends declared or accumulated and participation rights in undistributed earnings and losses. Prior to the Acquisition, the Company&#x2019;s net loss was attributed to common stock only, as there were no other classes of stock outstanding. In connection with the Acquisition, the Company issued non-voting redeemable convertible preferred stock that is considered to be a separate class of common stock for purposes of calculating net loss per share, as it does not have substantive preferential rights over the common stock. After the Acquisition, the Company allocates net loss to two classes: common stock and non-voting redeemable convertible preferred stock, as both classes participate in net loss allocation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company considers the Common Warrants (see Note 8) to be participating securities because their holders are entitled to receive dividends on a pari passu basis with common stockholders. The Common Warrants do not have a contractual obligation to share in the Company&#x2019;s losses, therefore, undistributed losses are not allocated to those securities. The Pre-Funded Warrants (see Note 8) are included in the computation of basic net loss per common share together with shares of common stock because their exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Basic net loss per share for each class is calculated by dividing the net loss allocated to that class by the weighted-average number of shares of that class outstanding during the period. Diluted net loss per share reflects the effect of potentially dilutive securities and any related adjustments to the numerator, unless their effect would be antidilutive. Potentially dilutive securities include restricted stock units, Public Warrants (see Note 8), Common Warrants and stock options. For the three and nine months ended September 30, 2026 and 2025, the diluted net loss per share for each class was the same as basic net loss per share, as the impact of potentially dilutive securities was antidilutive to the net loss per share. The performance restricted stock units are contingently issuable shares and are not included in the diluted net loss per share calculation until contingencies are resolved.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;Recent Accounting Pronouncements Adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;In September 2025, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2025-07, &lt;i&gt;Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract&lt;/i&gt; (&#x201c;ASU 2025-07&#x201d;), which applies to all entities that enter into non-exchange-traded contracts with underlyings based on operations or activities specific to one of the parties to the contract. The guidance in ASU 2025-07 expands the scope exceptions within Topic 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;, to include certain nonexchange-traded contracts with underlyings that are based on operations or activities specific to one of the parties to the contract, including research and development funding arrangements. The Company early-adopted ASU 2025-07 effective January 1, 2026, using the prospective method. The adoption of ASU 2025-07 was applied to the evaluation of the contingent value rights issued in July 2026, which qualify for the derivative scope exception following the adoption of this new accounting standard.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;i&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;, to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. In January 2025, the FASB issued ASU No. 2025-01, &lt;i&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date&lt;/i&gt; (&#x201c;ASU 2025-01&#x201d;). The amendments do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. The amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;In December 2025, the FASB issued ASU No. 2025-10, &lt;i&gt;Accounting for Government Grants Received by Business Entities (Topic 832)&lt;/i&gt;. This ASU provides recognition, measurement, presentation, and disclosure requirements for government grants, including guidance for grants related to an asset and grants related to income. ASU No. 2025-10 is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;In December 2025, the FASB issued ASU No. 2025-11, &lt;i&gt;Interim Reporting: Narrow-Scope Improvements (Topic 270)&lt;/i&gt;. This ASU improves clarity for interim financial reporting requirements under the existing guidance within ASC Topic 270, by creating a comprehensive list of interim disclosure requirements, clarifying scope and applicability, along with adding a principle to disclose all material events that have occurred since the most recently filed Annual Report on Form 10-K. ASU No. 2025-11 is effective for interim reporting for fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="cref_508417479" id="ixv-3290">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Basis of Presentation &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The condensed consolidated financial statements and accompanying notes are unaudited and have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the U.S. Securities and Exchange Commission (the &#x201c;SEC&#x201d;) for financial reporting.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The accompanying condensed financial statements are consolidated and include the accounts of Jasper Therapeutics, Inc. and its wholly-owned subsidiaries. The results of operations of Kira and its subsidiaries are included from July 16, 2026, the acquisition date. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Certain information and footnote disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the related notes thereto for the year ended December 31, 2025 included in the Company&#x2019;s Annual Report on Form 10-K filed with the SEC on March 30, 2026. There were no changes to the Company&#x2019;s significant accounting policies as described in the Annual Report on Form 10-K, except those disclosed below. The information as of December 31, 2025, included in the condensed consolidated balance sheets was derived from the Company&#x2019;s audited consolidated financial statements. These unaudited interim condensed consolidated financial statements have been prepared on the same basis as the Company&#x2019;s annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments necessary for a fair statement of the Company&#x2019;s consolidated financial statements. The results of operations for the three and nine months ended September 30, 2026 are not necessarily indicative of the results that may be expected for the year ending December 31, 2026 or for any other interim period or for any other future year.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <jspr:ReverseStockSplitPolicyTextBlock contextRef="cref_508417479" id="ixv-3309">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Reverse Stock Split&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; On November 6, 2026, the Company effected a 1-for-30 reverse stock split of the Company&#x2019;s outstanding common stock (the &#x201c;Reverse Stock Split&#x201d;). The number of authorized shares and par value per share were not adjusted as a result of the Reverse Stock Split. All references to shares, common stock, restricted stock units (&#x201c;RSUs&#x201d;), options to purchase common stock, warrants to purchase common stock, the conversion ratio of non-voting redeemable convertible preferred stock, share data, per share data, and related information contained in the condensed consolidated financial statements have been retrospectively adjusted to reflect the effect of the Reverse Stock Split for all periods presented. &lt;/p&gt;</jspr:ReverseStockSplitPolicyTextBlock>
    <us-gaap:StockholdersEquityReverseStockSplit contextRef="cref_927560703" id="ixv-14390">1-for-30</us-gaap:StockholdersEquityReverseStockSplit>
    <jspr:GoingConcernPolicyTextBlock contextRef="cref_508417479" id="ixv-3316">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Going Concern&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 205-40, Going Concern, the Company evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about its ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of the Company&#x2019;s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, the Company evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about its ability to continue as a going concern. The mitigating effect of the Company&#x2019;s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern within one year after the date that the condensed consolidated financial statements are issued. In performing this analysis, the Company excluded certain elements of its operating plan that cannot be considered probable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The Company has incurred significant losses and negative cash flows from operations since its inception. During the three and nine months ended September 30, 2026, the Company incurred net losses of $144.5&#160;million and $148.4&#160;million, respectively. During the three and nine months ended September 30, 2025, the Company incurred net losses of $18.7&#160;million and $66.7&#160;million, respectively. During the nine months ended September 30, 2026 and 2025, the Company had negative cash flows from operations of $27.0 million and $55.3&#160;million, respectively. As of September 30, 2026, the Company had an accumulated deficit of $465.1&#160;million.&#160;The Company expects to continue to incur substantial losses, and its ability to achieve and sustain profitability will depend on the successful development, approval and commercialization of product candidates and on the achievement of sufficient revenues to support the Company&#x2019;s cost structure. As of September 30, 2026, the Company had cash and cash equivalents of $135.3 million. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; Each share of non-voting redeemable convertible preferred stock is automatically convertible into 2.03 shares of voting common stock on the third business day following the Stockholder Approval (as defined below in Note 3). At any time following the earlier of the Stockholder Approval or 12 months after the initial issuance of the non-voting redeemable convertible preferred stock, if a holder submits a notice of conversion and the Company fails to deliver the applicable shares of voting common stock by the third trading day after the applicable share delivery date, the holder may require the Company to pay cash equal to the fair value of the undelivered shares. The Company has agreed to hold a stockholders&#x2019; meeting to submit the approval of conversion of non-voting redeemable convertible preferred stock to voting common stock to its stockholders for their consideration. In connection with this, the Company filed with the SEC a definitive proxy statement and other relevant materials. On November 13, 2026, the Company convened and then adjourned, without conducting any business, the special meeting of stockholders because a quorum was not present. The adjourned special meeting will reconvene on December 1, 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company&#x2019;s ability to satisfy these potential cash settlement obligations is not entirely within its control, as it is contingent on, among other things, the Company&#x2019;s ability to obtain the Stockholder Approval and to deliver shares of its voting common stock upon conversion within the set timeframe. If the Company is unable to obtain the Stockholder Approval in a timely manner, or is otherwise unable to timely deliver shares of voting common stock upon conversion, holders who submit conversion notices after the applicable trigger date could require the Company to make significant cash payments that could substantially reduce the Company&#x2019;s available cash resources.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;After evaluating the conditions described above in the aggregate, the Company has concluded that there is substantial doubt about its ability to continue as a going concern.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The accompanying unaudited interim condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. These unaudited interim condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.&lt;/p&gt;</jspr:GoingConcernPolicyTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="cref_425078768"
      decimals="-5"
      id="ixv-14391"
      unitRef="uref_1858178790">-144500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_508417479"
      decimals="-5"
      id="ixv-14392"
      unitRef="uref_1858178790">-148400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_412907873"
      decimals="-5"
      id="ixv-14393"
      unitRef="uref_1858178790">-18700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_695164559"
      decimals="-5"
      id="ixv-14394"
      unitRef="uref_1858178790">-66700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_508417479"
      decimals="-5"
      id="ixv-14395"
      unitRef="uref_1858178790">-27000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_695164559"
      decimals="-5"
      id="ixv-14396"
      unitRef="uref_1858178790">-55300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_672740131"
      decimals="-5"
      id="ixv-14397"
      unitRef="uref_1858178790">-465100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_672740131"
      decimals="-5"
      id="ixv-14398"
      unitRef="uref_1858178790">135300000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PreferredStockVotingRights contextRef="cref_231442692" id="ixv-14399">Each share of non-voting redeemable convertible preferred stock is automatically convertible into 2.03 shares of voting common stock on the third business day following the Stockholder Approval (as defined below in Note 3).</us-gaap:PreferredStockVotingRights>
    <us-gaap:UseOfEstimates contextRef="cref_508417479" id="ixv-3343">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The preparation of condensed consolidated financial statements in conformity with U.S.&#160;GAAP requires management to make estimates, assumptions and judgements that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as of the date of the condensed consolidated financial statements and the reported amounts of income and expenses during the reporting periods. Significant estimates and assumptions made in the condensed consolidated financial statements include, but are not limited to, the determination of the accrued research and development expenses, the measurement of stock-based compensation expense, the valuation of warrant liability, the valuation of consideration transferred and assets acquired and liabilities assumed in the Acquisition, valuation of CVR liability (see Note 3) and realizability of deferred tax assets. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="cref_508417479" id="ixv-3350">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Cash, Cash Equivalents, and Restricted Cash&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total amount shown in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;September 30,&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;December&#160;31,&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;2026&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;2025&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;135,349&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;28,692&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Restricted cash, current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;417&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_26421649;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Restricted cash, non-current&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_810636039;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;417&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;135,766&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;29,109&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Cash and cash equivalents consist of cash held in operating accounts and investments in money market funds. Restricted cash relates to the letter of credit secured in conjunction with the operating lease (Note 9) and was included in current assets in the condensed consolidated balance sheet as of September 30, 2026. Restricted cash was non-current in the condensed consolidated balance sheet as of December 31, 2025.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="cref_508417479" id="ixv-3355">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table provides a reconciliation of cash and cash equivalents and restricted cash reported within the condensed consolidated balance sheets that sum to the total amount shown in the condensed consolidated statements of cash flows (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;September 30,&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;December&#160;31,&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;2026&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;2025&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;135,349&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;28,692&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Restricted cash, current&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;417&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_26421649;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Restricted cash, non-current&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_810636039;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;417&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Total cash, cash equivalents and restricted cash&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;135,766&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;29,109&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14400"
      unitRef="uref_1858178790">135349000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14401"
      unitRef="uref_1858178790">28692000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="fc_1825961167"
      unitRef="uref_1858178790">417000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="fc_1112164444"
      unitRef="uref_1858178790">417000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14404"
      unitRef="uref_1858178790">135766000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14405"
      unitRef="uref_1858178790">29109000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="cref_508417479" id="ixv-3421">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Concentrations of Credit Risk and Other Risks and Uncertainties&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The Company&#x2019;s cash and cash equivalents are maintained with financial institutions in the United&#160;States of America (&#x201c;U.S.&#x201d;), PRC and Australia. The balances held at financial institutions in U.S. may exceed federally insured limits. As of September 30, 2026, the Company had cash on deposit with financial institutions in PRC and Australia of $1.0 million and less than $0.1 million, respectively. To date, the Company has not experienced any losses on its cash and cash equivalents balances and periodically evaluates the creditworthiness of its financial institutions. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company is subject to risks common to companies in the development stage, including, but not limited to, development and regulatory approval of new product candidates, development of markets and distribution channels, dependence on key personnel, and the ability to obtain additional capital as needed to fund its product development plans. To achieve profitable operations, the Company must successfully develop and obtain requisite regulatory approvals for, manufacture, and market its product candidates. There can be no assurance that any such product candidate can be developed and approved or manufactured at an acceptable cost and with appropriate performance characteristics, or that such product will be successfully marketed. These factors could have a material adverse effect on the Company&#x2019;s future financial results.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Products developed by the Company require approval from the U.S.&#160;Food and Drug Administration (the &#x201c;FDA&#x201d;) or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company&#x2019;s future products will receive the necessary clearances. If the Company were denied such clearances or such clearances were delayed, it could have a materially adverse impact on the Company.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashReserveDepositRequiredAndMade
      contextRef="cref_2054649991"
      decimals="-5"
      id="ixv-14406"
      unitRef="uref_1858178790">1000000</us-gaap:CashReserveDepositRequiredAndMade>
    <us-gaap:CashReserveDepositRequiredAndMade
      contextRef="cref_1564344885"
      decimals="-5"
      id="ixv-14407"
      unitRef="uref_1858178790">100000</us-gaap:CashReserveDepositRequiredAndMade>
    <jspr:AssetAcquisitionsPolicyTextBlock contextRef="cref_508417479" id="fc_2058023895">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Asset Acquisitions&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in;"&gt;The Company evaluates acquisitions of assets and other similar transactions to assess whether the transaction should be accounted for as a business combination or asset acquisition by first applying a screen test to determine if substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset or group of similar identifiable assets. If the screen test is met, the transaction is accounted for as an asset acquisition. If the screen test is not met, further determination is required as to whether the Company has acquired inputs and processes that have the ability to create outputs which would meet the definition of a business. Significant judgment is required in the application of the screen test to determine whether an acquisition is a business combination or an acquisition of assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company measures and recognizes asset acquisitions that are not deemed to be business combinations based on the cost to acquire the assets, which includes transaction costs. The cost to acquire is allocated to the identifiable assets acquired and liabilities assumed based on their relative fair values as of the acquisition date. Goodwill is not recognized in an asset acquisition. In an asset acquisition, the cost allocated to the acquired in-process research and development assets with no alternative future use is charged to research and development expense at the acquisition date.&lt;/p&gt;</jspr:AssetAcquisitionsPolicyTextBlock>
    <jspr:ContingentValueRightLiabilityPolicyTextBlock contextRef="cref_508417479" id="fc_475811553">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;CVR Liability&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The contingent value rights distributed by the Company pursuant to the terms of the CVR Agreement (see Note 3) represent a distribution to the Company&#x2019;s common stockholders that are initially recognized at their estimated fair value on the date of issuance of $1.9 million, with a corresponding CVR liability. Subsequent to initial recognition, the Company accounts for the CVR liability in accordance with ASC 450, &lt;i&gt;Contingencies&lt;/i&gt;. The liability is evaluated at each reporting date based on changes in facts and circumstances related to the underlying payment obligation. &lt;/p&gt;</jspr:ContingentValueRightLiabilityPolicyTextBlock>
    <jspr:ContingentValueRightLiabilityNoncurrent
      contextRef="cref_672740131"
      decimals="-5"
      id="ixv-14408"
      unitRef="uref_1858178790">1900000</jspr:ContingentValueRightLiabilityNoncurrent>
    <us-gaap:RevenueRecognitionRevenueReductions contextRef="cref_508417479" id="ixv-3457">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company&#x2019;s revenue relates to the license agreement with Mirador Therapeutics, Inc. (&#x201c;Mirador&#x201d;), which the Company assumed the contractual rights and obligations in connection with the Acquisition. Consideration under the agreement includes an upfront license payment, a payment for delivery of drug supplies and compounds, potential development, regulatory and commercial milestone payments, and royalties on future net sales. See Note 7 for additional information.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company recognizes revenue when or as control of promised goods or services transfers to the customer, in an amount that reflects the consideration it expects to receive. The Company follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations and (v) recognize revenue when (or as) the customer obtains control of the product or service.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;A promised good or service is accounted for as a separate performance obligation when the customer can benefit from it on its own or together with readily available resources and the promise is separately identifiable from other promises in the arrangement. The transaction price is allocated to separate performance obligations based on their relative standalone selling prices, except when the criteria for allocating variable consideration to a specific performance obligation are met. When standalone selling prices are not directly observable, the Company estimates them using available information concerning the goods or services and relevant market conditions.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Transaction price allocated to a distinct license that provides a right to use intellectual property is recognized when Mirador can use and benefit from the license. The license was transferred to Mirador before the Acquisition, and the related license revenue was recognized by Kira prior to the closing of the Acquisition (see Note 7). Transaction price allocated to drug supplies and compounds is recognized when control transfers to Mirador in accordance with the contractual delivery and acceptance provisions. Accordingly, no revenue associated with the upfront license payment was recognized by the Company following the Acquisition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Development and regulatory milestone payments are included in the transaction price only when it is probable that a significant reversal of cumulative revenue will not occur upon resolution of the related uncertainty. The Company reassesses variable consideration at each reporting date. Sales-based milestones and royalties attributable to licenses of intellectual property are recognized at the later of the occurrence of the underlying sales or satisfaction of the related performance obligation.&lt;/p&gt;</us-gaap:RevenueRecognitionRevenueReductions>
    <us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="cref_508417479" id="ixv-3482">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Accounts Receivable and Contract Balances&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company records amounts as accounts receivable when the right to consideration is deemed unconditional, for which only the passage of time is required before payment is due. Accounts receivable are presented net of an allowance for expected credit losses. The allowance for credit losses is based on the Company&#x2019;s assessment of collectability. Accounts receivable deemed uncollectible are charged against the allowance for credit losses. There was no allowance for credit losses activity for the periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Contract assets represent rights to consideration that remain conditional on factors other than the passage of time. Amounts received or due before the related performance obligations are satisfied are recorded as contract liabilities. A contract liability is an obligation to transfer goods or services for which the Company has received consideration, or for which an amount of consideration is due from the customer. Contract liabilities consist of deferred revenue and relate to amounts invoiced to, or advance consideration received from the customer that precede the Company&#x2019;s satisfaction of the associated performance obligations.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; As of September 30, 2026, the accounts receivable and deferred revenue balances were $8.0 million and zero, respectively. The accounts receivable related to delivered drug supplies and compounds under the Mirador license agreement. &lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
    <us-gaap:AccountsNotesAndLoansReceivableNetCurrent
      contextRef="cref_672740131"
      decimals="-5"
      id="ixv-14409"
      unitRef="uref_1858178790">8000000</us-gaap:AccountsNotesAndLoansReceivableNetCurrent>
    <us-gaap:DeferredRevenue
      contextRef="cref_672740131"
      decimals="-6"
      id="ixv-14410"
      unitRef="uref_1858178790">0</us-gaap:DeferredRevenue>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="cref_508417479" id="ixv-3495">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Foreign Currency Transaction Gains and Losses&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The Company&#x2019;s reporting currency and the functional currency of all of its subsidiaries is the U.S. dollar. Monetary assets and liabilities denominated in such currencies are remeasured at exchange rates in effect at the balance sheet date. Nonmonetary assets and liabilities are remeasured at historical exchange rates. Revenues and expenses are remeasured using average exchange rates prevailing during the period, unless historical rates are required. Transactions denominated in currencies other than an entity&#x2019;s functional currency are recorded at exchange rates in effect on the transaction dates. Resulting foreign currency transaction gains and losses are recognized in other income (expense), net, in the condensed consolidated statements of operations and comprehensive loss. Net foreign currency transaction loss was $0.1 million for the three and nine months ended September 30, 2026. Net foreign currency transaction loss was $0.1 million and less than $0.1 million for the three and nine months ended September 30, 2025, respectively. &lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossAfterTax
      contextRef="cref_425078768"
      decimals="-5"
      id="ixv-14411"
      unitRef="uref_1858178790">100000</us-gaap:ForeignCurrencyTransactionGainLossAfterTax>
    <us-gaap:ForeignCurrencyTransactionGainLossAfterTax
      contextRef="cref_508417479"
      decimals="-5"
      id="ixv-14412"
      unitRef="uref_1858178790">100000</us-gaap:ForeignCurrencyTransactionGainLossAfterTax>
    <us-gaap:ForeignCurrencyTransactionGainLossAfterTax
      contextRef="cref_412907873"
      decimals="-5"
      id="ixv-14413"
      unitRef="uref_1858178790">100000</us-gaap:ForeignCurrencyTransactionGainLossAfterTax>
    <us-gaap:ForeignCurrencyTransactionGainLossAfterTax
      contextRef="cref_695164559"
      decimals="-5"
      id="ixv-14414"
      unitRef="uref_1858178790">100000</us-gaap:ForeignCurrencyTransactionGainLossAfterTax>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy contextRef="cref_508417479" id="ixv-3506">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Non-Voting Redeemable Convertible Preferred Stock&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company classifies its non-voting redeemable convertible preferred stock as temporary equity, outside of stockholders&#x2019; equity, because it contains contingent redemption provisions that are not solely within the Company&#x2019;s control. As of September 30, 2026, the shares were not currently redeemable, and the Company concluded that it was not probable that they would become redeemable. Accordingly, no adjustment to their carrying amount was recognized.&lt;/p&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <jspr:ComprehensiveLossPolicyTextBlock contextRef="cref_508417479" id="ixv-3515">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Comprehensive Loss&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; Comprehensive loss represents all changes in stockholders&#x2019; equity except those resulting from distributions to stockholders. There have been &lt;span style="-sec-ix-hidden:fc_1389371738;"&gt;&lt;span style="-sec-ix-hidden:fc_1394114044;"&gt;&lt;span style="-sec-ix-hidden:fc_1841360430;"&gt;&lt;span style="-sec-ix-hidden:fc_1849020020;"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; items qualifying as other comprehensive income (loss) during the three and nine months ended September 30, 2026 and 2025. &lt;/p&gt;</jspr:ComprehensiveLossPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="cref_508417479" id="ixv-3528">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Net Loss per Share&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company calculates basic and diluted net loss per share using the two-class method for multiple classes of common stock and participating securities. Under the two-class method, earnings and losses are allocated based on dividends declared or accumulated and participation rights in undistributed earnings and losses. Prior to the Acquisition, the Company&#x2019;s net loss was attributed to common stock only, as there were no other classes of stock outstanding. In connection with the Acquisition, the Company issued non-voting redeemable convertible preferred stock that is considered to be a separate class of common stock for purposes of calculating net loss per share, as it does not have substantive preferential rights over the common stock. After the Acquisition, the Company allocates net loss to two classes: common stock and non-voting redeemable convertible preferred stock, as both classes participate in net loss allocation.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company considers the Common Warrants (see Note 8) to be participating securities because their holders are entitled to receive dividends on a pari passu basis with common stockholders. The Common Warrants do not have a contractual obligation to share in the Company&#x2019;s losses, therefore, undistributed losses are not allocated to those securities. The Pre-Funded Warrants (see Note 8) are included in the computation of basic net loss per common share together with shares of common stock because their exercise price is negligible and they are fully vested and exercisable at any time after the original issuance date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Basic net loss per share for each class is calculated by dividing the net loss allocated to that class by the weighted-average number of shares of that class outstanding during the period. Diluted net loss per share reflects the effect of potentially dilutive securities and any related adjustments to the numerator, unless their effect would be antidilutive. Potentially dilutive securities include restricted stock units, Public Warrants (see Note 8), Common Warrants and stock options. For the three and nine months ended September 30, 2026 and 2025, the diluted net loss per share for each class was the same as basic net loss per share, as the impact of potentially dilutive securities was antidilutive to the net loss per share. The performance restricted stock units are contingently issuable shares and are not included in the diluted net loss per share calculation until contingencies are resolved.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="cref_508417479" id="ixv-3547">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Recent Accounting Pronouncements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;Recent Accounting Pronouncements Adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;In September 2025, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU No. 2025-07, &lt;i&gt;Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract&lt;/i&gt; (&#x201c;ASU 2025-07&#x201d;), which applies to all entities that enter into non-exchange-traded contracts with underlyings based on operations or activities specific to one of the parties to the contract. The guidance in ASU 2025-07 expands the scope exceptions within Topic 815, &lt;i&gt;Derivatives and Hedging&lt;/i&gt;, to include certain nonexchange-traded contracts with underlyings that are based on operations or activities specific to one of the parties to the contract, including research and development funding arrangements. The Company early-adopted ASU 2025-07 effective January 1, 2026, using the prospective method. The adoption of ASU 2025-07 was applied to the evaluation of the contingent value rights issued in July 2026, which qualify for the derivative scope exception following the adoption of this new accounting standard.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;i&gt;Accounting Pronouncements Not Yet Adopted&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;In November 2024, the FASB issued ASU No. 2024-03, &lt;i&gt;Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses&lt;/i&gt;, to improve financial reporting by requiring that public business entities disclose additional information about specific expense categories in the notes to financial statements at interim and annual reporting periods. In January 2025, the FASB issued ASU No. 2025-01, &lt;i&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date&lt;/i&gt; (&#x201c;ASU 2025-01&#x201d;). The amendments do not change or remove current expense disclosure requirements; however, the amendments affect where such information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. The amendments are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;In December 2025, the FASB issued ASU No. 2025-10, &lt;i&gt;Accounting for Government Grants Received by Business Entities (Topic 832)&lt;/i&gt;. This ASU provides recognition, measurement, presentation, and disclosure requirements for government grants, including guidance for grants related to an asset and grants related to income. ASU No. 2025-10 is effective for fiscal years beginning after December 15, 2028, including interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;In December 2025, the FASB issued ASU No. 2025-11, &lt;i&gt;Interim Reporting: Narrow-Scope Improvements (Topic 270)&lt;/i&gt;. This ASU improves clarity for interim financial reporting requirements under the existing guidance within ASC Topic 270, by creating a comprehensive list of interim disclosure requirements, clarifying scope and applicability, along with adding a principle to disclose all material events that have occurred since the most recently filed Annual Report on Form 10-K. ASU No. 2025-11 is effective for interim reporting for fiscal years beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of adopting this ASU to its consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="cref_508417479" id="ixv-3582">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 3. ACQUISITION, FINANCING AND CONTINGENT VALUE RIGHTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;On July 16, 2026, the Company acquired Kira pursuant to the Merger Agreement. The Acquisition is intended to qualify as a tax-free reorganization for U.S. federal income tax purposes. The consummation of the Acquisition did not require the approval of the stockholders.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; Under the terms of the Merger Agreement, in exchange for all of the outstanding shares of Kira, the Company issued to former Kira shareholders an aggregate of (i) 173,149 shares of its voting common stock, and (ii) 4,644,977 shares of non-voting redeemable convertible preferred stock, each convertible into 2.03 shares of the Company&#x2019;s voting common stock upon the Stockholder Approval (as defined below). Outstanding Kira options were assumed and converted into options to purchase an aggregate of 12,953 shares of the Company&#x2019;s voting common stock and 347,808 shares of non-voting redeemable convertible preferred stock. In addition, a total of 254,462 shares of non-voting redeemable convertible preferred stock were issued in settlement of the simple agreements for future equity held by certain Kira investors as of the date of the Acquisition. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; Concurrently with the execution of the Merger Agreement, the Company entered into the Purchase Agreement with investors to issue 4,655,951 shares of non-voting redeemable convertible preferred stock for gross cash proceeds of approximately $132.0 million. This Financing closed on July 20, 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Pursuant to the Merger Agreement and the Purchase Agreement, the Company agreed to hold a stockholders&#x2019; meeting within 120 days following the closing of the Acquisition to seek approval of, among other matters, the conversion of the non-voting redeemable convertible preferred stock into the Company&#x2019;s voting common stock and an amendment to the Company&#x2019;s certificate of incorporation to increase authorized common stock sufficient to permit that conversion (the &#x201c;Stockholder Approval&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company concluded that it is an accounting acquirer in the Acquisition. This determination was primarily based on the facts that, immediately following the Acquisition: (1) Jasper&#x2019;s stockholders own a substantial majority of the voting rights of the Company; and (2) Jasper&#x2019;s board of directors held a majority of votes and Jasper&#x2019;s employees hold a majority of key positions in senior management of the Company. The Acquisition is accounted for as an asset acquisition under ASC 805, &lt;i&gt;Business Combinations&lt;/i&gt;. The Company performed an initial screen test and concluded the screen test was not met as gross assets acquired included, in addition to in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) programs, the rights to receive an upfront fee and a payment for materials deliverable to Mirador pursuant to the Mirador License Agreement, which constitute separately identifiable financial assets not similar to the IPR&amp;amp;D programs. Because the screen test was not met, a full assessment was performed under ASC 805. The Company concluded that the acquired set did not include the substantive processes or assembled workforce capable of producing outputs. Accordingly, the Merger is accounted for as an asset acquisition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table represents the total purchase consideration (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 88%; text-align: left;"&gt;Common stock (1)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4,021&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Non-voting redeemable convertible preferred stock (2)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;138,913&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Assumed options (3)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,722&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Transaction costs (4)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,376&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total purchase consideration&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;147,032&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0%;"&gt;&lt;/td&gt; &lt;td style="width: 0.5in;"&gt;(1)&lt;/td&gt; &lt;td&gt;The fair value of common stock was determined based on the last reported                                             sale price of the Company&#x2019;s common stock of $23.22 on the Nasdaq Capital Market on                                             July 16, 2026, the date of the Acquisition, times 173,149 shares issued to Kira&#x2019;s                                             investors.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.5in;"&gt;(2)&lt;/td&gt; &lt;td&gt;The fair value of the non-voting redeemable convertible preferred stock was determined based on the price per share of $28.3528 times 4,899,439 shares issued to Kira investors. The price per share is the same as the price paid by non-related party investors that participated in the Financing and it is an equivalent of $13.9440 per share of common stock based on a conversion ratio of 2.03 shares of common stock for each share of non-voting redeemable convertible preferred stock.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.5in;"&gt;(3)&lt;/td&gt; &lt;td&gt;Assumed options amount reflects the portion of the acquisition date fair-value                                             based measure of assumed options, that relates to the pre-Acquisition service period.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.5in;"&gt;(4)&lt;/td&gt; &lt;td&gt;Legal and advisory transaction costs of $1.4 million incurred by the Company                                             in connection with the Acquisition.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table represents the allocation of the purchase consideration to the acquired assets and assumed liabilities (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 88%; text-align: left;"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;9,054&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Prepaid expenses and other current assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;998&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Drug supplies and compounds&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,993&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Accounts receivable&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;12,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Property and equipment, net&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;13&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Operating lease right-of-use assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;23&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Other non-current assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;48&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;In process research and development&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;129,494&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Accounts payable&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(3,756&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Operating lease liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(25&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Accrued expenses and other current liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(7,516&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Other non-current liabilities&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(1,294&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Total net assets acquired&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;147,032&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; IPR&amp;amp;D assets relate to the acquired product candidates: KP104 (vensobafusp alfa) in clinical trials and preclinical KP701, as well as KP301 (Kira&#x2019;s anti-C5a monoclonal antibody) and KP402 (Kira&#x2019;s anti-C5aR small molecule compound) licensed to Mirador under the respective license agreement (see Note 7). The amount allocated to the acquired IPR&amp;amp;D includes approximately $8.7 million attributable to Kira&#x2019;s rights to receive potential milestone payments and royalties under the Mirador License Agreement related to KP301. The fair value of in-process research and development assets was estimated using a market approach based on comparable transactions involving similar assets, adjusted for differences in relevant characteristics. The Company concluded that the acquired IPR&amp;amp;D assets do not have an alternative future use and recognized the full amount of $129.5 million within operating expenses in the condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; Drug supplies and compounds of $8.0 million relate to a separate performance obligation under the Mirador license agreement (see Note 7) and were recorded at estimated fair value as assets held for sale. During the three and nine months ended September 30, 2026, the Company transferred control of the drug substance and compounds to Mirador and recognized revenue of $8.0 million and related costs of drug supplies and compounds of $8.0 million. Accounts receivable of $12.0 million relate to the intellectual property rights and licenses delivered to Mirador prior to the Acquisition date, which the Company collected in July 2026. In accordance with the license agreement with UPenn, (see Note 7), the Company paid a $1.5 million change of control fee during the three months ended September 30, 2026, as the Acquisition qualified as a change of control transaction. Accrued expenses and other current liabilities include a 15% sublicense fee on certain amounts received under the Mirador License agreement, which is immaterial. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; Concurrently with the closing of the Acquisition, the Company entered into the CVR Agreement with the Rights Agent, pursuant to which each holder of the Company&#x2019;s common stock of record immediately prior to the effective time of the Acquisition is entitled to one contractual contingent value right issued by the Company, subject to and in accordance with the terms and conditions of the CVR Agreement, for each share of the Company&#x2019;s common stock held by such holder. Each CVR entitles the holder to receive a pro rata portion of $30.0 million payment (the &#x201c;Milestone Payment&#x201d;) if the FDA issues a Priority Review Voucher, as defined in the CVR Agreement, in connection with briquilimab (the &#x201c;Milestone&#x201d;) on or prior to December 31, 2028 (the &#x201c;Expiration Date&#x201d;). If the Milestone is achieved on or prior to the Expiration Date and the Company undergoes a change of control, as defined in the CVR Agreement, the Company is obligated to pay the Milestone Payment on the earlier of (i) the date of the consummation of such change of control and (ii) 90 days following the monetization event. The monetization event (the &#x201c;Monetization Event&#x201d;) is the first occurrence of (i) the use of the Priority Review Voucher by the Company, the surviving corporation or an affiliate in connection with an FDA drug application, (ii) the sale, assignment, transfer or other disposition of the voucher to a third party or (iii) any other transaction through which the Company, the surviving corporation or an affiliate realizes economic value from the voucher. If the Milestone is achieved on or prior to the Expiration Date but a Monetization Event has not yet occurred on or prior to the Expiration Date, the CVRs will continue in full force and effect and do not expire until the Milestone Payment has been paid in full, with the Milestone Payment to be paid on the date that is 90 days following the Monetization Event. The CVRs are not transferable, except in certain limited circumstances as provided in the CVR Agreement, are not certificated or evidenced by any instrument, and are not registered with the SEC or listed for trading on any exchange. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The CVRs distributed pursuant to the terms of the CVR Agreement represent a declared dividend to certain Company&#x2019;s stockholders and a liability under ASC 450, &lt;i&gt;Contingencies&lt;/i&gt;. The Company recognized an initial fair value of CVR of $1.9 million as a liability and a reduction in additional paid-in capital. The Company used a probability weighted discounted cash flow method to determine the fair value of the CVR liability using Level 3 inputs. The significant unobservable inputs used in the fair value measurement of the CVR liability included the probability of receiving the Priority Review Voucher. Other key inputs include the estimated milestone term and the present value factor applied to the expected payment. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The key inputs into valuation models used to estimate the fair value of the CVR liability as of July 16, 2026, the issuance date:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;July 16,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 88%; text-align: left;"&gt;Estimated milestone term in years&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;2.70&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Estimated probability of receiving Priority Review Voucher&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7.5&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Present value factor&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.844&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; As of September 30, 2026, the carrying value of the CVR liability was $1.9 million. &lt;/p&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="cref_1310868310"
      decimals="0"
      id="ixv-14415"
      unitRef="uref_501881879">173149</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="cref_512327195"
      decimals="0"
      id="ixv-14416"
      unitRef="uref_501881879">4644977</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="cref_512327195"
      decimals="2"
      id="ixv-14417"
      unitRef="uref_501881879">2.03</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="cref_1787096341"
      decimals="0"
      id="ixv-14418"
      unitRef="uref_501881879">12953</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="cref_874463771"
      decimals="0"
      id="ixv-14419"
      unitRef="uref_501881879">347808</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="cref_1780751148"
      decimals="0"
      id="ixv-14420"
      unitRef="uref_501881879">254462</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="cref_1739629765"
      decimals="0"
      id="ixv-14421"
      unitRef="uref_501881879">4655951</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:ProceedsFromPreviousAcquisition
      contextRef="cref_2083879426"
      decimals="-5"
      id="ixv-14422"
      unitRef="uref_1858178790">132000000</us-gaap:ProceedsFromPreviousAcquisition>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock contextRef="cref_508417479" id="ixv-3597">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table represents the total purchase consideration (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 88%; text-align: left;"&gt;Common stock (1)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4,021&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Non-voting redeemable convertible preferred stock (2)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;138,913&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Assumed options (3)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,722&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Transaction costs (4)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,376&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total purchase consideration&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;147,032&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0%;"&gt;&lt;/td&gt; &lt;td style="width: 0.5in;"&gt;(1)&lt;/td&gt; &lt;td&gt;The fair value of common stock was determined based on the last reported                                             sale price of the Company&#x2019;s common stock of $23.22 on the Nasdaq Capital Market on                                             July 16, 2026, the date of the Acquisition, times 173,149 shares issued to Kira&#x2019;s                                             investors.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.5in;"&gt;(2)&lt;/td&gt; &lt;td&gt;The fair value of the non-voting redeemable convertible preferred stock was determined based on the price per share of $28.3528 times 4,899,439 shares issued to Kira investors. The price per share is the same as the price paid by non-related party investors that participated in the Financing and it is an equivalent of $13.9440 per share of common stock based on a conversion ratio of 2.03 shares of common stock for each share of non-voting redeemable convertible preferred stock.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.5in;"&gt;(3)&lt;/td&gt; &lt;td&gt;Assumed options amount reflects the portion of the acquisition date fair-value                                             based measure of assumed options, that relates to the pre-Acquisition service period.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt;" width="100%"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0;"&gt;&lt;/td&gt; &lt;td style="width: 0.5in;"&gt;(4)&lt;/td&gt; &lt;td&gt;Legal and advisory transaction costs of $1.4 million incurred by the Company                                             in connection with the Acquisition.&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="cref_1276532786"
      decimals="-3"
      id="fc_1276532786"
      unitRef="uref_1858178790">4021000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="cref_874463771"
      decimals="-3"
      id="fc_660020899"
      unitRef="uref_1858178790">138913000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <jspr:BusinessCombinationConsiderationTransferredAssumedOptions
      contextRef="cref_462183075"
      decimals="-3"
      id="fc_18519547"
      unitRef="uref_1858178790">2722000</jspr:BusinessCombinationConsiderationTransferredAssumedOptions>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="cref_462183075"
      decimals="-3"
      id="fc_2078260519"
      unitRef="uref_1858178790">1376000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="cref_462183075"
      decimals="-3"
      id="ixv-14427"
      unitRef="uref_1858178790">147032000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1263862735"
      decimals="2"
      id="ixv-14429"
      unitRef="uref_672740131">23.22</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="cref_462183075"
      decimals="0"
      id="ixv-14430"
      unitRef="uref_501881879">173149</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:PreferredStockLiquidationPreference
      contextRef="cref_624338329"
      decimals="4"
      id="ixv-14432"
      unitRef="uref_672740131">28.3528</us-gaap:PreferredStockLiquidationPreference>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="cref_874463771"
      decimals="0"
      id="ixv-14433"
      unitRef="uref_501881879">4899439</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_1148231922"
      decimals="4"
      id="ixv-14434"
      unitRef="uref_672740131">13.944</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="cref_533209010"
      decimals="2"
      id="ixv-14435"
      unitRef="uref_501881879">2.03</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts
      contextRef="cref_1441946775"
      decimals="-5"
      id="ixv-14438"
      unitRef="uref_1858178790">1400000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCosts>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="cref_508417479" id="ixv-3669">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table represents the allocation of the purchase consideration to the acquired assets and assumed liabilities (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 88%; text-align: left;"&gt;Cash and cash equivalents&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;9,054&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Prepaid expenses and other current assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;998&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Drug supplies and compounds&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,993&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Accounts receivable&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;12,000&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Property and equipment, net&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;13&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Operating lease right-of-use assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;23&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Other non-current assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;48&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;In process research and development&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;129,494&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Accounts payable&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(3,756&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Operating lease liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(25&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Accrued expenses and other current liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(7,516&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Other non-current liabilities&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(1,294&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Total net assets acquired&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;147,032&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="cref_1441946775"
      decimals="-3"
      id="ixv-14439"
      unitRef="uref_1858178790">9054000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="cref_1441946775"
      decimals="-3"
      id="ixv-14440"
      unitRef="uref_1858178790">998000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <jspr:BusinessCombinationRecognizedAssetAcquiredDrugSuppliesAndCompounds
      contextRef="cref_1441946775"
      decimals="-3"
      id="ixv-14441"
      unitRef="uref_1858178790">7993000</jspr:BusinessCombinationRecognizedAssetAcquiredDrugSuppliesAndCompounds>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="cref_1441946775"
      decimals="-3"
      id="ixv-14442"
      unitRef="uref_1858178790">12000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="cref_1441946775"
      decimals="-3"
      id="ixv-14443"
      unitRef="uref_1858178790">13000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <jspr:BusinessCombinationRecognizedAssetAcquiredOperatingLeaseRight-of-useAsset
      contextRef="cref_1441946775"
      decimals="-3"
      id="ixv-14444"
      unitRef="uref_1858178790">23000</jspr:BusinessCombinationRecognizedAssetAcquiredOperatingLeaseRight-of-useAsset>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="cref_1441946775"
      decimals="-3"
      id="ixv-14445"
      unitRef="uref_1858178790">48000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <jspr:BusinessCombinationRecognizedAssetAcquiredInProcessResearchAndDevelopment
      contextRef="cref_1441946775"
      decimals="-3"
      id="ixv-14446"
      unitRef="uref_1858178790">129494000</jspr:BusinessCombinationRecognizedAssetAcquiredInProcessResearchAndDevelopment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="cref_1441946775"
      decimals="-3"
      id="ixv-14447"
      unitRef="uref_1858178790">3756000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <jspr:BusinessCombinationRecognizedLiabilityAssumedOperatingLeaseLiabilitiesCurrent
      contextRef="cref_1441946775"
      decimals="-3"
      id="ixv-14448"
      unitRef="uref_1858178790">25000</jspr:BusinessCombinationRecognizedLiabilityAssumedOperatingLeaseLiabilitiesCurrent>
    <jspr:BusinessCombinationRecognizedLiabilityAssumedAccruedLiabilitiesAndOtherLiabilitiesCurrent
      contextRef="cref_1441946775"
      decimals="-3"
      id="ixv-14449"
      unitRef="uref_1858178790">7516000</jspr:BusinessCombinationRecognizedLiabilityAssumedAccruedLiabilitiesAndOtherLiabilitiesCurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="cref_1441946775"
      decimals="-3"
      id="ixv-14450"
      unitRef="uref_1858178790">1294000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
      contextRef="cref_1441946775"
      decimals="-3"
      id="ixv-14451"
      unitRef="uref_1858178790">147032000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <jspr:MilestonePaymentsAndRoyaltiesReceiveRightsAmount
      contextRef="cref_508417479"
      decimals="-5"
      id="ixv-14452"
      unitRef="uref_1858178790">8700000</jspr:MilestonePaymentsAndRoyaltiesReceiveRightsAmount>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="cref_1635995546"
      decimals="-5"
      id="ixv-14453"
      unitRef="uref_1858178790">129500000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="cref_207786416"
      decimals="-5"
      id="ixv-14454"
      unitRef="uref_1858178790">129500000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <jspr:BusinessCombinationRecognizedAssetAcquiredDrugSuppliesAndCompounds
      contextRef="cref_1129386989"
      decimals="-5"
      id="ixv-14455"
      unitRef="uref_1858178790">8000000</jspr:BusinessCombinationRecognizedAssetAcquiredDrugSuppliesAndCompounds>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized
      contextRef="cref_1005082927"
      decimals="-5"
      id="ixv-14456"
      unitRef="uref_1858178790">8000000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized
      contextRef="cref_923253358"
      decimals="-5"
      id="ixv-14457"
      unitRef="uref_1858178790">8000000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsRevenuesAndGainsRecognized>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed
      contextRef="cref_1005082927"
      decimals="-5"
      id="ixv-14458"
      unitRef="uref_1858178790">8000000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed
      contextRef="cref_923253358"
      decimals="-5"
      id="ixv-14459"
      unitRef="uref_1858178790">8000000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables
      contextRef="cref_1129386989"
      decimals="-5"
      id="ixv-14460"
      unitRef="uref_1858178790">12000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <jspr:MilestonePayment
      contextRef="cref_1005082927"
      decimals="-5"
      id="ixv-14461"
      unitRef="uref_1858178790">1500000</jspr:MilestonePayment>
    <jspr:PercentageOfSublicenseFee
      contextRef="cref_1247387906"
      decimals="2"
      id="ixv-14462"
      unitRef="uref_417554493">0.15</jspr:PercentageOfSublicenseFee>
    <jspr:MilestonePayment
      contextRef="cref_2015256046"
      decimals="-5"
      id="ixv-14463"
      unitRef="uref_1858178790">30000000</jspr:MilestonePayment>
    <jspr:BusinessCombinationRecognizedLiabilityAssumedAdditionalPaidInCapital
      contextRef="cref_612342829"
      decimals="-5"
      id="ixv-14464"
      unitRef="uref_1858178790">1900000</jspr:BusinessCombinationRecognizedLiabilityAssumedAdditionalPaidInCapital>
    <jspr:CVRLiabilityTableTextBlock contextRef="cref_508417479" id="ixv-3770">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The key inputs into valuation models used to estimate the fair value of the CVR liability as of July 16, 2026, the issuance date:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;July 16,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 88%; text-align: left;"&gt;Estimated milestone term in years&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;2.70&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Estimated probability of receiving Priority Review Voucher&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7.5&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Present value factor&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.844&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</jspr:CVRLiabilityTableTextBlock>
    <jspr:ContingentValuationRightMeasurementInput
      contextRef="cref_1479479981"
      decimals="2"
      id="ixv-14465"
      unitRef="uref_417554493">2.7</jspr:ContingentValuationRightMeasurementInput>
    <jspr:ContingentValuationRightMeasurementInput
      contextRef="cref_2052244175"
      decimals="1"
      id="ixv-14466"
      unitRef="uref_417554493">7.5</jspr:ContingentValuationRightMeasurementInput>
    <jspr:ContingentValuationRightMeasurementInput
      contextRef="cref_1259657621"
      decimals="3"
      id="ixv-14467"
      unitRef="uref_417554493">0.844</jspr:ContingentValuationRightMeasurementInput>
    <jspr:ContingentValueRightLiabilityNoncurrent
      contextRef="cref_672740131"
      decimals="-5"
      id="ixv-14468"
      unitRef="uref_1858178790">1900000</jspr:ContingentValueRightLiabilityNoncurrent>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="cref_508417479" id="ixv-3806">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 4. FAIR VALUE MEASUREMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Level 1 &#x2013; Inputs are unadjusted, quoted prices     in active markets for identical assets or liabilities at the measurement date;&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Level 2 &#x2013; Inputs are observable, unadjusted quoted     prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities     in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially     the full term of the related assets or liabilities; and&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#x25cf;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Level 3 &#x2013; Unobservable inputs that are significant     to the measurement of the fair value of the assets or liabilities that are supported by little or no market data.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The fair value of Level 1 securities is determined using quoted prices in active markets for identical assets. Level 1 securities consist of highly liquid money market funds. In addition, restricted cash collateralized by money market funds is a financial asset measured at fair value and is a Level 1 financial instrument under the fair value hierarchy.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Financial assets and liabilities are considered Level 2 when their fair values are determined using inputs that are observable in the market or can be derived principally from or corroborated by observable market data, such as pricing for similar securities, recently executed transactions, cash flow models with yield curves, and benchmark securities. In addition, Level 2 financial instruments are valued using comparisons to like-kind financial instruments and models that use readily observable market data as their basis. The Company had no financial instruments classified at Level 2 as of September 30, 2026 and December 31, 2025.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Financial assets and liabilities are considered Level 3 when their fair values are determined using pricing models, discounted cash flow methodologies, or similar techniques and at least one significant model assumption or input is unobservable. As of September 30, 2026 and December 31, 2025, the Company&#x2019;s Level 3 liabilities consisted of the warrant liability.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;There were no transfers within the hierarchy during the three and nine months ended September 30, 2026 and 2025.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following tables set forth the fair value of the Company&#x2019;s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy (in thousands):&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 1&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 2&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 3&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Financial assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt; text-indent: 9pt;"&gt;Money market funds&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;131,544&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1051121782;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1194750343;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;131,544&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 4pt;"&gt;Total fair value of assets&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;131,544&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_544678935;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1820792883;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;131,544&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Financial liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left; text-indent: 9pt;"&gt;Warrant liability&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_610462204;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_440997632;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,784&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,784&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Total fair value of financial liabilities&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1162495712;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_310659570;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3,784&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3,784&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;December 31, 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 1&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 2&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 3&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Financial assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt; text-indent: 9pt;"&gt;Money market funds&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;27,692&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_142531149;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1287142805;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;27,692&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Total fair value of assets&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;27,692&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_372230478;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_780334193;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;27,692&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Financial liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 9pt;"&gt;Warrant liability&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1570879240;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1562155616;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;16,164&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;16,164&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total fair value of financial liabilities&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_775168835;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_706986998;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;16,164&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;16,164&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s&#160;warrant liability (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Warrant&lt;br/&gt; Liability&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 88%; font-weight: bold;"&gt;Fair Value as of December 31, 2025&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;16,164&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-left: 9pt;"&gt;Change in the fair value&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(9,640&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold;"&gt;Fair Value as of March 31, 2026&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,524&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-left: 9pt;"&gt;Change in the fair value&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(3,980&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold;"&gt;Fair Value as of June 30, 2026&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,544&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Change in the fair value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,240&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; padding-bottom: 4pt;"&gt;Fair Value as of September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3,784&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company uses the Black-Scholes pricing model to determine the fair value of its warrant liability using Level 3 inputs. Inputs used to determine estimated fair value of the warrant liability include the fair value of the underlying stock at the valuation date, the term of the warrants, and the expected volatility of the underlying stock. The significant unobservable input used in the fair value measurement of the warrant liability is the expected volatility of the warrants. The estimates of fair value are uncertain and&#160;changes in&#160;any of the estimated inputs used as of the date of this report could have resulted in significant adjustments to the fair value.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The key inputs into valuation models used to estimate the fair value of the warrant liability as of September 30, 2026 and December 31, 2025 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;September 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;December 31,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%;"&gt;Common stock price&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;17.4&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;54.9&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Expected term (in years)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.47&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;4.22&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;121.72&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;113.30&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5.02&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.66&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="cref_508417479" id="ixv-3851">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following tables set forth the fair value of the Company&#x2019;s financial assets and liabilities measured on a recurring basis by level within the fair value hierarchy (in thousands):&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 1&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 2&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 3&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Financial assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt; text-indent: 9pt;"&gt;Money market funds&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;131,544&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1051121782;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1194750343;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;131,544&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 4pt;"&gt;Total fair value of assets&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;131,544&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_544678935;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1820792883;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;131,544&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Financial liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left; text-indent: 9pt;"&gt;Warrant liability&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_610462204;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_440997632;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,784&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;3,784&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Total fair value of financial liabilities&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1162495712;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_310659570;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3,784&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3,784&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;December 31, 2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 1&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 2&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Level 3&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Financial assets&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt; text-indent: 9pt;"&gt;Money market funds&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;27,692&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_142531149;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1287142805;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;27,692&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Total fair value of assets&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;27,692&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_372230478;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_780334193;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;27,692&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Financial liabilities&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; text-indent: 9pt;"&gt;Warrant liability&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1570879240;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1562155616;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;16,164&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;16,164&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total fair value of financial liabilities&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_775168835;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_706986998;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;16,164&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;16,164&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1486452983"
      decimals="-3"
      id="ixv-14469"
      unitRef="uref_1858178790">131544000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1113287897"
      decimals="-3"
      id="ixv-14470"
      unitRef="uref_1858178790">131544000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1459298868"
      decimals="-3"
      id="ixv-14471"
      unitRef="uref_1858178790">131544000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_470969475"
      decimals="-3"
      id="ixv-14472"
      unitRef="uref_1858178790">131544000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_515151336"
      decimals="-3"
      id="ixv-14473"
      unitRef="uref_1858178790">3784000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_1762904961"
      decimals="-3"
      id="ixv-14474"
      unitRef="uref_1858178790">3784000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_1423913122"
      decimals="-3"
      id="ixv-14475"
      unitRef="uref_1858178790">3784000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_470969475"
      decimals="-3"
      id="ixv-14476"
      unitRef="uref_1858178790">3784000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_1523632232"
      decimals="-3"
      id="ixv-14477"
      unitRef="uref_1858178790">27692000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_611839070"
      decimals="-3"
      id="ixv-14478"
      unitRef="uref_1858178790">27692000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_269678243"
      decimals="-3"
      id="ixv-14479"
      unitRef="uref_1858178790">27692000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="cref_902515789"
      decimals="-3"
      id="ixv-14480"
      unitRef="uref_1858178790">27692000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_531380622"
      decimals="-3"
      id="ixv-14481"
      unitRef="uref_1858178790">16164000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_765934275"
      decimals="-3"
      id="ixv-14482"
      unitRef="uref_1858178790">16164000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_429255704"
      decimals="-3"
      id="ixv-14483"
      unitRef="uref_1858178790">16164000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_902515789"
      decimals="-3"
      id="ixv-14484"
      unitRef="uref_1858178790">16164000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="cref_508417479" id="ixv-4166">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s&#160;warrant liability (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Warrant&lt;br/&gt; Liability&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 88%; font-weight: bold;"&gt;Fair Value as of December 31, 2025&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;16,164&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-left: 9pt;"&gt;Change in the fair value&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(9,640&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold;"&gt;Fair Value as of March 31, 2026&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,524&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-left: 9pt;"&gt;Change in the fair value&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(3,980&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold;"&gt;Fair Value as of June 30, 2026&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,544&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Change in the fair value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,240&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; padding-bottom: 4pt;"&gt;Fair Value as of September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3,784&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_706617466"
      decimals="-3"
      id="ixv-14485"
      unitRef="uref_1858178790">16164000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="cref_433218626"
      decimals="-3"
      id="ixv-14486"
      unitRef="uref_1858178790">-9640000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_399747609"
      decimals="-3"
      id="ixv-14487"
      unitRef="uref_1858178790">6524000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="cref_1672252480"
      decimals="-3"
      id="ixv-14488"
      unitRef="uref_1858178790">-3980000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_1855552252"
      decimals="-3"
      id="fc_1855552252"
      unitRef="uref_1858178790">2544000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueOptionChangesInFairValueGainLoss1
      contextRef="cref_1540488194"
      decimals="-3"
      id="ixv-14490"
      unitRef="uref_1858178790">1240000</us-gaap:FairValueOptionChangesInFairValueGainLoss1>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="cref_2117277377"
      decimals="-3"
      id="ixv-14491"
      unitRef="uref_1858178790">3784000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="cref_508417479" id="ixv-4222">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The key inputs into valuation models used to estimate the fair value of the warrant liability as of September 30, 2026 and December 31, 2025 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;September 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;December 31,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%;"&gt;Common stock price&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;17.4&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;54.9&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Expected term (in years)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.47&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;4.22&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;121.72&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;113.30&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5.02&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3.66&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_370614834"
      decimals="1"
      id="ixv-14492"
      unitRef="uref_417554493">17.4</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_252467714"
      decimals="1"
      id="ixv-14493"
      unitRef="uref_417554493">54.9</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1552244561"
      decimals="2"
      id="ixv-14494"
      unitRef="uref_417554493">3.47</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1177742945"
      decimals="2"
      id="ixv-14495"
      unitRef="uref_417554493">4.22</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_371832694"
      decimals="2"
      id="ixv-14496"
      unitRef="uref_417554493">121.72</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_2091543422"
      decimals="2"
      id="ixv-14497"
      unitRef="uref_417554493">113.3</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_1004583299"
      decimals="2"
      id="ixv-14498"
      unitRef="uref_417554493">5.02</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="cref_175017037"
      decimals="2"
      id="ixv-14499"
      unitRef="uref_417554493">3.66</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <srt:CondensedFinancialStatementsTextBlock contextRef="cref_508417479" id="ixv-4291">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 5. CONDENSED CONSOLIDATED BALANCE SHEET COMPONENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Prepaid expenses and other current assets&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table summarizes the details of prepaid expenses and other current assets as of the dates set forth below (in thousands):&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;September 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Research and development prepaid expenses&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;2,400&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4,320&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Prepaid insurance&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;325&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;866&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Prepaid travel expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;147&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;103&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Other prepaid expenses and current assets&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;636&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;664&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3,508&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;5,953&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Property and equipment, net&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table summarizes the details of property and equipment, net as of the dates set forth below (in thousands):&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;September 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Leasehold improvements&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;2,799&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;2,711&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Lab equipment&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1764515244;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,513&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Office furniture &amp;amp; fixtures&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;570&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;522&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Computer equipment&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;238&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;170&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-left: 9pt;"&gt;Property and equipment, gross&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,607&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;4,916&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Less: accumulated depreciation and amortization&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(3,550&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(4,814&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Property and equipment, net&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;57&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;102&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; Depreciation and amortization expense was $16,000 and $0.2 million for the three months ended September 30, 2026 and 2025, respectively, and $0.1 million and $0.8 million for the nine months ended September 30, 2026 and 2025, respectively. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Accrued expenses and other current liabilities&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table summarizes the details of accrued expenses and other current liabilities as of the dates set forth below (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;September 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Research and development accrued expenses&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4,932&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;3,775&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Accrued employee and related compensation expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,678&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,589&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Accrued legal and professional expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,132&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;261&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Accrued Financing costs&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,240&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_773892869;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;Other&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;102&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;120&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 4pt;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;10,084&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;5,745&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</srt:CondensedFinancialStatementsTextBlock>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="cref_508417479" id="ixv-4301">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table summarizes the details of prepaid expenses and other current assets as of the dates set forth below (in thousands):&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;September 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Research and development prepaid expenses&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;2,400&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4,320&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Prepaid insurance&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;325&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;866&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Prepaid travel expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;147&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;103&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Other prepaid expenses and current assets&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;636&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;664&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3,508&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;5,953&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <jspr:ResearchAndDevelopmentPrepaidExpenses
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14500"
      unitRef="uref_1858178790">2400000</jspr:ResearchAndDevelopmentPrepaidExpenses>
    <jspr:ResearchAndDevelopmentPrepaidExpenses
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14501"
      unitRef="uref_1858178790">4320000</jspr:ResearchAndDevelopmentPrepaidExpenses>
    <us-gaap:PrepaidInsurance
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14502"
      unitRef="uref_1858178790">325000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14503"
      unitRef="uref_1858178790">866000</us-gaap:PrepaidInsurance>
    <jspr:PrepaidTravelExpenses
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14504"
      unitRef="uref_1858178790">147000</jspr:PrepaidTravelExpenses>
    <jspr:PrepaidTravelExpenses
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14505"
      unitRef="uref_1858178790">103000</jspr:PrepaidTravelExpenses>
    <us-gaap:OtherAssetsCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14506"
      unitRef="uref_1858178790">636000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14507"
      unitRef="uref_1858178790">664000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14508"
      unitRef="uref_1858178790">3508000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14509"
      unitRef="uref_1858178790">5953000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="cref_508417479" id="ixv-4377">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table summarizes the details of property and equipment, net as of the dates set forth below (in thousands):&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;September 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Leasehold improvements&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;2,799&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;2,711&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Lab equipment&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1764515244;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,513&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Office furniture &amp;amp; fixtures&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;570&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;522&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Computer equipment&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;238&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;170&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-left: 9pt;"&gt;Property and equipment, gross&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,607&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;4,916&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Less: accumulated depreciation and amortization&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(3,550&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(4,814&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Property and equipment, net&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;57&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;102&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_1202149676"
      decimals="-3"
      id="ixv-14510"
      unitRef="uref_1858178790">2799000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_1307131979"
      decimals="-3"
      id="ixv-14511"
      unitRef="uref_1858178790">2711000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_944162999"
      decimals="-3"
      id="ixv-14512"
      unitRef="uref_1858178790">1513000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_2015909371"
      decimals="-3"
      id="ixv-14513"
      unitRef="uref_1858178790">570000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_1446456635"
      decimals="-3"
      id="ixv-14514"
      unitRef="uref_1858178790">522000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_771486823"
      decimals="-3"
      id="ixv-14515"
      unitRef="uref_1858178790">238000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_313204812"
      decimals="-3"
      id="ixv-14516"
      unitRef="uref_1858178790">170000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14517"
      unitRef="uref_1858178790">3607000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14518"
      unitRef="uref_1858178790">4916000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14519"
      unitRef="uref_1858178790">3550000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14520"
      unitRef="uref_1858178790">4814000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14521"
      unitRef="uref_1858178790">57000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14522"
      unitRef="uref_1858178790">102000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14523"
      unitRef="uref_1858178790">16000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="cref_412907873"
      decimals="-5"
      id="ixv-14524"
      unitRef="uref_1858178790">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="cref_508417479"
      decimals="-5"
      id="ixv-14525"
      unitRef="uref_1858178790">100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="cref_695164559"
      decimals="-5"
      id="ixv-14526"
      unitRef="uref_1858178790">800000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="cref_508417479" id="ixv-4476">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table summarizes the details of accrued expenses and other current liabilities as of the dates set forth below (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;September 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Research and development accrued expenses&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4,932&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;3,775&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Accrued employee and related compensation expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,678&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,589&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Accrued legal and professional expenses&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,132&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;261&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Accrued Financing costs&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,240&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_773892869;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;Other&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;102&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;120&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 4pt;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;10,084&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;5,745&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <jspr:ResearchAndDevelopmentAccruedExpensesCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14527"
      unitRef="uref_1858178790">4932000</jspr:ResearchAndDevelopmentAccruedExpensesCurrent>
    <jspr:ResearchAndDevelopmentAccruedExpensesCurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14528"
      unitRef="uref_1858178790">3775000</jspr:ResearchAndDevelopmentAccruedExpensesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14529"
      unitRef="uref_1858178790">2678000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14530"
      unitRef="uref_1858178790">1589000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14531"
      unitRef="uref_1858178790">1132000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14532"
      unitRef="uref_1858178790">261000</us-gaap:AccruedProfessionalFeesCurrent>
    <jspr:AccruedFinancingCosts
      contextRef="cref_672740131"
      decimals="-3"
      id="fc_599862718"
      unitRef="uref_1858178790">1240000</jspr:AccruedFinancingCosts>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14534"
      unitRef="uref_1858178790">102000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14535"
      unitRef="uref_1858178790">120000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14536"
      unitRef="uref_1858178790">10084000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="cref_1785065301"
      decimals="-3"
      id="ixv-14537"
      unitRef="uref_1858178790">5745000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <jspr:CirmGrantDisclosureTextBlock contextRef="cref_508417479" id="ixv-4572">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 6. CIRM GRANT&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; In November 2020, California Institute for Regenerative Medicine (&#x201c;CIRM&#x201d;) awarded the Company $2.3 million in support of the research project related to a monoclonal antibody that depletes blood stem cells and enables chemotherapy-free transplants. The Company has received an aggregate of $2.3 million from CIRM through September 30, 2026. There are no further amounts available for future distribution to the Company under the grant. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; Under the terms of the grant, both CIRM and the Company agreed to co-fund the research project and the amount of the Company&#x2019;s co-funding requirement was predetermined as a part of the award. Under the terms of the CIRM grant, the Company is obligated to pay royalties and licensing fees based on 0.1% of net sales of CIRM-funded inventions per $1.0 million of CIRM grant. As an alternative to revenue sharing, the Company has the option to convert the award to a loan. In the event the Company exercises its right to convert the award to a loan, it would be obligated to repay the loan within ten business days of making such election. Repayment amounts vary dependent on when the award is converted to a loan, ranging from 60% of the award granted to amounts received plus interest at the rate of the three-month LIBOR rate plus 25% per annum. Since the Company may be required to repay some or all of the amounts awarded by CIRM, the Company had historically accounted for this award as a liability, recorded without discount or interest given the uncertainty as to amounts that would become due. In the absence of explicit U.S. GAAP guidance on contributions received by business entities from government entities, the Company applied the recognition and measurement guidance in ASC Topic 958-605 Not-for-Profit Entities: Revenue Recognition&#x2014;Contributions to the CIRM grant by analogy. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; As of June 30, 2026, the Company determined that the principal path for briquilimab is obtaining and monetizing a priority review voucher, proceeds from which are excluded from royalty-bearing net sales under the CIRM grant. As a result, the Company determined it would not elect to convert the award to a loan and concluded that repayment is no longer probable. Accordingly, the Company reversed the $2.3 million liability and recognized a corresponding gain in other income during the three months ended June 30, 2026. As of September 30, 2026, no amount related to the CIRM grant is recorded in other non-current liabilities in the condensed consolidated balance sheet (compared to $2.3 million as of December 31, 2025). &lt;/p&gt;</jspr:CirmGrantDisclosureTextBlock>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="cref_618204288"
      decimals="-5"
      id="ixv-14538"
      unitRef="uref_1858178790">2300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <jspr:ReceivedAggregateFromCIRM
      contextRef="cref_508417479"
      decimals="-5"
      id="ixv-14539"
      unitRef="uref_1858178790">2300000</jspr:ReceivedAggregateFromCIRM>
    <jspr:PercentageOfLicensingFees
      contextRef="cref_508417479"
      decimals="3"
      id="ixv-14540"
      unitRef="uref_417554493">0.001</jspr:PercentageOfLicensingFees>
    <jspr:NetSales
      contextRef="cref_1024002468"
      decimals="-5"
      id="ixv-14541"
      unitRef="uref_1858178790">1000000</jspr:NetSales>
    <us-gaap:DebtConversionConvertedInstrumentRate
      contextRef="cref_508417479"
      decimals="2"
      id="ixv-14542"
      unitRef="uref_417554493">0.60</us-gaap:DebtConversionConvertedInstrumentRate>
    <us-gaap:InvestmentInterestRate
      contextRef="cref_672740131"
      decimals="2"
      id="ixv-14543"
      unitRef="uref_417554493">0.25</us-gaap:InvestmentInterestRate>
    <us-gaap:OtherIncome
      contextRef="cref_1678293840"
      decimals="-5"
      id="ixv-14544"
      unitRef="uref_1858178790">2300000</us-gaap:OtherIncome>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="cref_1220081959"
      decimals="-5"
      id="ixv-14545"
      unitRef="uref_1858178790">2300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="cref_508417479" id="ixv-4582">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 7. SIGNIFICANT AGREEMENTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Mirador License Agreement&lt;/i&gt;&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; On July 13, 2026, Kira entered into a license agreement with Mirador granting an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize products containing KP301 and KP402 product candidates. The agreement provided for a $12.0 million upfront payment, an $8.0 million payment upon delivery of drug substance and compounds, potential development and regulatory milestone payments of up to $108.5 million, commercial milestone payments of up to $350.0 million, and tiered royalties ranging from low to mid-single digits on annual net sales. The Company acquired Kira&#x2019;s rights and obligations under the agreement on July 16, 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The license was transferred to Mirador before the Acquisition, and the related license revenue was recognized by Kira before the Acquisition date. During the three and nine months ended September 30, 2026, the Company transferred control of the drug substance and compounds to Mirador and recognized revenue of $8.0 million and related costs of drug supplies and compounds of $8.0 million. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; As of September 30, 2026, accounts receivable related to the delivered drug supplies and materials were $8.0 million, which were collected in October 2026. As of September 30, 2026, all future development milestones were not probable and revenue was fully constrained. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; Unless terminated earlier, the Mirador License Agreement continues until the expiration of royalty term of all licensed products in all countries. For each licensed product and country, the royalty term continues until the latest of expiration of the applicable licensed patent rights, 12 years after first commercial sale, or expiration of applicable regulatory exclusivity. Mirador may terminate the agreement, in whole or by licensed product or country, for convenience upon 90 days&#x2019; written notice. Either party may terminate for material breach or certain insolvency events. Upon termination, the applicable licenses generally terminate, subject to certain surviving sublicenses and specified reversion rights. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;UPenn License Agreement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;In connection with the Acquisition, the Company assumed Kira&#x2019;s rights and obligations under an exclusive license agreement with The Trustees of the University of Pennsylvania (&#x201c;UPenn&#x201d;), originally entered into in June 2017 and subsequently amended in June 2019, February 2021 and July 2026 (the &#x201c;UPenn License Agreement&#x201d;). The UPenn License Agreement provides the Company with an exclusive, worldwide, royalty-bearing license, with the right to sublicense, under certain patent rights relating to complement-targeted therapeutics. The Company is required to use commercially reasonable efforts to develop and commercialize covered products, achieve specified development milestones and reimburse UPenn for patent and maintenance costs.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The July 2026 amendment established a minimum change of control fee of $1.5 million and the Acquisition qualified as a change of control transaction. In addition, the execution of the Mirador License Agreement before the Acquisition resulted in a 15% sublicense fee on certain amounts received under the Mirador License agreement. These amounts were included in accrued expenses and other current liabilities assumed in the Acquisition. The Company paid the $1.5 million change-of-control fee during the three months ended September 30, 2026. The 15% sublicense fee remained outstanding as of September 30, 2026 and was included in accrued expenses and other current liabilities in the condensed consolidated balance sheet. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The UPenn License Agreement provides for development, regulatory and commercial milestone payments totaling up to $16.2 million for each covered product. Certain development milestones had been achieved prior to the Acquisition, and the respective milestone payments totaling $0.4 million were made prior to the Acquisition. None of the remaining contingent milestones were considered probable of achievement as of September 30, 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The Company is also obligated to pay annual license maintenance fees of $15,000 until the year in which minimum annual royalties become payable and tiered low single-digit royalties on annual net sales of covered products. Minimum annual royalties of $150,000 become payable beginning in the calendar year following the first commercial sale. Royalty obligations apply on a product-by-product and country-by-country basis through the later of the expiration of the last valid patent claim covering the product and ten years after the first commercial sale of the first product in the applicable country. All licensed product candidates remained in development and no sales-based royalties were paid in the three and nine months ended September 30, 2026. The Company recognized $0.1 million in patent reimbursement costs as general and administrative expense in the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2026. As of September 30, 2026, there was $0.1 million recorded in accounts payable in the condensed consolidated balance sheet related to the patent reimbursement costs. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Unless terminated earlier, the UPenn License Agreement continues on a patent-family-by-patent-family basis until the expiration or abandonment of the last valid claim within the applicable patent family. The Company may terminate the agreement in its entirety or with respect to an individual patent family upon at least 60 days&#x2019; written notice, subject to ceasing the applicable licensed activities. UPenn may terminate the agreement or relevant licensed rights under specified circumstances, including uncured material breaches, failure to satisfy development obligations and certain insolvency events.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Stanford License Agreements&lt;/i&gt;&lt;/span&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;In March 2021, the Company entered into an exclusive license agreement with Stanford (as amended through June 2026, the &#x201c;2021 Stanford License Agreement&#x201d;). Each amendment modified certain milestones set forth thereunder. The Company received a worldwide, exclusive license, with a right to sublicense, for briquilimab in the field of depleting endogenous blood stem cells in patients for whom hematopoietic cell transplantation is indicated. Stanford transferred to the Company certain know-how and patents related to briquilimab (together, the &#x201c;Licensed Technology&#x201d;). Under the terms of this agreement, the Company is required to use commercially reasonable efforts to develop, manufacture and sell licensed product and to develop markets for a licensed product. In addition, the Company is required to use commercially reasonable efforts to meet the milestones as specified in the agreement over the approximately eight years from execution of the 2021 Stanford License Agreement and must notify Stanford in writing as each milestone is met.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The Company is obligated to pay annual license maintenance fees, beginning on the first anniversary of the effective date of the agreement and ending upon the first commercial sale of a product, method, or service in the licensed field of use, as follows: $25,000 for each first and second year, $35,000 for each third and fourth year and $50,000 at each anniversary thereafter ending upon the first commercial sale. The Company is also obligated to pay late-stage clinical development milestone payments and first commercial sales milestone payments of up to $9.0 million in total. The Company will also pay low single-digit royalties on net sales of licensed products, if approved. The Company recognized $50,000 and $35,000 in annual license maintenance fees as research and development expense in the condensed consolidated statements of operations and comprehensive loss for the nine months ended September 30, 2026 and 2025, respectively. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The 2021 Stanford License Agreement expires on a country-by-country basis on the last-to-expire valid claim of a licensed patent in such country. The Company may terminate the agreement by giving Stanford written notice at least 12 months in advance of the effective date of termination. The Company may also terminate the agreement solely with respect to any particular patent application or patent by giving Stanford written notice at least 60 days in advance of the effective date of termination. Stanford may terminate the agreement after 90 days from a written notice by Stanford, specifying a problem, including a delinquency on any report required pursuant to the agreement or any payment, missing a milestone or a material breach, unless the Company remediates the problem in that 90-day period.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; In December 2024, the Company entered into a co-exclusive license agreement with Stanford (the &#x201c;2024 Stanford License Agreement&#x201d;). The Company received a co-exclusive license in the United States, with a right to sublicense, for a certain patent to be used in the field of the treatment and prevention of human diseases, including the use of anti-CD117 antibodies (other than JSP191) for the purpose of depleting endogenous blood stem cells in patients for whom hematopoietic cell transplantation is indicated (the &#x201c;Co-Exclusive Licensed Field of Use&#x201d;) and an exclusive license in the United States for the use of the same patent in the field provided in the 2021 Stanford License Agreement (the &#x201c;Exclusive Licensed Field of Use&#x201d;). Stanford will have at most one other commercial license for the licensed patent in the Co-Exclusive Licensed Field of Use. Under the terms of this agreement, the Company is required to use commercially reasonable efforts to develop, manufacture and sell a licensed product and to develop markets for a licensed product. In addition, the Company is required to use commercially reasonable efforts to meet the milestones as specified in the agreement over approximately 4.5 years from the execution of the agreement and must notify Stanford in writing when, and if, each milestone is met. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;In June 2026, the Company entered into Amendment No. 3 to the Stanford License Agreement, which amended and restated the milestone schedule under the agreement, including milestones that extend through July 31, 2029.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The Company paid a license issue fee of $75,000, following the execution of the agreement, in January 2025. The Company is also obligated to pay annual license maintenance fees, beginning on the first anniversary of the effective date of the agreement, as follows: $25,000 for each of the first through third years, $50,000 for each of the fourth through sixth years and $65,000 at each anniversary thereafter. The Company is also obligated to pay clinical development milestone payments of up to $1.3 million and sales milestone payments of up to $7.0 million in total. The Company will pay low single-digit royalties on net sales of licensed products, if approved. The Company will pay Stanford a portion of sublicensee consideration if a sublicense is granted. As of September 30, 2026 and December 31, 2025, there was $0 and $25,000, respectively, of accounts payable recorded in the condensed consolidated balance sheets related to the annual license maintenance fee. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company may terminate the agreement by giving Stanford written notice at least 30 days in advance of the effective date of termination. Stanford may terminate the agreement by giving the Company 90 days written notice for a problem, including a delinquency on any report required pursuant to the agreement, missing a milestone or a material breach, and by giving the Company 30 days written notice for a payment default, unless the Company remediates the problem in that 90-day or 30-day period.&#160;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <jspr:UpfrontPayment
      contextRef="cref_508417479"
      decimals="-5"
      id="ixv-14546"
      unitRef="uref_1858178790">12000000</jspr:UpfrontPayment>
    <jspr:PaymentUponDelivery
      contextRef="cref_508417479"
      decimals="-5"
      id="ixv-14547"
      unitRef="uref_1858178790">8000000</jspr:PaymentUponDelivery>
    <jspr:CommercialMilestonePayments
      contextRef="cref_508417479"
      decimals="-5"
      id="ixv-14548"
      unitRef="uref_1858178790">108500000</jspr:CommercialMilestonePayments>
    <jspr:RoyaltiesOnAnnualNetSales
      contextRef="cref_508417479"
      decimals="-5"
      id="ixv-14549"
      unitRef="uref_1858178790">350000000</jspr:RoyaltiesOnAnnualNetSales>
    <jspr:RecognizedRevenueForDrugSubstanceCompounds
      contextRef="cref_425078768"
      decimals="-5"
      id="ixv-14550"
      unitRef="uref_1858178790">8000000</jspr:RecognizedRevenueForDrugSubstanceCompounds>
    <jspr:RecognizedRevenueForDrugSubstanceCompounds
      contextRef="cref_508417479"
      decimals="-5"
      id="ixv-14551"
      unitRef="uref_1858178790">8000000</jspr:RecognizedRevenueForDrugSubstanceCompounds>
    <jspr:CostsOfDrugSuppliesAndCompounds
      contextRef="cref_508417479"
      decimals="-5"
      id="ixv-14552"
      unitRef="uref_1858178790">8000000</jspr:CostsOfDrugSuppliesAndCompounds>
    <jspr:CostsOfDrugSuppliesAndCompounds
      contextRef="cref_425078768"
      decimals="-5"
      id="ixv-14553"
      unitRef="uref_1858178790">8000000</jspr:CostsOfDrugSuppliesAndCompounds>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="cref_672740131"
      decimals="-5"
      id="ixv-14554"
      unitRef="uref_1858178790">8000000</us-gaap:AccountsReceivableNetCurrent>
    <jspr:ApproximatelyAgreement contextRef="cref_508417479" id="ixv-14555">P12Y</jspr:ApproximatelyAgreement>
    <jspr:ControlFeesForAgreement
      contextRef="cref_1369165700"
      decimals="-5"
      id="ixv-14556"
      unitRef="uref_1858178790">1500000</jspr:ControlFeesForAgreement>
    <jspr:PercentageOfSublicenseFee
      contextRef="cref_1473213167"
      decimals="2"
      id="ixv-14557"
      unitRef="uref_417554493">0.15</jspr:PercentageOfSublicenseFee>
    <jspr:PaymentOfControlFee
      contextRef="cref_425078768"
      decimals="-5"
      id="ixv-14558"
      unitRef="uref_1858178790">1500000</jspr:PaymentOfControlFee>
    <jspr:PercentageOfSublicenseFee
      contextRef="cref_508417479"
      decimals="2"
      id="ixv-14559"
      unitRef="uref_417554493">0.15</jspr:PercentageOfSublicenseFee>
    <jspr:SalesMilestonePayments
      contextRef="cref_508417479"
      decimals="-5"
      id="ixv-14560"
      unitRef="uref_1858178790">16200000</jspr:SalesMilestonePayments>
    <jspr:CommercialMilestonePayments
      contextRef="cref_1715336576"
      decimals="-5"
      id="ixv-14561"
      unitRef="uref_1858178790">400000</jspr:CommercialMilestonePayments>
    <us-gaap:CostMaintenance
      contextRef="cref_1715336576"
      decimals="-3"
      id="ixv-14562"
      unitRef="uref_1858178790">15000000</us-gaap:CostMaintenance>
    <us-gaap:AdvanceRoyalties
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14563"
      unitRef="uref_1858178790">150000000</us-gaap:AdvanceRoyalties>
    <us-gaap:DisaggregationOfIncomeStatementExpenseCaptionReimbursementToAnotherEntityAmount
      contextRef="cref_425078768"
      decimals="-5"
      id="ixv-14564"
      unitRef="uref_1858178790">100000</us-gaap:DisaggregationOfIncomeStatementExpenseCaptionReimbursementToAnotherEntityAmount>
    <us-gaap:DisaggregationOfIncomeStatementExpenseCaptionReimbursementToAnotherEntityAmount
      contextRef="cref_508417479"
      decimals="-5"
      id="ixv-14565"
      unitRef="uref_1858178790">100000</us-gaap:DisaggregationOfIncomeStatementExpenseCaptionReimbursementToAnotherEntityAmount>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilities
      contextRef="cref_672740131"
      decimals="-5"
      id="ixv-14566"
      unitRef="uref_1858178790">100000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
    <jspr:MilestonePaymentsObligationToBePaidFirstAndSecondYear
      contextRef="cref_1820753273"
      decimals="-3"
      id="ixv-14567"
      unitRef="uref_1858178790">25000000</jspr:MilestonePaymentsObligationToBePaidFirstAndSecondYear>
    <jspr:MilestonePaymentsObligationToBePaidThirdAndFourthYear
      contextRef="cref_1820753273"
      decimals="-3"
      id="ixv-14568"
      unitRef="uref_1858178790">35000000</jspr:MilestonePaymentsObligationToBePaidThirdAndFourthYear>
    <jspr:MilestonePaymentsObligationToBePaidThereafter
      contextRef="cref_1820753273"
      decimals="-3"
      id="ixv-14569"
      unitRef="uref_1858178790">50000000</jspr:MilestonePaymentsObligationToBePaidThereafter>
    <jspr:SalesMilestonePayments
      contextRef="cref_1037550575"
      decimals="-5"
      id="ixv-14570"
      unitRef="uref_1858178790">9000000</jspr:SalesMilestonePayments>
    <us-gaap:CostMaintenance
      contextRef="cref_1037550575"
      decimals="-3"
      id="ixv-14571"
      unitRef="uref_1858178790">50000000</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="cref_1899529043"
      decimals="-3"
      id="ixv-14572"
      unitRef="uref_1858178790">35000000</us-gaap:CostMaintenance>
    <jspr:ApproximatelyAgreement contextRef="cref_486113179" id="ixv-14573">P4Y6M</jspr:ApproximatelyAgreement>
    <jspr:LicenseMaintenanceFee
      contextRef="cref_486113179"
      decimals="-3"
      id="ixv-14574"
      unitRef="uref_1858178790">75000000</jspr:LicenseMaintenanceFee>
    <jspr:MilestonePaymentsObligationToBePaidFirstThroughThirdYear
      contextRef="cref_388220087"
      decimals="-3"
      id="ixv-14575"
      unitRef="uref_1858178790">25000000</jspr:MilestonePaymentsObligationToBePaidFirstThroughThirdYear>
    <jspr:MilestonePaymentsObligationToBePaidFourthThroughSixthYear
      contextRef="cref_388220087"
      decimals="-3"
      id="ixv-14576"
      unitRef="uref_1858178790">50000000</jspr:MilestonePaymentsObligationToBePaidFourthThroughSixthYear>
    <jspr:MilestonePaymentsObligationToBePaidThereafter
      contextRef="cref_388220087"
      decimals="-3"
      id="ixv-14577"
      unitRef="uref_1858178790">65000000</jspr:MilestonePaymentsObligationToBePaidThereafter>
    <jspr:SalesMilestonePayments
      contextRef="cref_486113179"
      decimals="-5"
      id="ixv-14578"
      unitRef="uref_1858178790">1300000</jspr:SalesMilestonePayments>
    <jspr:ClinicalDevelopmentMilestonePayments
      contextRef="cref_486113179"
      decimals="-5"
      id="ixv-14579"
      unitRef="uref_1858178790">7000000</jspr:ClinicalDevelopmentMilestonePayments>
    <us-gaap:CostMaintenance
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14580"
      unitRef="uref_1858178790">0</us-gaap:CostMaintenance>
    <us-gaap:CostMaintenance
      contextRef="cref_251733876"
      decimals="-3"
      id="ixv-14581"
      unitRef="uref_1858178790">25000000</us-gaap:CostMaintenance>
    <jspr:WarrantsTextBlock contextRef="cref_508417479" id="fc_480945608">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 8. WARRANTS&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; In September 2025, in connection and together with the issuance of 389,023 shares of the Company&#x2019;s voting common stock through the underwritten offering (the &#x201c;September 2025 Offering&#x201d;), the Company issued pre-funded warrants to purchase 22,500 shares of common stock (the &#x201c;Pre-Funded Warrants&#x201d;) and common stock warrants to purchase 411,523&#160;shares of common stock (the &#x201c;Common Warrants&#x201d;). See Note 11 for additional details about the September 2025 Offering. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;Pre-Funded Warrants&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The exercise price of each Pre-Funded Warrant is $0.003 per share. The Pre-Funded Warrants are exercisable at the option of each holder in whole or in part at any time after their original issuance and have no expiration date. The Pre-Funded Warrants may be exercised by means of cash or the cashless settlement of the net number of shares of common stock determined according to a formula set forth in the Pre-Funded Warrants. However, a holder will not be entitled to exercise any portion of any Pre-Funded Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by such holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99% or 19.99%) of the number of issued and outstanding shares of common stock following such exercise. However, any holder of a Pre-Funded Warrant may increase or decrease such percentage to any other percentage not in excess of 19.99%, provided that the holder shall provide at least 61 days&#x2019; prior written notice to the Company prior to the date such increase shall be effective. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Pursuant to the terms of the Pre-Funded Warrant, upon the consummation of a Fundamental Transaction, as defined in the Pre-Funded Warrants, the holders of the Pre-Funded Warrants are entitled to receive, upon exercise of the Pre-Funded Warrants, the kind and amount of securities, cash or other property that such holders would have received had they exercised the Pre-Funded Warrants immediately prior to such Fundamental Transaction, without regard to any limitations on exercise contained in the Pre-Funded Warrants.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The Company concluded that the Pre-Funded Warrants met the equity indexation criteria and the Pre-Funded Warrants are therefore accounted for in stockholders&#x2019; equity. In the quarter-ended September 30, 2025 the Company recorded $0.3&#160;million to additional paid-in capital upon issuance of the Pre-Funded Warrants. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; As of September 30, 2026,&#160;&lt;span style="-sec-ix-hidden:fc_1053105136;"&gt;none&lt;/span&gt;&#160;of the Pre-Funded Warrants have been exercised. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Common Warrants&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The exercise price of each Common Warrant is $87.60 per share. Each Common Warrant is exercisable commencing on the six month anniversary of the date of issuance and thereafter for a period of four years. The Common Warrants may be exercised by means of cash or the cashless settlement of the net number of shares of common stock determined according to a formula set forth in the Common Warrants. However, a holder will not be entitled to exercise any portion of any Common Warrant that, upon giving effect to such exercise, would cause the aggregate number of shares of common stock beneficially owned by such holder (together with its affiliates) to exceed 4.99% (or, at the election of the holder, 9.99% or 19.99%) of the number of issued and outstanding shares of common stock following such exercise. However, any holder of a Common Warrant may increase or decrease such percentage to any other percentage not in excess of 19.99%, provided that the holder shall provide at least 61 days&#x2019; prior written notice to the Company prior to the date such increase shall be effective. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Pursuant to the terms of the Common Warrant, upon the consummation of a Fundamental Transaction, as defined in the Common Warrants, the holders of the Common Warrants are entitled to receive, upon exercise of the Common Warrant, the kind and amount of securities, cash or other property that such holders would have received had they exercised the Common Warrants immediately prior to such Fundamental Transaction, without regard to any limitations on exercise contained in the Common Warrants or the holder may require the Company or the successor entity to repurchase the unexercised portion of the Common Warrant for its Black Scholes Value, as defined in the Common Warrant; provided, however, if the holder shall only be entitled to receive from the Company or any successor entity the same type or form of consideration (and in the same proportion) at the Black Scholes Value of the unexercised portion of the Common Warrant, that is being offered and paid to the holders of common stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, shares or any combination thereof, or whether the holders of common stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of common stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of common stock will be deemed to have received common stock of the successor entity (which successor entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The Company concluded that the Common Warrants did not meet the equity indexation criteria due to the certain inputs to estimate the number of shares issuable in a Fundamental Transaction and the Common Warrants are therefore accounted for as liabilities. The Company recorded $24.7&#160;million to warrant liability upon issuance of the Common Warrants. The Company estimated fair value of the Common Warrants at the issuance date using the Black-Scholes valuation model and will remeasure the liability at each reporting date. The Company recorded a change in fair value of warrant liability of $1.2 million and $12.4&#160;million in its condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2026, respectively. Refer to Note 4 for assumptions used to estimate the Common Warrants fair value. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; As of September 30, 2026,&#160;&lt;span style="-sec-ix-hidden:fc_1976852577;"&gt;none&lt;/span&gt;&#160;of the Common Warrants were exercised. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; On October 7, 2026, the Company commenced a cash tender offer to purchase any and all outstanding Common Warrants for $9.72 per warrant. The offer expired on November 7, 2026, and the Company repurchased and cancelled 283,689 Common Warrants for an aggregate cash payment of $2.8 million. Following completion of the offer, 127,834 Common Warrants remained outstanding. &lt;/p&gt;</jspr:WarrantsTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="cref_1018411722"
      decimals="0"
      id="ixv-14582"
      unitRef="uref_501881879">389023</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_1181131728"
      decimals="0"
      id="ixv-14583"
      unitRef="uref_501881879">22500</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_546811629"
      decimals="0"
      id="ixv-14584"
      unitRef="uref_501881879">411523</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_1946265291"
      decimals="3"
      id="ixv-14585"
      unitRef="uref_672740131">0.003</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <jspr:PreFundedWarrantPercentage
      contextRef="cref_508417479"
      decimals="4"
      id="ixv-14586"
      unitRef="uref_417554493">0.0499</jspr:PreFundedWarrantPercentage>
    <jspr:PercentageOfElectionHolderWarrants
      contextRef="cref_1004196278"
      decimals="4"
      id="ixv-14587"
      unitRef="uref_417554493">0.0999</jspr:PercentageOfElectionHolderWarrants>
    <jspr:PercentageOfElectionHolderWarrants
      contextRef="cref_941820053"
      decimals="4"
      id="ixv-14588"
      unitRef="uref_417554493">0.1999</jspr:PercentageOfElectionHolderWarrants>
    <jspr:PercentagePreFundedWarrants
      contextRef="cref_508417479"
      decimals="4"
      id="ixv-14589"
      unitRef="uref_417554493">0.1999</jspr:PercentagePreFundedWarrants>
    <us-gaap:AdditionalPaidInCapital
      contextRef="cref_1946265291"
      decimals="-5"
      id="ixv-14590"
      unitRef="uref_1858178790">300000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_885096443"
      decimals="2"
      id="ixv-14591"
      unitRef="uref_672740131">87.6</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <jspr:PreFundedWarrantPercentage
      contextRef="cref_183127202"
      decimals="4"
      id="ixv-14592"
      unitRef="uref_417554493">0.0499</jspr:PreFundedWarrantPercentage>
    <jspr:PercentageOfElectionHolderWarrants
      contextRef="cref_183127202"
      decimals="4"
      id="ixv-14593"
      unitRef="uref_417554493">0.0999</jspr:PercentageOfElectionHolderWarrants>
    <jspr:PercentageOfElectionHolderWarrants
      contextRef="cref_508417479"
      decimals="4"
      id="ixv-14594"
      unitRef="uref_417554493">0.1999</jspr:PercentageOfElectionHolderWarrants>
    <jspr:PercentageOfCommonWarrants
      contextRef="cref_508417479"
      decimals="4"
      id="ixv-14595"
      unitRef="uref_417554493">0.1999</jspr:PercentageOfCommonWarrants>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="cref_885096443"
      decimals="-5"
      id="ixv-14596"
      unitRef="uref_1858178790">24700000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_1588263218"
      decimals="-5"
      id="ixv-14597"
      unitRef="uref_1858178790">1200000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="cref_183127202"
      decimals="-5"
      id="ixv-14598"
      unitRef="uref_1858178790">12400000</us-gaap:FairValueAdjustmentOfWarrants>
    <jspr:OutstandingCommonWarrants
      contextRef="cref_125041417"
      decimals="2"
      id="ixv-14599"
      unitRef="uref_672740131">9.72</jspr:OutstandingCommonWarrants>
    <jspr:RepurchasesAndCancellationOfCommonWarrants
      contextRef="cref_1061460467"
      decimals="0"
      id="ixv-14600"
      unitRef="uref_501881879">283689</jspr:RepurchasesAndCancellationOfCommonWarrants>
    <jspr:AggregateCashPayment
      contextRef="cref_1061460467"
      decimals="-5"
      id="ixv-14601"
      unitRef="uref_1858178790">2800000</jspr:AggregateCashPayment>
    <jspr:NumberOfRemainingWarrantsOutstanding
      contextRef="cref_1033720489"
      decimals="0"
      id="fc_1033720489"
      unitRef="uref_501881879">127834</jspr:NumberOfRemainingWarrantsOutstanding>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="cref_508417479" id="ixv-4699">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 9. COMMITMENTS AND CONTINGENCIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Operating Leases&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company leases office and laboratory space in Redwood City, California and Suzhou, PRC under operating leases expiring in February 2027 and April 2027, respectively. The Suzhou lease was assumed in connection with the Acquisition.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; In conjunction with the California lease, the Company secured a letter of credit in favor of the lessor in the amount of $0.4 million. The funds related to this letter of credit are presented as restricted cash on the Company&#x2019;s condensed consolidated balance sheets. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; In December 2025, in connection with the cessation of the Company&#x2019;s vivarium operations and consolidation of personnel office space, the Company ceased use of a portion of its leased headquarters space in California. As a result, the right-of-use asset associated with that lease was impaired by $0.4 million. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Under its operating leases, the Company pays fixed base rent and variable costs related to its share of operating expenses and taxes. These variable costs are recorded as lease expense as incurred and presented as operating expenses in the condensed consolidated statements of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The components of lease costs, which were included in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss, are as follows (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Nine Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Lease cost&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Operating lease cost&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;609&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;953&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Short-term lease cost&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1689173779;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;169&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Variable lease cost&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;535&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;856&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 9.05pt;"&gt;Total lease cost&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;1,144&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;1,978&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Supplemental information related to the Company&#x2019;s operating leases is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Nine Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Cash paid for amounts included in the measurement of lease liabilities (in thousands)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,276&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,327&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Weighted average remaining lease term (years)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.47&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.89&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Weighted average discount rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;9.33&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8.00&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table summarizes a maturity analysis of the Company&#x2019;s operating lease liabilities showing the aggregate lease payments as of September 30, 2026 (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Year Ending December 31,&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Amount&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 88%; text-align: left;"&gt;2026 (remainder of the year)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;39&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;2027&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;32&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-left: 9pt;"&gt;Total undiscounted lease payments&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;71&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Less imputed interest&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(2&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Total discounted lease payments&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;69&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Current portion of lease liability&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;69&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;License Agreements&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The Company is required to make milestone payments upon the achievement of specific development, regulatory and commercialization events and to pay royalties on net sales of licensed products under its license agreements, including its agreements with Stanford and UPenn, as described in Note 7. As of September 30, 2026, all licensed product candidates remained in development and no sales-based royalties were payable. None of the remaining contingent milestones were considered probable of achievement as of September 30, 2026, and &lt;span style="-sec-ix-hidden:fc_1717637872;"&gt;no&lt;/span&gt; amounts were accrued for those milestones. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Legal Proceedings&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The Company, from time to time, may be party to litigation arising in the ordinary course of business. On September 19, 2025, a shareholder class action complaint captioned&#160;&lt;i&gt;Grant v. Jasper Therapeutics, Inc., et al.&lt;/i&gt;&#160;(Case No. 25-cv-08010) was filed in the United States District Court for the Northern District of California against us and certain of our current and former officers. The complaint alleges that certain material misstatements or omissions related to the ongoing clinical trials of briquilimab were made in violation of federal securities laws. The plaintiffs are seeking unspecified monetary&#160;damages&#160;and an award of costs and expenses, including reasonable attorneys&#x2019; fees, expert fees and other costs. On December 3, 2025, a stipulated order was entered appointing co-lead plaintiffs and approving their selection of co-lead counsel, and on December 16, 2025, a stipulated order was entered setting a schedule for the filing and responses to an amended complaint. Per the terms of the December 16, 2025 stipulated order, an amended complaint captioned &lt;i&gt;Allard, et al. v. Jasper Therapeutics, Inc., et al.&lt;/i&gt; (Case No. 25-cv-08010) was filed, and defendants&#x2019; motion to dismiss was filed on April 20, 2026.&#160;A hearing on defendants&#x2019; motion to dismiss took place October 15, 2026, and the parties are awaiting an order.&#160;In addition, on November 5, 2025, a shareholder derivative complaint captioned &lt;i&gt;Bardauskas v. Martell, et al&lt;/i&gt;. (Case No. 25-cv-09561) was filed in the United States District Court for the Northern District of California, and on December 22, 2025, another shareholder derivative complaint was filed in the same court and captioned &lt;i&gt;Walsh v. Martell, et al.&lt;/i&gt; (Case No. 25-cv-10899). The derivative complaints name as defendants certain of our current and former officers and directors, and allege claims related to the allegations raised in the shareholder class action complaint. On January 21, 2026, a stipulated order was entered, among other things, consolidating and staying the derivative actions.&#160;We believe the claims raised in these lawsuits are without merit, and intend to defend these matters vigorously. However, there can be no assurance that we will prevail. We are unable to determine whether any loss ultimately will occur or to estimate the range of such loss; therefore, &lt;span style="-sec-ix-hidden:fc_664243033;"&gt;&lt;span style="-sec-ix-hidden:fc_1845022880;"&gt;no&lt;/span&gt;&lt;/span&gt; amount of loss has been accrued in our financial statements as of and for the three months ended September 30, 2026. Regardless of outcome, litigation can have an adverse impact on us due to costs involved, diversion of management resources, negative publicity, reputational harm, and other factors. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company believes that it is not currently a party to any other legal proceedings which, individually or in the aggregate, would have a material adverse effect on its consolidated financial position, results of operations&#160;or cash flows.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Guarantees and Indemnifications &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of September 30, 2026 and December 31, 2025, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LinesOfCreditCurrent
      contextRef="cref_672740131"
      decimals="-5"
      id="ixv-14603"
      unitRef="uref_1858178790">400000</us-gaap:LinesOfCreditCurrent>
    <us-gaap:OperatingLeaseImpairmentLoss
      contextRef="cref_447920408"
      decimals="-5"
      id="ixv-14604"
      unitRef="uref_1858178790">400000</us-gaap:OperatingLeaseImpairmentLoss>
    <us-gaap:LeaseCostTableTextBlock contextRef="cref_508417479" id="ixv-4717">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The components of lease costs, which were included in the Company&#x2019;s condensed consolidated statements of operations and comprehensive loss, are as follows (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Nine Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold;"&gt;Lease cost&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Operating lease cost&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;609&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;953&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Short-term lease cost&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1689173779;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;169&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Variable lease cost&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;535&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;856&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="font-weight: bold; text-align: left; padding-bottom: 2.5pt; text-indent: 9.05pt;"&gt;Total lease cost&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;1,144&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;1,978&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Supplemental information related to the Company&#x2019;s operating leases is as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Nine Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Cash paid for amounts included in the measurement of lease liabilities (in thousands)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,276&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,327&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Weighted average remaining lease term (years)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.47&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.89&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Weighted average discount rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;9.33&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;8.00&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14605"
      unitRef="uref_1858178790">609000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14606"
      unitRef="uref_1858178790">953000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14607"
      unitRef="uref_1858178790">169000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14608"
      unitRef="uref_1858178790">535000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14609"
      unitRef="uref_1858178790">856000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14610"
      unitRef="uref_1858178790">1144000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14611"
      unitRef="uref_1858178790">1978000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14612"
      unitRef="uref_1858178790">1276000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14613"
      unitRef="uref_1858178790">1327000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="cref_672740131" id="ixv-14614">P0Y5M19D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="cref_1663002504" id="ixv-14615">P0Y10M20D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="cref_672740131"
      decimals="4"
      id="ixv-14616"
      unitRef="uref_417554493">0.0933</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="cref_1663002504"
      decimals="4"
      id="ixv-14617"
      unitRef="uref_417554493">0.08</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="cref_508417479" id="ixv-4836">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table summarizes a maturity analysis of the Company&#x2019;s operating lease liabilities showing the aggregate lease payments as of September 30, 2026 (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-weight: bold; border-bottom: Black 1.5pt solid;"&gt;Year Ending December 31,&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Amount&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 88%; text-align: left;"&gt;2026 (remainder of the year)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;39&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;2027&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;32&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-left: 9pt;"&gt;Total undiscounted lease payments&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;71&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Less imputed interest&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(2&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Total discounted lease payments&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;69&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Current portion of lease liability&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;69&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14618"
      unitRef="uref_1858178790">39000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14619"
      unitRef="uref_1858178790">32000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14620"
      unitRef="uref_1858178790">71000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14621"
      unitRef="uref_1858178790">2000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14622"
      unitRef="uref_1858178790">69000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_672740131"
      decimals="-3"
      id="ixv-14623"
      unitRef="uref_1858178790">69000</us-gaap:OperatingLeaseLiabilityCurrent>
    <jspr:TemporaryEquityRedeemableConvertiblePreferredStockTextBlock contextRef="cref_508417479" id="fc_61569059">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 10. NON-VOTING REDEEMABLE CONVERTIBLE PREFERRED STOCK&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; As of September 30, 2026, the Company is authorized to issue 9,906,591 shares of non-voting redeemable convertible preferred stock with par value $0.0001 per share. In connection with the Acquisition and the Financing, as discussed in Note 3, the Company issued 9,555,390 shares. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; In connection with the Acquisition, the Company assumed outstanding options to purchase Kira common stock and converted a portion of those options into options to purchase 347,808 shares of the Company&#x2019;s non-voting redeemable convertible preferred stock (see Note 12). Upon the Stockholder Approval, these options will automatically convert into options to purchase the Company&#x2019;s common stock. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The holders of non-voting redeemable convertible preferred stock have the following rights and privileges:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Dividends&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The holders of the non-voting redeemable convertible preferred stock are entitled to receive dividends on an as-if-converted-to-voting common-stock basis in the same form and manner as dividends paid on the Company&#x2019;s voting common stock, other than dividends payable in shares of voting common stock. Holders of the non-voting redeemable convertible preferred stock are not entitled to receive contingent value rights distributed pursuant to the CVR Agreement or any payments made under the CVR Agreement. No other dividends are payable on the non-voting redeemable convertible preferred stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Voting Rights&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The non-voting redeemable convertible preferred stock has no voting rights, except as required by law or provided in the certificate of designation. However, for as long as any shares of non-voting redeemable convertible preferred stock remain outstanding, the Company may not, without the affirmative vote of holders of a majority of the then-outstanding non-voting redeemable convertible preferred stock: (i) adversely alter the powers, preferences or rights of the non-voting redeemable convertible preferred stock or amend the certificate of designation, the Company&#x2019;s certificate of incorporation or bylaws in a manner adverse to the non-voting redeemable convertible preferred stock; (ii) issue further shares of non-voting redeemable convertible preferred stock or increase or decrease the authorized number of shares of non-voting redeemable convertible preferred stock; (iii) prior to the Stockholder Approval, consummate a fundamental transaction, including certain business combinations, dispositions of substantially all assets, tender or exchange offers, or reclassifications of voting common stock into other securities, cash or property, or certain other mergers, consolidations or business combinations; (iv) prior to the Stockholder Approval, authorize or issue any class or series of stock senior to or on parity with the non-voting redeemable convertible preferred stock; (v) amend, waive or modify the Merger Agreement in a manner reasonably likely to prevent, impede or materially delay the Stockholder Approval or the automatic conversion of the non-voting redeemable convertible preferred stock.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Liquidation &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The non-voting redeemable convertible preferred stock ranks on parity with the Company&#x2019;s common stock upon liquidation, dissolution or winding up. Holders are entitled to receive the amount they would have received had their shares been fully converted into voting common stock, without regard to beneficial ownership limitations, plus any declared but unpaid dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Conversion&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; Each share of non-voting redeemable convertible preferred stock will automatically convert into 2.03 shares of voting common stock on the third business day following the Stockholder Approval, subject to applicable beneficial ownership limitations. The Stockholder Approval includes approval of the conversion under The Nasdaq Stock Market LLC listing rules and an amendment to the Company&#x2019;s certificate of incorporation authorizing sufficient shares of voting common stock. Shares not automatically converted because of a beneficial ownership limitation will remain outstanding and may subsequently be converted at the holder&#x2019;s option. The conversion ratio is subject to proportionate adjustment for stock dividends, stock splits and combinations of voting common stock and, following a fundamental transaction, will be adjusted so that holders receive upon conversion the same securities, cash or other property they would have received had the shares been converted immediately before the transaction. The beneficial ownership limitation is initially set by each holder at between 4.9% and 19.9% of the voting common stock outstanding after giving effect to the conversion. A holder may reduce its limitation immediately or increase it, up to 19.9%, upon 61 days&#x2019; prior written notice. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Redemption &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;At any time following the earlier of the Stockholder Approval or 12 months after the initial issuance of the non-voting redeemable convertible preferred stock, if a holder submits a notice of conversion and the Company fails to deliver the applicable shares of voting common stock by the third trading day after the applicable share delivery date, the holder may require the Company, out of legally available funds, to pay cash equal to the fair value of the undelivered shares. The cash payment is due within two business days after the holder&#x2019;s request and extinguishes the Company&#x2019;s obligation to deliver the related shares. If the Stockholder Approval has not been obtained when the conversion notice is delivered, the holder&#x2019;s cash-settlement request is deemed to have been made automatically. The fair value is based on the last reported closing price of the voting common stock on its principal trading market on the trading day immediately preceding delivery of the conversion notice.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Other than the holders&#x2019; cash-settlement rights described above, the non-voting redeemable convertible preferred stock is not redeemable.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The stockholders&#x2019; vote is scheduled on November 13, 2026.&lt;/p&gt;</jspr:TemporaryEquityRedeemableConvertiblePreferredStockTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="cref_137967644"
      decimals="0"
      id="ixv-14624"
      unitRef="uref_501881879">9906591</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="cref_137967644"
      decimals="4"
      id="ixv-14625"
      unitRef="uref_672740131">0.0001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="cref_137967644"
      decimals="0"
      id="ixv-14626"
      unitRef="uref_501881879">9555390</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance
      contextRef="cref_137967644"
      decimals="0"
      id="ixv-14627"
      unitRef="uref_501881879">347808</us-gaap:ConvertiblePreferredStockSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_65068980"
      decimals="2"
      id="ixv-14628"
      unitRef="uref_501881879">2.03</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <jspr:SubsidiaryBeneficialOwnershipPercentage
      contextRef="cref_508417479"
      decimals="3"
      id="fc_849400752"
      unitRef="uref_417554493">0.049</jspr:SubsidiaryBeneficialOwnershipPercentage>
    <jspr:SubsidiaryBeneficialShareholderPercentage
      contextRef="cref_508417479"
      decimals="3"
      id="fc_1567028306"
      unitRef="uref_417554493">0.199</jspr:SubsidiaryBeneficialShareholderPercentage>
    <jspr:IncreaseOrDecreaseOfLimitationsOfPercentage
      contextRef="cref_65068980"
      decimals="3"
      id="ixv-14631"
      unitRef="uref_417554493">0.199</jspr:IncreaseOrDecreaseOfLimitationsOfPercentage>
    <jspr:NumberOfDaysPriorWrittenNotice contextRef="cref_65068980" id="ixv-14632">P61D</jspr:NumberOfDaysPriorWrittenNotice>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="cref_508417479" id="ixv-4985">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 11. COMMON STOCK&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; As of September 30, 2026, the Company is authorized to issue 490,000,000&#160;shares of voting common stock, 2,000,000&#160;shares of non-voting&#160;common stock, and 93,409&#160;shares of undesignated preferred stock. There were&#160;1,109,133&#160;shares of voting common stock, &lt;span style="-sec-ix-hidden:fc_1200041397;"&gt;&lt;span style="-sec-ix-hidden:fc_1958742004;"&gt;no&lt;/span&gt;&lt;/span&gt; shares of non-voting common stock&#160;issued and outstanding as of September 30, 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; Holders of the voting common stock and the non-voting&#160;common stock have similar rights, except that non-voting stockholders are not entitled to vote, including for the election of directors. Holders of voting common stock do not have conversion rights, while holders of non-voting&#160;common stock have the right to convert each share of non-voting&#160;common stock held by such holder into one share of voting common stock at such holder&#x2019;s election by providing written notice to the Company, provided that as a result of such conversion, such holder, together with its affiliates, would not beneficially own in excess of 9.9% of the Company&#x2019;s voting common stock following such conversion. There were &lt;span style="-sec-ix-hidden:fc_869020569;"&gt;&lt;span style="-sec-ix-hidden:fc_1135442090;"&gt;no&lt;/span&gt;&lt;/span&gt; outstanding shares of non-voting common stock as of September 30, 2026 and December 31, 2025. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;As of September 30, 2026 and December 31, 2025, the Company had common stock reserved for future issuance as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;September 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Outstanding and issued shares of non-voting redeemable convertible preferred stock, as converted&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;19,429,255&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2117742345;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Outstanding and issued common stock options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;85,470&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;74,783&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Outstanding and issued non-voting redeemable convertible preferred stock options, as converted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;707,195&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_344846042;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Outstanding and issued restricted stock units&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,790&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,624&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Outstanding and issued performance-based restricted stock units&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1215539598;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;666&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;Shares issuable upon exercise of Public Warrants (1)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_161023939;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;16,666&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Shares issuable upon exercise of Common Warrants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;411,523&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;411,523&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;Shares issuable upon exercise of Pre-Funded Warrants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;22,500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;22,500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Shares available for grant under Equity Incentive Plans&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;27,759&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;28,147&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Shares available for grant under Employee Stock Purchase Plan&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;30,261&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;30,689&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Shares available for grant under 2022 Inducement Equity Incentive Plan&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;7,033&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;4,429&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total shares of common stock reserved&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;20,722,786&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;596,027&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The Company has 4,999,863 outstanding warrants to purchase an aggregate of&#160;16,666&#160;shares of its common stock (the &#x201c;Public Warrants&#x201d;). A holder may purchase&#160;one&#160;share of the Company&#x2019;s common stock for every&#160;ten&#160;Public Warrants at an exercise price of $3,450.00&#160;per share. The Public Warrants are publicly traded and exercisable during the exercise period, which commenced on October 24, 2021 and ended on September 24, 2026, for cash or, in certain circumstances, on a cashless basis. The Public Warrants were reclassified to equity in January 2023. The Public Warrants were fully unexercised and expired in September 2026.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Shelf Registration Statement&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; On March 19, 2025, the Company filed a new shelf registration statement on Form S-3 (the &#x201c;S-3&#x201d;) with the SEC, which was declared effective on March 26, 2025. As of September 30, 2026, the Company can sell from time to time up to $263.5 million of common stock, preferred stock, debt securities, warrants, rights, units and depositary shares comprised of any combination of these securities, for the Company&#x2019;s own account in one or more offerings under the S-3. The terms of any offering under the S-3 will be established at the time of such offering and will be described in a prospectus supplement to the S-3 filed with the SEC prior to the completion of any such offering. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;ATM Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; On March 19, 2025, the Company entered into an Open Market Sale Agreement&lt;sup&gt;SM&lt;/sup&gt;&#160;with Jefferies LLC (&#x201c;Jefferies&#x201d;), pursuant to which the Company may offer and sell through or to Jefferies, as sales agent or principal, shares of common stock from time to time (the &#x201c;ATM Offering&#x201d;). On March 26, 2025, the Company filed with the SEC a prospectus under the S-3 in connection with the ATM Offering (the &#x201c;ATM Prospectus&#x201d;), pursuant to which the Company may offer and sell shares of common stock having an aggregate offering price of up to $100.0 million. As of September 30, 2026, the Company issued and sold an aggregate of 41,035 shares of common stock for net proceeds of approximately $6.5 million pursuant to the ATM Prospectus. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; As of September 30, 2026, $93.5 million remained available under the ATM Prospectus. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Underwritten Offering&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; On September 18, 2025, the Company entered into an underwriting agreement with TD Securities (USA) LLC as the representative of the several underwriters, relating to an underwritten public offering under the S-3 of an aggregate of 389,023 shares of common stock, Pre-Funded Warrants to purchase 22,500 shares of common stock and Common Warrants to purchase 411,523 shares of common stock. The Company received net proceeds of $27.5&#160;million. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; As of September 30, 2026, $170.0 million remained available and unallocated under the S-3. &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_1387491772"
      decimals="0"
      id="ixv-14633"
      unitRef="uref_501881879">490000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_610464657"
      decimals="0"
      id="ixv-14634"
      unitRef="uref_501881879">2000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="cref_672740131"
      decimals="0"
      id="ixv-14635"
      unitRef="uref_501881879">93409</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_1387491772"
      decimals="0"
      id="ixv-14636"
      unitRef="uref_501881879">1109133</us-gaap:CommonStockSharesIssued>
    <jspr:NumberOfSharePurchase
      contextRef="cref_672740131"
      decimals="0"
      id="ixv-14637"
      unitRef="uref_501881879">1</jspr:NumberOfSharePurchase>
    <jspr:VotingCommonStockPercent
      contextRef="cref_672740131"
      decimals="3"
      id="ixv-14638"
      unitRef="uref_417554493">0.099</jspr:VotingCommonStockPercent>
    <us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock contextRef="cref_508417479" id="ixv-4997">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;As of September 30, 2026 and December 31, 2025, the Company had common stock reserved for future issuance as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;September 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;December&#160;31,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Outstanding and issued shares of non-voting redeemable convertible preferred stock, as converted&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;19,429,255&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2117742345;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Outstanding and issued common stock options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;85,470&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;74,783&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Outstanding and issued non-voting redeemable convertible preferred stock options, as converted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;707,195&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_344846042;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Outstanding and issued restricted stock units&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,790&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,624&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Outstanding and issued performance-based restricted stock units&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1215539598;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;666&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;Shares issuable upon exercise of Public Warrants (1)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_161023939;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;16,666&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Shares issuable upon exercise of Common Warrants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;411,523&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;411,523&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;Shares issuable upon exercise of Pre-Funded Warrants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;22,500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;22,500&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Shares available for grant under Equity Incentive Plans&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;27,759&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;28,147&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Shares available for grant under Employee Stock Purchase Plan&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;30,261&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;30,689&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Shares available for grant under 2022 Inducement Equity Incentive Plan&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;7,033&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;4,429&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Total shares of common stock reserved&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;20,722,786&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;596,027&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;sup&gt;&#160;&lt;/sup&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;(1)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The Company has 4,999,863 outstanding warrants to purchase an aggregate of&#160;16,666&#160;shares of its common stock (the &#x201c;Public Warrants&#x201d;). A holder may purchase&#160;one&#160;share of the Company&#x2019;s common stock for every&#160;ten&#160;Public Warrants at an exercise price of $3,450.00&#160;per share. The Public Warrants are publicly traded and exercisable during the exercise period, which commenced on October 24, 2021 and ended on September 24, 2026, for cash or, in certain circumstances, on a cashless basis. The Public Warrants were reclassified to equity in January 2023. The Public Warrants were fully unexercised and expired in September 2026.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_2116292910"
      decimals="0"
      id="ixv-14639"
      unitRef="uref_501881879">19429255</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_2055620455"
      decimals="0"
      id="ixv-14640"
      unitRef="uref_501881879">85470</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1052254435"
      decimals="0"
      id="ixv-14641"
      unitRef="uref_501881879">74783</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1080596398"
      decimals="0"
      id="ixv-14642"
      unitRef="uref_501881879">707195</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_2019022675"
      decimals="0"
      id="ixv-14643"
      unitRef="uref_501881879">1790</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_261132654"
      decimals="0"
      id="ixv-14644"
      unitRef="uref_501881879">6624</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_2018067789"
      decimals="0"
      id="ixv-14645"
      unitRef="uref_501881879">666</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1412025843"
      decimals="0"
      id="fc_1412025843"
      unitRef="uref_501881879">16666</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_460567013"
      decimals="0"
      id="ixv-14647"
      unitRef="uref_501881879">411523</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_747199849"
      decimals="0"
      id="ixv-14648"
      unitRef="uref_501881879">411523</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1108093153"
      decimals="0"
      id="ixv-14649"
      unitRef="uref_501881879">22500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1045102301"
      decimals="0"
      id="ixv-14650"
      unitRef="uref_501881879">22500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1601700699"
      decimals="0"
      id="ixv-14651"
      unitRef="uref_501881879">27759</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_559681780"
      decimals="0"
      id="ixv-14652"
      unitRef="uref_501881879">28147</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_517669350"
      decimals="0"
      id="ixv-14653"
      unitRef="uref_501881879">30261</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1695691226"
      decimals="0"
      id="ixv-14654"
      unitRef="uref_501881879">30689</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1525217165"
      decimals="0"
      id="ixv-14655"
      unitRef="uref_501881879">7033</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1144305534"
      decimals="0"
      id="ixv-14656"
      unitRef="uref_501881879">4429</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_672740131"
      decimals="0"
      id="ixv-14657"
      unitRef="uref_501881879">20722786</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_1785065301"
      decimals="0"
      id="ixv-14658"
      unitRef="uref_501881879">596027</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="cref_831031631"
      decimals="0"
      id="ixv-14660"
      unitRef="uref_501881879">4999863</us-gaap:ClassOfWarrantOrRightOutstanding>
    <jspr:PurchaseAnAggregateShares
      contextRef="cref_1406249857"
      decimals="0"
      id="ixv-14661"
      unitRef="uref_501881879">16666</jspr:PurchaseAnAggregateShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="cref_927708732"
      decimals="2"
      id="fc_927708732"
      unitRef="uref_672740131">3450</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="cref_672740131"
      decimals="-5"
      id="ixv-14663"
      unitRef="uref_1858178790">263500000</us-gaap:EquitySecuritiesFvNi>
    <jspr:AggregateOfferingPrice
      contextRef="cref_1339959004"
      decimals="-5"
      id="ixv-14664"
      unitRef="uref_1858178790">100000000</jspr:AggregateOfferingPrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="cref_1004196278"
      decimals="0"
      id="ixv-14665"
      unitRef="uref_501881879">41035</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="cref_1004196278"
      decimals="-5"
      id="ixv-14666"
      unitRef="uref_1858178790">6500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <jspr:UnderwrittenOfferingRemainedAvailable
      contextRef="cref_508417479"
      decimals="-5"
      id="ixv-14667"
      unitRef="uref_1858178790">93500000</jspr:UnderwrittenOfferingRemainedAvailable>
    <jspr:AggregateShares
      contextRef="cref_254503131"
      decimals="0"
      id="ixv-14668"
      unitRef="uref_501881879">389023</jspr:AggregateShares>
    <jspr:PreFundedWarrantsToPurchase
      contextRef="cref_254503131"
      decimals="0"
      id="ixv-14669"
      unitRef="uref_501881879">22500</jspr:PreFundedWarrantsToPurchase>
    <jspr:CommonWarrantsToPurchaseShares
      contextRef="cref_254503131"
      decimals="0"
      id="ixv-14670"
      unitRef="uref_501881879">411523</jspr:CommonWarrantsToPurchaseShares>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="cref_254503131"
      decimals="-5"
      id="fc_254503131"
      unitRef="uref_1858178790">27500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <jspr:AvailableOfferingAmount
      contextRef="cref_2103363847"
      decimals="-5"
      id="ixv-14672"
      unitRef="uref_1858178790">170000000</jspr:AvailableOfferingAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="cref_508417479" id="ixv-5188">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 12. STOCK-BASED COMPENSATION&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; As of September 30, 2026, 89,324 shares were reserved for issuance under the 2024 Equity Incentive Plan (the &#x201c;2024 Plan&#x201d;), of which 27,759 shares were available for future grant and 61,565 shares were subject to outstanding options and restricted stock units (&#x201c;RSUs&#x201d;), including shares subject to performance-based awards of 541. As of September 30, 2026, options to purchase 1,445 shares of common stock remained outstanding and unexercised and continue to be governed by the 2019 Equity Incentive Plan (the &#x201c;2019 EIP&#x201d;). As of September 30, 2026, 33,332 shares were reserved under the 2024 Employee Stock Purchase Plan (the &#x201c;2024 ESPP&#x201d;), of which 30,261 shares were available for future issuance and 3,071 shares had been issued. As of September 30, 2026, 18,330 shares were reserved for issuance under the 2022 Inducement Equity Incentive Plan (the &#x201c;2022 Inducement Plan&#x201d;), of which 7,033 shares were available for future grant and 11,297 shares were subject to outstanding stock options. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Kira Plan &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;On July 16, 2026, in connection with the Acquisition, the Company assumed Kira&#x2019;s 2017 Stock Plan (the &#x201c;Kira Plan&#x201d;). The Kira Plan permits the granting of options and share purchase rights to employees, directors and consultants of the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; In connection with the Acquisition, each outstanding stock option to purchase one share of Kira common stock was converted into stock options to purchase approximately 0.0057 shares of the Company&#x2019;s common stock and 0.17 shares of the Company&#x2019;s non-voting redeemable convertible preferred stock, resulting in options to purchase an aggregate of 12,953 shares of common stock and 347,808 shares of non-voting redeemable convertible preferred stock of the Company. The assumed options that were unvested at the acquisition date retain their original vesting terms, which were either ratable vesting over four years from the original vesting commencement date or immediately vested of 50% of the award, with the remaining 50% vesting ratably over 18 months from the original vesting commencement date. As of September 30, 2026, no shares were available for future grants under the Kira Plan. New awards may be granted under the Kira Plan only to the extent that shares become available upon the forfeiture, expiration or cancellation of options assumed in the Acquisition. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The assumed Kira&#x2019;s options were revalued at their acquisition-date fair value and then attributed to pre and post-combination service. The Company recognized $2.7 million representing the fair value of the assumed options attributable to the pre-combination service period as part of the consideration transferred (see Note 3). As of the acquisition date, the remaining unrecognized compensation expense associated with the unvested options was $7.0 million which would be recognized over a weighted-average period of approximately 3.2 years. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Common Stock Option Activity&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table summarizes the common stock option activities, including performance-based stock options, under the 2024 Plan, the 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;), the 2022 Inducement Plan, the 2019 EIP and the Kira Plan for the nine months ended September 30, 2026:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Options&lt;br/&gt; Outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&#160;(Years)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Aggregate&lt;br/&gt; Intrinsic &lt;br/&gt; Value &lt;br/&gt; (in thousands)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%;"&gt;Balance, December 31, 2025&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;74,783&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;411.51&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4.81&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_818916274;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Assumed in connection with the Acquisition&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;12,953&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;5.32&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Options granted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;51,917&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;43.65&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Options cancelled/forfeited/expired&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(54,183&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;363.85&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Balance, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;85,470&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;156.72&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;7.45&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;210&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Vested and expected to vest, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;85,470&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;156.72&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;7.45&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;210&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Exercisable, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;26,007&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;327.99&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;5.64&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;67&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The aggregate intrinsic value represents the difference between the estimated fair value of the underlying common stock or the underlying non-voting redeemable convertible preferred stock on as-converted to common stock basis, and the exercise price of outstanding, in-the-money options. &lt;span style="-sec-ix-hidden:fc_2089850336;"&gt;&lt;span style="-sec-ix-hidden:fc_1162855172;"&gt;No&lt;/span&gt;&lt;/span&gt; options were exercised during the three and nine months ended September 30, 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The total fair value of options that vested during the nine months ended September 30, 2026 and 2025 was $2.3 million and $6.4 million, respectively. The weighted-average grant date fair value of options granted during the nine months ended September 30, 2026 and 2025 was $35.23 and $143.29 per share, respectively. The weighted-average acquisition date fair value of common stock options assumed in the Acquisition was $22.36 per share. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; Unamortized stock-based compensation expense related to common stock options as of September 30, 2026 was $3.8 million, which is expected to be recognized over a weighted-average period of 2.9 years. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Non-Voting Redeemable Convertible Preferred Stock Option Activity&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table summarizes the stock option activity under the Kira Plan for non-voting redeemable convertible preferred stock options:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;Options&lt;br/&gt; Outstanding&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;Weighted Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&#160;(Years)&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;Aggregate&lt;br/&gt; Intrinsic Value &lt;br/&gt; (in thousands)&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Balance, December 31, 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2125509794;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1700199582;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1075624723;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_114941406;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt;"&gt;Assumed in connection with the Acquisition&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;347,808&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right;"&gt;11.02&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Balance, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;347,808&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;11.02&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;9.45&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;11,470&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Vested and expected to vest, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;347,808&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;11.02&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;9.45&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;11,470&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Exercisable, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;122,302&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;30.21&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;9.15&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;3,629&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;No options were exercised during the three and nine months ended September 30, 2026.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The total fair value of non-voting redeemable convertible preferred stock options that vested during the nine months ended September 30, 2026 was $0.6 million. The weighted-average acquisition date fair value of non-voting redeemable convertible preferred stock options assumed in the Acquisition was $27.00 per share. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; Unamortized stock-based compensation expense related to unvested non-voting redeemable convertible preferred stock options as of September 30, 2026 was $6.1 million, which is expected to be recognized over a weighted-average period of 3.1 years. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Performance-Based Stock Options&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table provides a summary of performance-based stock options activity under the 2024 Plan and the 2021 Plan during the nine months ended September 30, 2026:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Options&lt;br/&gt; Outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&#160;(Years)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;br/&gt; (in thousands)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%;"&gt;Balance, December 31, 2025&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,027&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;219.87&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4.43&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_233473549;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Options expired&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(486&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;213.00&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Balance, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;541&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;226.04&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3.69&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1387955129;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Vested and expected to vest, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;541&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;226.04&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3.69&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_806152820;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Exercisable, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;541&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;226.04&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3.69&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1727881323;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Restricted Stock Units (RSUs)&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table provides a summary of RSU activity under the 2024 Plan during the nine months ended September 30, 2026:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Grant Date &lt;br/&gt; Fair Value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Unvested restricted stock units at December 31, 2025&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;6,624&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;180.00&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;Vested&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(2,322&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;180.00&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;Forfeited&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(2,512&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;180.00&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Unvested restricted stock units at September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;1,790&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;180.00&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Performance Restricted Stock Units (PSUs) &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; In June 2024, the Company granted PSUs for 666 shares that would vest in full if the closing price of the Company&#x2019;s common stock on the Nasdaq Capital Market reached or exceeded $1,050.00 per share (subject to adjustment for recapitalizations, stock splits and similar transactions) for thirty consecutive calendar days within two years from the grant date. If the vesting condition was not met within two years from the grant date, the PSUs would be forfeited. The Company concluded that issued PSUs were equity-based awards and included a market based vesting condition. The Company used a Monte Carlo simulation model to estimate the fair value of the PSUs with the following assumptions: common stock fair value of $718.50, which was the closing market price of the Company&#x2019;s common stock at the grant date, volatility of 133.00%, risk free rate of 4.87%, and vesting term of 2.0 years. Total estimated fair value of $0.4 million was recognized as stock-based compensation expense over 0.4 years, the derived requisite service period from the grant date. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; In January 2026, the employee holding the PSUs was terminated and the award was forfeited. &lt;span style="-sec-ix-hidden:fc_2085834406;"&gt;No&lt;/span&gt; stock-based compensation expense was reversed upon forfeiture, as the award included only a market-based vesting condition and the derived requisite service period had been completed. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Employee Stock Purchase Plans&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The Company issued 428 shares and 1,572 shares of common stock under the ESPP during the nine months ended September 30, 2026 and 2025, respectively, and recognized $0.1 million and $0.4 million compensation expense related to the ESPP during the nine months ended September 30, 2026 and 2025, respectively. All remaining participants in the ESPP withdrew from the offering in the second quarter of 2026. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Stock-Based Compensation Expense&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table presents stock-based compensation expenses related to common stock options, non-voting redeemable convertible preferred stock options, PSUs and RSUs granted to employees and non-employees, employee stock purchase plan awards and restricted common stock shares issued to founders (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Three Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Nine Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left;"&gt;General and administrative&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;615&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;938&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,396&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;3,452&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Research and development&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;604&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;486&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,010&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,600&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;1,219&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;1,424&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;2,406&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;5,052&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;Stock-based compensation expense related to common stock awards is recorded with a corresponding increase in additional paid-in capital. Stock-based compensation expense related to non-voting redeemable convertible preferred stock options is recorded with a corresponding increase in temporary equity, outside of stockholders&#x2019; equity, in the condensed consolidated balance sheets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The Company recognized $0.1 million stock-based compensation expense and $0.1 million of reversal of stock-based compensation expense related to performance-based options, PSUs and RSUs during the three months ended September 30, 2026 and 2025, respectively. The Company recognized $0.2 million and $0.1 million stock-based compensation expense related to performance-based options, PSUs and RSUs during the nine months ended September 30, 2026 and 2025, respectively. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Valuation of Stock Options&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The grant date fair value of stock options granted under the 2024 Plan was estimated using a Black-Scholes option-pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Three Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Nine Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Expected term (in years)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5.5-6.08&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5.27-5.50&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5.5-6.08&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5.27-6.08&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;99.09%-101.63&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;98.34%-99.81&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;99.09%-101.63&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;97.37%-99.81&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left;"&gt;Risk-free interest rate&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;4.31%-4.84&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;3.99&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.85%-4.84&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.83%-4.25&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Expected dividend yield&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_146200286;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_866586732;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_310841094;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2024905596;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The fair value of the stock options assumed in connection with the Acquisition was calculated using a Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Common Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Non-Voting &lt;br/&gt; Redeemable &lt;br/&gt; Convertible &lt;br/&gt; Preferred Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Expected term (in years)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1.62-5.91&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1.62-5.91&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;99.62%-108.55&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;99.62%-108.55&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;4.1%-4.34&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;4.1%-4.34&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Expected dividend yield&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1144374733;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1870289881;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Fair value of common stock or non-voting redeemable convertible preferred stock, as applicable&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;23.22&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;28.3528&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Valuation of ESPP Shares &lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company did not grant ESPP awards under the 2024 ESPP during the three months and nine months ended September 30, 2026. The grant date fair value of ESPP awards granted under the 2024 ESPP during the three and nine months ended September 30, 2025 was estimated using a Black-Scholes option-pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Nine                                                                  Months&lt;br/&gt; Ended&lt;br/&gt; September 30,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 88%; text-align: left;"&gt;Expected term (in years)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;0.49-2.00&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;104.93%-155.78&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.94%-4.31&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yield&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_607498816;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_783103872"
      decimals="0"
      id="ixv-14673"
      unitRef="uref_501881879">89324</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="cref_783103872"
      decimals="0"
      id="ixv-14674"
      unitRef="uref_501881879">27759</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_783103872"
      decimals="0"
      id="ixv-14675"
      unitRef="uref_501881879">61565</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="cref_783103872"
      decimals="0"
      id="ixv-14676"
      unitRef="uref_501881879">541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_366835540"
      decimals="0"
      id="ixv-14677"
      unitRef="uref_501881879">1445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="cref_603642347"
      decimals="0"
      id="ixv-14678"
      unitRef="uref_501881879">33332</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="cref_603642347"
      decimals="0"
      id="ixv-14679"
      unitRef="uref_501881879">30261</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="cref_1678542402"
      decimals="0"
      id="fc_1678542402"
      unitRef="uref_501881879">3071</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance
      contextRef="cref_570178122"
      decimals="0"
      id="ixv-14681"
      unitRef="uref_501881879">18330</us-gaap:DeferredCompensationArrangementWithIndividualCommonStockReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="cref_570178122"
      decimals="0"
      id="ixv-14682"
      unitRef="uref_501881879">7033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_603642347"
      decimals="0"
      id="ixv-14683"
      unitRef="uref_501881879">11297</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="cref_727048804"
      decimals="4"
      id="ixv-14684"
      unitRef="uref_501881879">0.0057</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="cref_282179714"
      decimals="2"
      id="ixv-14685"
      unitRef="uref_501881879">0.17</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="cref_2015256046"
      decimals="0"
      id="ixv-14686"
      unitRef="uref_501881879">12953</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="cref_1369093598"
      decimals="0"
      id="ixv-14687"
      unitRef="uref_501881879">347808</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="cref_1533801715"
      decimals="2"
      id="ixv-14688"
      unitRef="uref_417554493">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="cref_392200963"
      decimals="2"
      id="ixv-14689"
      unitRef="uref_417554493">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="cref_727048804" id="ixv-14690">P18M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="cref_2143834460"
      decimals="-5"
      id="ixv-14691"
      unitRef="uref_1858178790">2700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="cref_1369093598"
      decimals="-5"
      id="ixv-14692"
      unitRef="uref_1858178790">7000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="cref_727048804" id="ixv-14693">P3Y2M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="cref_508417479" id="ixv-5208">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table summarizes the common stock option activities, including performance-based stock options, under the 2024 Plan, the 2021 Equity Incentive Plan (the &#x201c;2021 Plan&#x201d;), the 2022 Inducement Plan, the 2019 EIP and the Kira Plan for the nine months ended September 30, 2026:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Options&lt;br/&gt; Outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&#160;(Years)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Aggregate&lt;br/&gt; Intrinsic &lt;br/&gt; Value &lt;br/&gt; (in thousands)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%;"&gt;Balance, December 31, 2025&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;74,783&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;411.51&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4.81&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_818916274;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Assumed in connection with the Acquisition&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;12,953&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;5.32&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Options granted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;51,917&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;43.65&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Options cancelled/forfeited/expired&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(54,183&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;363.85&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Balance, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;85,470&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;156.72&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;7.45&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;210&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Vested and expected to vest, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;85,470&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;156.72&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;7.45&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;210&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Exercisable, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;26,007&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;327.99&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;5.64&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;67&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table provides a summary of performance-based stock options activity under the 2024 Plan and the 2021 Plan during the nine months ended September 30, 2026:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Options&lt;br/&gt; Outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&#160;(Years)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;br/&gt; (in thousands)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%;"&gt;Balance, December 31, 2025&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,027&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;219.87&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4.43&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_233473549;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Options expired&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(486&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;213.00&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Balance, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;541&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;226.04&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3.69&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1387955129;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Vested and expected to vest, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;541&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;226.04&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3.69&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_806152820;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Exercisable, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;541&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;226.04&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3.69&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1727881323;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_190705790"
      decimals="0"
      id="ixv-14694"
      unitRef="uref_501881879">74783</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_190705790"
      decimals="2"
      id="ixv-14695"
      unitRef="uref_672740131">411.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_717715067" id="ixv-14696">P4Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="cref_2064041890"
      decimals="0"
      id="ixv-14697"
      unitRef="uref_501881879">12953</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <jspr:Share-BasedCompensationArrangementsByShare-BasedPaymentAwardOptionsAssumedInAcquisitionPeriodWeightedAverageExercisePrice
      contextRef="cref_2064041890"
      decimals="2"
      id="fc_445406746"
      unitRef="uref_672740131">5.32</jspr:Share-BasedCompensationArrangementsByShare-BasedPaymentAwardOptionsAssumedInAcquisitionPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="cref_2064041890"
      decimals="0"
      id="ixv-14699"
      unitRef="uref_501881879">51917</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="cref_2064041890"
      decimals="2"
      id="fc_39378664"
      unitRef="uref_672740131">43.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="cref_2064041890"
      decimals="0"
      id="ixv-14701"
      unitRef="uref_501881879">54183</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="cref_2064041890"
      decimals="2"
      id="ixv-14702"
      unitRef="uref_672740131">363.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_1856018927"
      decimals="0"
      id="ixv-14703"
      unitRef="uref_501881879">85470</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_1856018927"
      decimals="2"
      id="ixv-14704"
      unitRef="uref_672740131">156.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_2064041890" id="ixv-14705">P7Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_1856018927"
      decimals="-3"
      id="ixv-14706"
      unitRef="uref_1858178790">210000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="cref_1856018927"
      decimals="0"
      id="ixv-14707"
      unitRef="uref_501881879">85470</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="cref_1856018927"
      decimals="2"
      id="ixv-14708"
      unitRef="uref_672740131">156.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="cref_2064041890" id="ixv-14709">P7Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="cref_1856018927"
      decimals="-3"
      id="ixv-14710"
      unitRef="uref_1858178790">210000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="cref_1856018927"
      decimals="0"
      id="ixv-14711"
      unitRef="uref_501881879">26007</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_1856018927"
      decimals="2"
      id="fc_1005144937"
      unitRef="uref_672740131">327.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="cref_2064041890" id="ixv-14713">P5Y7M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="cref_1856018927"
      decimals="-3"
      id="ixv-14714"
      unitRef="uref_1858178790">67000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="cref_477524601"
      decimals="-5"
      id="ixv-14715"
      unitRef="uref_1858178790">2300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="cref_1482373684"
      decimals="-5"
      id="ixv-14716"
      unitRef="uref_1858178790">6400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="cref_477524601"
      decimals="2"
      id="ixv-14717"
      unitRef="uref_672740131">35.23</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="cref_1482373684"
      decimals="2"
      id="ixv-14718"
      unitRef="uref_672740131">143.29</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="cref_791341145"
      decimals="2"
      id="ixv-14719"
      unitRef="uref_672740131">22.36</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="cref_672740131"
      decimals="-5"
      id="ixv-14720"
      unitRef="uref_1858178790">3800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="cref_477524601" id="ixv-14721">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <jspr:ScheduleOfNon-VotingRedeemableConvertiblePreferredStockOptionsTableTextBlock contextRef="cref_508417479" id="ixv-5381">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&lt;i&gt;Non-Voting Redeemable Convertible Preferred Stock Option Activity&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table summarizes the stock option activity under the Kira Plan for non-voting redeemable convertible preferred stock options:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;Options&lt;br/&gt; Outstanding&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;Weighted Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&#160;(Years)&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;Aggregate&lt;br/&gt; Intrinsic Value &lt;br/&gt; (in thousands)&lt;/td&gt; &lt;td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td&gt;Balance, December 31, 2025&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2125509794;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1700199582;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1075624723;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;$&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_114941406;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 1.5pt;"&gt;Assumed in connection with the Acquisition&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right;"&gt;347,808&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right;"&gt;11.02&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; padding-bottom: 1.5pt; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Balance, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;347,808&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;11.02&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;9.45&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;11,470&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Vested and expected to vest, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;347,808&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;11.02&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;9.45&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;11,470&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Exercisable, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;122,302&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;30.21&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;9.15&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;3,629&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</jspr:ScheduleOfNon-VotingRedeemableConvertiblePreferredStockOptionsTableTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesAcquisitions
      contextRef="cref_568691185"
      decimals="0"
      id="ixv-14722"
      unitRef="uref_501881879">347808</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
    <jspr:Share-BasedCompensationArrangementsByShare-BasedPaymentAwardOptionsAssumedInAcquisitionPeriodWeightedAverageExercisePrice
      contextRef="cref_568691185"
      decimals="2"
      id="fc_1046221558"
      unitRef="uref_672740131">11.02</jspr:Share-BasedCompensationArrangementsByShare-BasedPaymentAwardOptionsAssumedInAcquisitionPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_742412452"
      decimals="0"
      id="ixv-14724"
      unitRef="uref_501881879">347808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_742412452"
      decimals="2"
      id="ixv-14725"
      unitRef="uref_672740131">11.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_568691185" id="ixv-14726">P9Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_742412452"
      decimals="-3"
      id="ixv-14727"
      unitRef="uref_1858178790">11470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="cref_742412452"
      decimals="0"
      id="ixv-14728"
      unitRef="uref_501881879">347808</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="cref_742412452"
      decimals="2"
      id="ixv-14729"
      unitRef="uref_672740131">11.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="cref_568691185" id="ixv-14730">P9Y5M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="cref_742412452"
      decimals="-3"
      id="ixv-14731"
      unitRef="uref_1858178790">11470000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="cref_742412452"
      decimals="0"
      id="ixv-14732"
      unitRef="uref_501881879">122302</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_742412452"
      decimals="2"
      id="ixv-14733"
      unitRef="uref_672740131">30.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="cref_568691185" id="ixv-14734">P9Y1M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="cref_742412452"
      decimals="-3"
      id="ixv-14735"
      unitRef="uref_1858178790">3629000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock
      contextRef="cref_508417479"
      decimals="-2"
      id="fc_1161691325"
      unitRef="uref_1858178790">600</us-gaap:PaymentsForRepurchaseOfRedeemablePreferredStock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="cref_672740131"
      decimals="2"
      id="ixv-14737"
      unitRef="uref_672740131">27</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="cref_1624526096"
      decimals="1"
      id="fc_1624526096"
      unitRef="uref_501881879">6.1</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="cref_508417479" id="ixv-14739">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock contextRef="cref_508417479" id="ixv-5519">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table provides a summary of performance-based stock options activity under the 2024 Plan and the 2021 Plan during the nine months ended September 30, 2026:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Options&lt;br/&gt; Outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Life&#160;(Years)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;br/&gt; (in thousands)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%;"&gt;Balance, December 31, 2025&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,027&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;219.87&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4.43&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_233473549;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Options expired&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(486&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;213.00&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Balance, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;541&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;226.04&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3.69&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1387955129;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Vested and expected to vest, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;541&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;226.04&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3.69&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_806152820;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;Exercisable, September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;541&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;226.04&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3.69&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1727881323;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardPerformanceBasedUnitsVestedAndExpectedToVestTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_864588011"
      decimals="0"
      id="ixv-14740"
      unitRef="uref_501881879">1027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_864588011"
      decimals="2"
      id="ixv-14741"
      unitRef="uref_672740131">219.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_643612063" id="ixv-14742">P4Y5M4D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="cref_1518962523"
      decimals="0"
      id="ixv-14743"
      unitRef="uref_501881879">486</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="cref_1518962523"
      decimals="2"
      id="ixv-14744"
      unitRef="uref_672740131">213</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_703287044"
      decimals="0"
      id="ixv-14745"
      unitRef="uref_501881879">541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_703287044"
      decimals="2"
      id="ixv-14746"
      unitRef="uref_672740131">226.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_1518962523" id="ixv-14747">P3Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="cref_703287044"
      decimals="0"
      id="ixv-14748"
      unitRef="uref_501881879">541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="cref_703287044"
      decimals="2"
      id="ixv-14749"
      unitRef="uref_672740131">226.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="cref_1518962523" id="ixv-14750">P3Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="cref_703287044"
      decimals="0"
      id="ixv-14751"
      unitRef="uref_501881879">541</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_703287044"
      decimals="2"
      id="ixv-14752"
      unitRef="uref_672740131">226.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="cref_1518962523" id="ixv-14753">P3Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="cref_508417479" id="ixv-5656">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table provides a summary of RSU activity under the 2024 Plan during the nine months ended September 30, 2026:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Number of&lt;br/&gt; Shares&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted-&lt;br/&gt; Average&lt;br/&gt; Grant Date &lt;br/&gt; Fair Value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Unvested restricted stock units at December 31, 2025&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;6,624&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;180.00&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td&gt;Vested&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;(2,322&lt;/td&gt; &lt;td style="text-align: left;"&gt;)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;180.00&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;Forfeited&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(2,512&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: right;"&gt;180.00&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Unvested restricted stock units at September 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;1,790&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: right;"&gt;180.00&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="cref_1965311085"
      decimals="0"
      id="ixv-14754"
      unitRef="uref_501881879">6624</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="cref_1965311085"
      decimals="2"
      id="ixv-14755"
      unitRef="uref_672740131">180</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="cref_1441139425"
      decimals="0"
      id="ixv-14756"
      unitRef="uref_501881879">2322</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="cref_1441139425"
      decimals="2"
      id="ixv-14757"
      unitRef="uref_672740131">180</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="cref_1441139425"
      decimals="0"
      id="ixv-14758"
      unitRef="uref_501881879">2512</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="cref_1441139425"
      decimals="2"
      id="ixv-14759"
      unitRef="uref_672740131">180</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="cref_264924557"
      decimals="0"
      id="ixv-14760"
      unitRef="uref_501881879">1790</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="cref_264924557"
      decimals="2"
      id="ixv-14761"
      unitRef="uref_672740131">180</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="cref_715354114"
      decimals="0"
      id="ixv-14762"
      unitRef="uref_501881879">666</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
      contextRef="cref_715354114"
      decimals="2"
      id="ixv-14763"
      unitRef="uref_672740131">1050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="cref_1562358810"
      decimals="2"
      id="ixv-14764"
      unitRef="uref_672740131">718.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_715354114"
      decimals="4"
      id="ixv-14765"
      unitRef="uref_417554493">1.33</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_715354114"
      decimals="4"
      id="ixv-14766"
      unitRef="uref_417554493">0.0487</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_715354114" id="ixv-14767">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <jspr:TotalEstimatedFairValue
      contextRef="cref_508417479"
      decimals="-5"
      id="ixv-14768"
      unitRef="uref_1858178790">400000</jspr:TotalEstimatedFairValue>
    <jspr:RecognizedCompensationExpensePeriod contextRef="cref_508417479" id="ixv-14769">P0Y4M24D</jspr:RecognizedCompensationExpensePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="cref_596601295"
      decimals="0"
      id="ixv-14770"
      unitRef="uref_501881879">428</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="cref_516925813"
      decimals="0"
      id="ixv-14771"
      unitRef="uref_501881879">1572</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="cref_596601295"
      decimals="-5"
      id="ixv-14772"
      unitRef="uref_1858178790">100000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="cref_516925813"
      decimals="-5"
      id="ixv-14773"
      unitRef="uref_1858178790">400000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="cref_508417479" id="ixv-5733">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table presents stock-based compensation expenses related to common stock options, non-voting redeemable convertible preferred stock options, PSUs and RSUs granted to employees and non-employees, employee stock purchase plan awards and restricted common stock shares issued to founders (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Three Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Nine Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left;"&gt;General and administrative&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;615&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;938&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,396&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;3,452&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;Research and development&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;604&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;486&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,010&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,600&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Total&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;1,219&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;1,424&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;2,406&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; font-weight: bold; text-align: right;"&gt;5,052&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; font-weight: bold; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_181449592"
      decimals="-3"
      id="ixv-14774"
      unitRef="uref_1858178790">615000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_314860208"
      decimals="-3"
      id="ixv-14775"
      unitRef="uref_1858178790">938000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_728870186"
      decimals="-3"
      id="ixv-14776"
      unitRef="uref_1858178790">1396000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1780130885"
      decimals="-3"
      id="ixv-14777"
      unitRef="uref_1858178790">3452000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1353539073"
      decimals="-3"
      id="ixv-14778"
      unitRef="uref_1858178790">604000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_2001091885"
      decimals="-3"
      id="ixv-14779"
      unitRef="uref_1858178790">486000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_2086284145"
      decimals="-3"
      id="ixv-14780"
      unitRef="uref_1858178790">1010000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1539927539"
      decimals="-3"
      id="ixv-14781"
      unitRef="uref_1858178790">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1317305563"
      decimals="-3"
      id="ixv-14782"
      unitRef="uref_1858178790">1219000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_911663582"
      decimals="-3"
      id="ixv-14783"
      unitRef="uref_1858178790">1424000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1162832620"
      decimals="-3"
      id="ixv-14784"
      unitRef="uref_1858178790">2406000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1700925523"
      decimals="-3"
      id="ixv-14785"
      unitRef="uref_1858178790">5052000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_679251772"
      decimals="-5"
      id="ixv-14786"
      unitRef="uref_1858178790">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1802387595"
      decimals="-5"
      id="ixv-14787"
      unitRef="uref_1858178790">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1518962523"
      decimals="-5"
      id="ixv-14788"
      unitRef="uref_1858178790">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1132710420"
      decimals="-5"
      id="ixv-14789"
      unitRef="uref_1858178790">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="cref_508417479" id="ixv-5832">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The grant date fair value of stock options granted under the 2024 Plan was estimated using a Black-Scholes option-pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Three Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Nine Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Expected term (in years)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5.5-6.08&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5.27-5.50&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5.5-6.08&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;5.27-6.08&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;99.09%-101.63&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;98.34%-99.81&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;99.09%-101.63&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;97.37%-99.81&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left;"&gt;Risk-free interest rate&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;4.31%-4.84&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;3.99&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.85%-4.84&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.83%-4.25&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Expected dividend yield&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_146200286;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_866586732;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_310841094;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2024905596;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The fair value of the stock options assumed in connection with the Acquisition was calculated using a Black-Scholes option pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Common Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Non-Voting &lt;br/&gt; Redeemable &lt;br/&gt; Convertible &lt;br/&gt; Preferred Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Expected term (in years)&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1.62-5.91&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;1.62-5.91&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;99.62%-108.55&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;99.62%-108.55&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;4.1%-4.34&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;4.1%-4.34&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Expected dividend yield&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1144374733;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1870289881;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 76%; text-align: left;"&gt;Fair value of common stock or non-voting redeemable convertible preferred stock, as applicable&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;23.22&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;28.3528&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The Company did not grant ESPP awards under the 2024 ESPP during the three months and nine months ended September 30, 2026. The grant date fair value of ESPP awards granted under the 2024 ESPP during the three and nine months ended September 30, 2025 was estimated using a Black-Scholes option-pricing model with the following assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Nine                                                                  Months&lt;br/&gt; Ended&lt;br/&gt; September 30,&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="font-weight: bold; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: center; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="width: 88%; text-align: left;"&gt;Expected term (in years)&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;0.49-2.00&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Expected volatility&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;104.93%-155.78&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: left;"&gt;Risk-free interest rate&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;3.94%-4.31&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;%&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Expected dividend yield&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_607498816;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_993582515" id="ixv-14790">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_550751598" id="ixv-14791">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_559150147" id="ixv-14792">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_345633811" id="ixv-14793">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_633509554" id="ixv-14794">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_615715924" id="ixv-14795">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_14848088" id="ixv-14796">P5Y3M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_448202803" id="ixv-14797">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_993582515"
      decimals="4"
      id="ixv-14798"
      unitRef="uref_417554493">0.9909</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_550751598"
      decimals="4"
      id="ixv-14799"
      unitRef="uref_417554493">1.0163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_559150147"
      decimals="4"
      id="ixv-14800"
      unitRef="uref_417554493">0.9834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_345633811"
      decimals="4"
      id="ixv-14801"
      unitRef="uref_417554493">0.9981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_633509554"
      decimals="4"
      id="ixv-14802"
      unitRef="uref_417554493">0.9909</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_615715924"
      decimals="4"
      id="ixv-14803"
      unitRef="uref_417554493">1.0163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_14848088"
      decimals="4"
      id="ixv-14804"
      unitRef="uref_417554493">0.9737</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_448202803"
      decimals="4"
      id="ixv-14805"
      unitRef="uref_417554493">0.9981</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_993582515"
      decimals="4"
      id="ixv-14806"
      unitRef="uref_417554493">0.0431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_550751598"
      decimals="4"
      id="ixv-14807"
      unitRef="uref_417554493">0.0484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_1420393742"
      decimals="4"
      id="ixv-14808"
      unitRef="uref_417554493">0.0399</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_633509554"
      decimals="4"
      id="ixv-14809"
      unitRef="uref_417554493">0.0385</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_615715924"
      decimals="4"
      id="ixv-14810"
      unitRef="uref_417554493">0.0484</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_14848088"
      decimals="4"
      id="ixv-14811"
      unitRef="uref_417554493">0.0383</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_448202803"
      decimals="4"
      id="ixv-14812"
      unitRef="uref_417554493">0.0425</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_1726680811" id="ixv-14813">P1Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_30173999" id="ixv-14814">P5Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_953568589" id="ixv-14815">P1Y7M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_1933079880" id="ixv-14816">P5Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_1726680811"
      decimals="4"
      id="ixv-14817"
      unitRef="uref_417554493">0.9962</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_30173999"
      decimals="4"
      id="ixv-14818"
      unitRef="uref_417554493">1.0855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_953568589"
      decimals="4"
      id="ixv-14819"
      unitRef="uref_417554493">0.9962</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_1933079880"
      decimals="4"
      id="ixv-14820"
      unitRef="uref_417554493">1.0855</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_1726680811"
      decimals="3"
      id="ixv-14821"
      unitRef="uref_417554493">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_30173999"
      decimals="4"
      id="ixv-14822"
      unitRef="uref_417554493">0.0434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_953568589"
      decimals="3"
      id="ixv-14823"
      unitRef="uref_417554493">0.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="cref_1197670068"
      decimals="4"
      id="ixv-14824"
      unitRef="uref_417554493">0.0434</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <jspr:FairValueOfCommonStockOrNon-VotingRedeemableConvertiblePreferredStockAsApplicable
      contextRef="cref_525949808"
      decimals="2"
      id="ixv-14825"
      unitRef="uref_672740131">23.22</jspr:FairValueOfCommonStockOrNon-VotingRedeemableConvertiblePreferredStockAsApplicable>
    <jspr:FairValueOfCommonStockOrNon-VotingRedeemableConvertiblePreferredStockAsApplicable
      contextRef="cref_842698381"
      decimals="4"
      id="ixv-14826"
      unitRef="uref_672740131">28.3528</jspr:FairValueOfCommonStockOrNon-VotingRedeemableConvertiblePreferredStockAsApplicable>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_1893202121" id="ixv-14827">P0Y5M26D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="cref_417554493" id="ixv-14828">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_1893202121"
      decimals="4"
      id="ixv-14829"
      unitRef="uref_417554493">1.0493</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_417554493"
      decimals="4"
      id="ixv-14830"
      unitRef="uref_417554493">1.5578</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_1893202121"
      decimals="4"
      id="ixv-14831"
      unitRef="uref_417554493">0.0394</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="cref_417554493"
      decimals="4"
      id="ixv-14832"
      unitRef="uref_417554493">0.0431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:EarningsPerShareTextBlock contextRef="cref_508417479" id="ixv-6086">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 13. NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common and non-voting redeemable convertible preferred stockholders (in thousands, except share and per share data):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Three Months Ended September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;span style="font-weight: bold;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Non-Voting &lt;br/&gt; Redeemable &lt;br/&gt; Convertible &lt;br/&gt; Preferred &lt;br/&gt; Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Common &lt;br/&gt; Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Non-Voting &lt;br/&gt; Redeemable &lt;br/&gt; Convertible &lt;br/&gt; Preferred &lt;br/&gt; Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Common &lt;br/&gt; Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Numerator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in;"&gt;Allocated net loss&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;(133,499&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;(10,956&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_1722163284;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;(18,736&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -9pt; padding-left: 9pt;"&gt;Denominator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in;"&gt;Weighted average shares outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,555,390&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,075,259&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_890442523;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;584,056&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in;"&gt;Weighted average shares used to compute basic and diluted net loss per share&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;9,555,390&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;1,075,259&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_20060263;"&gt;&lt;span style="-sec-ix-hidden:fc_847985134;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;584,056&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -9pt; padding-left: 9pt;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt;"&gt;Net loss per share &#x2013; basic and diluted&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(13.97&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(10.19&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1229535605;"&gt;&lt;span style="-sec-ix-hidden:fc_452590843;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(32.08&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Nine Months Ended September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;span style="font-weight: bold;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Non-Voting &lt;br/&gt; Redeemable &lt;br/&gt; Convertible &lt;br/&gt; Preferred &lt;br/&gt; Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Common &lt;br/&gt; Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Non-Voting &lt;br/&gt; Redeemable &lt;br/&gt; Convertible &lt;br/&gt; Preferred &lt;br/&gt; Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Common &lt;br/&gt; Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Numerator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Allocated net loss&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;(133,499&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;(14,890&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_451150944;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;(66,700&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;Denominator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Weighted average shares outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,555,390&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,040,513&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_104311661;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;532,312&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Weighted average shares used to compute basic and diluted net loss per share&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;9,555,390&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;1,040,513&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_69411533;"&gt;&lt;span style="-sec-ix-hidden:fc_496555976;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;532,312&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Net loss per share &#x2013; basic and diluted&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(13.97&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(14.31&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2030684856;"&gt;&lt;span style="-sec-ix-hidden:fc_210306356;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(125.30&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.25in;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;(a)&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Weighted average common stock shares outstanding include     22,500 weighted-average shares underlying pre-funded warrants outstanding during the period, as such warrants are exercisable at     any time for nominal consideration ($0.003 per share).&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have had an antidilutive effect were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Three Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Nine Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left;"&gt;Outstanding and issued common stock options&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;85,470&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;79,416&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;85,470&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;79,416&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Outstanding and issued restricted stock units&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,790&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,389&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,790&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,389&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Outstanding and issued non-voting redeemable convertible preferred stock options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;347,808&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_43420443;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;347,808&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1278649306;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Shares issuable upon exercise of Public Warrants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_165816062;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;16,666&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1889385037;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;16,666&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Shares issuable upon exercise of Common Warrants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;411,523&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;411,523&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;411,523&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;411,523&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Unvested performance-based restricted stock units&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1522608553;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;666&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_801368141;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;666&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;846,591&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;515,660&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;846,591&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;515,660&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="cref_508417479" id="ixv-6090">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common and non-voting redeemable convertible preferred stockholders (in thousands, except share and per share data):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Three Months Ended September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;span style="font-weight: bold;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Non-Voting &lt;br/&gt; Redeemable &lt;br/&gt; Convertible &lt;br/&gt; Preferred &lt;br/&gt; Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Common &lt;br/&gt; Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Non-Voting &lt;br/&gt; Redeemable &lt;br/&gt; Convertible &lt;br/&gt; Preferred &lt;br/&gt; Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Common &lt;br/&gt; Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Numerator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in;"&gt;Allocated net loss&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;(133,499&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;(10,956&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_1722163284;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;(18,736&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-indent: -9pt; padding-left: 9pt;"&gt;Denominator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 0.25in;"&gt;Weighted average shares outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,555,390&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,075,259&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_890442523;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;584,056&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 0.25in;"&gt;Weighted average shares used to compute basic and diluted net loss per share&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;9,555,390&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;1,075,259&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_20060263;"&gt;&lt;span style="-sec-ix-hidden:fc_847985134;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;584,056&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-indent: -9pt; padding-left: 9pt;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; text-indent: -9pt; padding-left: 9pt;"&gt;Net loss per share &#x2013; basic and diluted&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(13.97&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(10.19&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1229535605;"&gt;&lt;span style="-sec-ix-hidden:fc_452590843;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(32.08&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Nine Months Ended September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="text-align: center; border-bottom: Black 1.5pt solid;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;span style="font-weight: bold;"&gt;2025&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Non-Voting &lt;br/&gt; Redeemable &lt;br/&gt; Convertible &lt;br/&gt; Preferred &lt;br/&gt; Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Common &lt;br/&gt; Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Non-Voting &lt;br/&gt; Redeemable &lt;br/&gt; Convertible &lt;br/&gt; Preferred &lt;br/&gt; Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Common &lt;br/&gt; Stock&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Numerator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Allocated net loss&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;(133,499&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;(14,890&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden:fc_451150944;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; border-bottom: Black 4pt double; text-align: right;"&gt;(66,700&lt;/td&gt; &lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;Denominator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Weighted average shares outstanding&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,555,390&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,040,513&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_104311661;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;532,312&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 9pt;"&gt;Weighted average shares used to compute basic and diluted net loss per share&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;9,555,390&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;1,040,513&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_69411533;"&gt;&lt;span style="-sec-ix-hidden:fc_496555976;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;532,312&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 4pt;"&gt;Net loss per share &#x2013; basic and diluted&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(13.97&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(14.31&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_2030684856;"&gt;&lt;span style="-sec-ix-hidden:fc_210306356;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 4pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(125.30&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="cref_2064740571"
      decimals="-3"
      id="ixv-14833"
      unitRef="uref_1858178790">-133499000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_693960815"
      decimals="-3"
      id="ixv-14834"
      unitRef="uref_1858178790">-10956000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_2133907001"
      decimals="-3"
      id="ixv-14835"
      unitRef="uref_1858178790">-18736000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="cref_2064740571"
      decimals="0"
      id="ixv-14836"
      unitRef="uref_501881879">9555390</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="cref_693960815"
      decimals="0"
      id="ixv-14837"
      unitRef="uref_501881879">1075259</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="cref_2133907001"
      decimals="0"
      id="ixv-14838"
      unitRef="uref_501881879">584056</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_2064740571"
      decimals="0"
      id="ixv-14839"
      unitRef="uref_501881879">9555390</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_2064740571"
      decimals="0"
      id="ixv-14840"
      unitRef="uref_501881879">9555390</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_693960815"
      decimals="0"
      id="ixv-14841"
      unitRef="uref_501881879">1075259</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_693960815"
      decimals="0"
      id="ixv-14842"
      unitRef="uref_501881879">1075259</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_2133907001"
      decimals="0"
      id="ixv-14843"
      unitRef="uref_501881879">584056</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_2133907001"
      decimals="0"
      id="ixv-14844"
      unitRef="uref_501881879">584056</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_2064740571"
      decimals="2"
      id="ixv-14845"
      unitRef="uref_672740131">-13.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_2064740571"
      decimals="2"
      id="ixv-14846"
      unitRef="uref_672740131">13.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_693960815"
      decimals="2"
      id="ixv-14847"
      unitRef="uref_672740131">-10.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_693960815"
      decimals="2"
      id="ixv-14848"
      unitRef="uref_672740131">10.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_2133907001"
      decimals="2"
      id="ixv-14849"
      unitRef="uref_672740131">-32.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_2133907001"
      decimals="2"
      id="ixv-14850"
      unitRef="uref_672740131">-32.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:NetIncomeLoss
      contextRef="cref_917246047"
      decimals="-3"
      id="ixv-14851"
      unitRef="uref_1858178790">-133499000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_467222934"
      decimals="-3"
      id="ixv-14852"
      unitRef="uref_1858178790">-14890000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_115941406"
      decimals="-3"
      id="ixv-14853"
      unitRef="uref_1858178790">-66700000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="cref_917246047"
      decimals="0"
      id="ixv-14854"
      unitRef="uref_501881879">9555390</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="cref_467222934"
      decimals="0"
      id="ixv-14855"
      unitRef="uref_501881879">1040513</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="cref_115941406"
      decimals="0"
      id="ixv-14856"
      unitRef="uref_501881879">532312</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_917246047"
      decimals="0"
      id="ixv-14857"
      unitRef="uref_501881879">9555390</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_917246047"
      decimals="0"
      id="ixv-14858"
      unitRef="uref_501881879">9555390</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_467222934"
      decimals="0"
      id="ixv-14859"
      unitRef="uref_501881879">1040513</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_467222934"
      decimals="0"
      id="ixv-14860"
      unitRef="uref_501881879">1040513</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_115941406"
      decimals="0"
      id="ixv-14861"
      unitRef="uref_501881879">532312</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_115941406"
      decimals="0"
      id="ixv-14862"
      unitRef="uref_501881879">532312</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_917246047"
      decimals="2"
      id="ixv-14863"
      unitRef="uref_672740131">-13.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_917246047"
      decimals="2"
      id="ixv-14864"
      unitRef="uref_672740131">13.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_467222934"
      decimals="2"
      id="ixv-14865"
      unitRef="uref_672740131">-14.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_467222934"
      decimals="2"
      id="ixv-14866"
      unitRef="uref_672740131">-14.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_115941406"
      decimals="2"
      id="ixv-14867"
      unitRef="uref_672740131">-125.3</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_115941406"
      decimals="2"
      id="ixv-14868"
      unitRef="uref_672740131">-125.3</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable
      contextRef="cref_508417479"
      decimals="0"
      id="ixv-14869"
      unitRef="uref_501881879">22500</us-gaap:WeightedAverageNumberOfSharesContingentlyIssuable>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="cref_672740131"
      decimals="3"
      id="ixv-14870"
      unitRef="uref_672740131">0.003</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="cref_508417479" id="ixv-6449">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have had an antidilutive effect were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Three Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Nine Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; width: 52%; text-align: left;"&gt;Outstanding and issued common stock options&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;85,470&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;79,416&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;85,470&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;79,416&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Outstanding and issued restricted stock units&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,790&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,389&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;1,790&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,389&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left;"&gt;Outstanding and issued non-voting redeemable convertible preferred stock options&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;347,808&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_43420443;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;347,808&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1278649306;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Shares issuable upon exercise of Public Warrants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_165816062;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;16,666&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1889385037;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;16,666&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in;"&gt;Shares issuable upon exercise of Common Warrants&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;411,523&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;411,523&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;411,523&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;411,523&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt;"&gt;Unvested performance-based restricted stock units&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1522608553;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;666&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_801368141;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;666&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold; padding-bottom: 2.5pt;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;846,591&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;515,660&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;846,591&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;515,660&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1286531519"
      decimals="0"
      id="ixv-14871"
      unitRef="uref_501881879">85470</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_550033926"
      decimals="0"
      id="ixv-14872"
      unitRef="uref_501881879">79416</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_348542625"
      decimals="0"
      id="ixv-14873"
      unitRef="uref_501881879">85470</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1737323973"
      decimals="0"
      id="ixv-14874"
      unitRef="uref_501881879">79416</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_104973327"
      decimals="0"
      id="ixv-14875"
      unitRef="uref_501881879">1790</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1322910456"
      decimals="0"
      id="ixv-14876"
      unitRef="uref_501881879">7389</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_219886843"
      decimals="0"
      id="ixv-14877"
      unitRef="uref_501881879">1790</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_2074272259"
      decimals="0"
      id="ixv-14878"
      unitRef="uref_501881879">7389</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_800311341"
      decimals="0"
      id="ixv-14879"
      unitRef="uref_501881879">347808</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_113149684"
      decimals="0"
      id="ixv-14880"
      unitRef="uref_501881879">347808</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_2055775269"
      decimals="0"
      id="ixv-14881"
      unitRef="uref_501881879">16666</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1363913454"
      decimals="0"
      id="ixv-14882"
      unitRef="uref_501881879">16666</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1219709907"
      decimals="0"
      id="ixv-14883"
      unitRef="uref_501881879">411523</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_2041185935"
      decimals="0"
      id="ixv-14884"
      unitRef="uref_501881879">411523</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1915775068"
      decimals="0"
      id="ixv-14885"
      unitRef="uref_501881879">411523</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_715971754"
      decimals="0"
      id="ixv-14886"
      unitRef="uref_501881879">411523</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_1525021411"
      decimals="0"
      id="ixv-14887"
      unitRef="uref_501881879">666</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_783867749"
      decimals="0"
      id="ixv-14888"
      unitRef="uref_501881879">666</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_425078768"
      decimals="0"
      id="ixv-14889"
      unitRef="uref_501881879">846591</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_412907873"
      decimals="0"
      id="ixv-14890"
      unitRef="uref_501881879">515660</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_508417479"
      decimals="0"
      id="ixv-14891"
      unitRef="uref_501881879">846591</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="cref_695164559"
      decimals="0"
      id="ixv-14892"
      unitRef="uref_501881879">515660</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="cref_508417479" id="ixv-6611">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 14. RELATED PARTIES&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; In the first quarter of 2024, a senior executive of the Company joined the board of directors of an information technology service provider that the Company has utilized to support a broad array of the Company&#x2019;s systems infrastructure as well as for general information technology support services. For each of the three months ended September 30, 2026 and 2025, the Company incurred $0.2&#160;million for various information technology support services performed by this service provider. For the nine months ended September 30, 2026 and 2025, the Company incurred $0.7 million and $0.6&#160;million, respectively, for various information technology support services performed by this service provider. There was $0.1 million of accounts payable recognized in the condensed consolidated balance sheets as of each of September 30, 2026 and December 31, 2025. As of September 30, 2026 and December 31, 2025, there was $0.1 million and less than $0.1 million accrued expenses, respectively, included in the accrued expenses and other current liabilities in the condensed consolidated balance sheets. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; In March 2026, Kira entered into forgivable loan arrangements totaling $0.5 million with certain members of its management. The rights related to the forgivable loan arrangement were acquired by the Company as part of the Acquisition. The arrangements are retention-based compensation arrangements structured as forgivable loans and are subject to forgiveness upon continued employment through January 15, 2027. The Company accounts for the arrangements as compensation and recognizes compensation expense on a straight-line basis over the requisite service period. During the three and nine months ended September 30, 2026, the Company recognized approximately $0.1 million of research and development expense in the condensed consolidated statements of operations related to the arrangements, including accrued employer payroll taxes. As of September 30, 2026, approximately $0.2 million remained outstanding under the arrangements and is included in prepaid expenses and other current assets on the condensed consolidated balance sheets. &lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:InterestCostsIncurred
      contextRef="cref_1408331276"
      decimals="-5"
      id="ixv-14893"
      unitRef="uref_1858178790">200000</us-gaap:InterestCostsIncurred>
    <us-gaap:InterestCostsIncurred
      contextRef="cref_720969816"
      decimals="-5"
      id="ixv-14894"
      unitRef="uref_1858178790">200000</us-gaap:InterestCostsIncurred>
    <us-gaap:InterestCostsIncurred
      contextRef="cref_831143890"
      decimals="-5"
      id="ixv-14895"
      unitRef="uref_1858178790">700000</us-gaap:InterestCostsIncurred>
    <us-gaap:InterestCostsIncurred
      contextRef="cref_1949907198"
      decimals="-5"
      id="ixv-14896"
      unitRef="uref_1858178790">600000</us-gaap:InterestCostsIncurred>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="cref_1158453148"
      decimals="-5"
      id="ixv-14897"
      unitRef="uref_1858178790">100000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent
      contextRef="cref_1022455718"
      decimals="-5"
      id="ixv-14898"
      unitRef="uref_1858178790">100000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="cref_1158453148"
      decimals="-5"
      id="ixv-14899"
      unitRef="uref_1858178790">100000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="cref_1022455718"
      decimals="-5"
      id="ixv-14900"
      unitRef="uref_1858178790">100000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <jspr:ForgivableLoanArrangements
      contextRef="cref_1983631772"
      decimals="-5"
      id="ixv-14901"
      unitRef="uref_1858178790">500000</jspr:ForgivableLoanArrangements>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_1408331276"
      decimals="-5"
      id="ixv-14902"
      unitRef="uref_1858178790">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_831143890"
      decimals="-5"
      id="ixv-14903"
      unitRef="uref_1858178790">100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="cref_1158453148"
      decimals="-5"
      id="ixv-14904"
      unitRef="uref_1858178790">200000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="cref_508417479" id="ixv-6626">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 15. SEGMENT INFORMATION&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; The Company has determined it operates as a &lt;span style="-sec-ix-hidden:fc_2058416657;"&gt;&lt;span style="-sec-ix-hidden:fc_947699899;"&gt;single&lt;/span&gt;&lt;/span&gt; operating and reportable segment, which is the research and development of therapeutic products in the field of immunologically-driven disorders. The Company&#x2019;s chief operating decision maker, its &lt;span style="-sec-ix-hidden:fc_1986956982;"&gt;Chief Executive Officer&lt;/span&gt; (the &#x201c;CEO&#x201d;), manages the Company&#x2019;s operations on a consolidated basis. The CEO assesses the segment&#x2019;s performance and allocates resources based on review of various development, manufacturing and clinical programs expenses, along with the segment&#x2019;s personnel and general and overhead costs. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The table below presents the financial information used by the CEO to assess performance, which reconciles to the net loss (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Three Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Nine Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%;"&gt;Revenue&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;8,000&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1899066660;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;8,000&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1275356602;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Acquired in-process research and development&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;129,494&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_796581455;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;129,494&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_277937578;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Cost of drug supplies and compounds&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,993&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_27895422;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,993&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_694187185;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Personnel-related costs&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,807&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,902&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;12,019&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;22,508&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;General and overhead costs&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;4,561&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,919&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;11,301&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,662&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Program costs&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 9pt;"&gt;CMO&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,370&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,618&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,195&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;11,269&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-left: 9pt;"&gt;Jasper legacy programs&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;728&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,727&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,110&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;23,605&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Kira programs&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;220&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_789684937;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;220&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_412084137;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in;"&gt;Total program costs&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;4,318&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,345&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;11,525&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;34,874&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in;"&gt;Total operating expense&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;152,173&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;19,166&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;172,332&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;68,044&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;Other income (expense), net&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(282&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;430&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;15,943&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,344&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Net loss&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(144,455&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(18,736&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(148,389&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(66,700&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; As of September 30, 2026, the Company&#x2019;s long-lived assets located in the United States and the PRC were $0.1 million and less than $0.1 million, respectively. &lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription contextRef="cref_508417479" id="ixv-6634"> The Company&#x2019;s chief operating decision maker, its Chief Executive Officer (the &#x201c;CEO&#x201d;), manages the Company&#x2019;s operations on a consolidated basis. The CEO assesses the segment&#x2019;s performance and allocates resources based on review of various development, manufacturing and clinical programs expenses, along with the segment&#x2019;s personnel and general and overhead costs.</us-gaap:SegmentReportingCodmProfitLossMeasureHowUsedDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="cref_508417479" id="ixv-6637">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;The table below presents the financial information used by the CEO to assess performance, which reconciles to the net loss (in thousands):&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Three Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Nine Months Ended &lt;br/&gt; September 30,&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%;"&gt;Revenue&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;8,000&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1899066660;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;8,000&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1275356602;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Acquired in-process research and development&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;129,494&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_796581455;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;129,494&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_277937578;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Cost of drug supplies and compounds&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,993&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_27895422;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;7,993&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_694187185;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Personnel-related costs&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,807&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,902&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;12,019&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;22,508&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;General and overhead costs&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;4,561&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,919&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;11,301&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;10,662&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td style="text-align: left;"&gt;Program costs&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="padding-left: 9pt;"&gt;CMO&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;3,370&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;2,618&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;5,195&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;11,269&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-left: 9pt;"&gt;Jasper legacy programs&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;728&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,727&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;6,110&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;23,605&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 9pt;"&gt;Kira programs&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;220&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_789684937;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;220&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_412084137;"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in;"&gt;Total program costs&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;4,318&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;9,345&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;11,525&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;34,874&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.25in;"&gt;Total operating expense&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;152,173&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;19,166&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;172,332&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;68,044&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;Other income (expense), net&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(282&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;430&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;15,943&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;1,344&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left; padding-bottom: 2.5pt;"&gt;Net loss&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(144,455&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(18,736&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(148,389&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;$&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;(66,700&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14905"
      unitRef="uref_1858178790">8000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14906"
      unitRef="uref_1858178790">8000000</us-gaap:Revenues>
    <jspr:AcquiredIn-ProcessResearchAndDevelopment
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14907"
      unitRef="uref_1858178790">129494000</jspr:AcquiredIn-ProcessResearchAndDevelopment>
    <jspr:AcquiredIn-ProcessResearchAndDevelopment
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14908"
      unitRef="uref_1858178790">129494000</jspr:AcquiredIn-ProcessResearchAndDevelopment>
    <jspr:CostOfDrugSuppliesAndCompounds
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14909"
      unitRef="uref_1858178790">7993000</jspr:CostOfDrugSuppliesAndCompounds>
    <jspr:CostOfDrugSuppliesAndCompounds
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14910"
      unitRef="uref_1858178790">7993000</jspr:CostOfDrugSuppliesAndCompounds>
    <jspr:PersonnelCosts
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14911"
      unitRef="uref_1858178790">5807000</jspr:PersonnelCosts>
    <jspr:PersonnelCosts
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14912"
      unitRef="uref_1858178790">6902000</jspr:PersonnelCosts>
    <jspr:PersonnelCosts
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14913"
      unitRef="uref_1858178790">12019000</jspr:PersonnelCosts>
    <jspr:PersonnelCosts
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14914"
      unitRef="uref_1858178790">22508000</jspr:PersonnelCosts>
    <jspr:FacilitiesAndOverheadCosts
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14915"
      unitRef="uref_1858178790">4561000</jspr:FacilitiesAndOverheadCosts>
    <jspr:FacilitiesAndOverheadCosts
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14916"
      unitRef="uref_1858178790">2919000</jspr:FacilitiesAndOverheadCosts>
    <jspr:FacilitiesAndOverheadCosts
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14917"
      unitRef="uref_1858178790">11301000</jspr:FacilitiesAndOverheadCosts>
    <jspr:FacilitiesAndOverheadCosts
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14918"
      unitRef="uref_1858178790">10662000</jspr:FacilitiesAndOverheadCosts>
    <us-gaap:CostOfRevenue
      contextRef="cref_1036589198"
      decimals="-3"
      id="ixv-14919"
      unitRef="uref_1858178790">3370000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_250823479"
      decimals="-3"
      id="ixv-14920"
      unitRef="uref_1858178790">2618000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_670150753"
      decimals="-3"
      id="ixv-14921"
      unitRef="uref_1858178790">5195000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_95503200"
      decimals="-3"
      id="ixv-14922"
      unitRef="uref_1858178790">11269000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_1014094683"
      decimals="-3"
      id="ixv-14923"
      unitRef="uref_1858178790">728000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_1363313740"
      decimals="-3"
      id="ixv-14924"
      unitRef="uref_1858178790">6727000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_179629139"
      decimals="-3"
      id="ixv-14925"
      unitRef="uref_1858178790">6110000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_1899411762"
      decimals="-3"
      id="ixv-14926"
      unitRef="uref_1858178790">23605000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_496941438"
      decimals="-3"
      id="ixv-14927"
      unitRef="uref_1858178790">220000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_958635761"
      decimals="-3"
      id="ixv-14928"
      unitRef="uref_1858178790">220000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14929"
      unitRef="uref_1858178790">4318000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14930"
      unitRef="uref_1858178790">9345000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14931"
      unitRef="uref_1858178790">11525000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14932"
      unitRef="uref_1858178790">34874000</us-gaap:CostOfRevenue>
    <us-gaap:OperatingExpenses
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14933"
      unitRef="uref_1858178790">152173000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14934"
      unitRef="uref_1858178790">19166000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14935"
      unitRef="uref_1858178790">172332000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14936"
      unitRef="uref_1858178790">68044000</us-gaap:OperatingExpenses>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14937"
      unitRef="uref_1858178790">-282000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14938"
      unitRef="uref_1858178790">430000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14939"
      unitRef="uref_1858178790">15943000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14940"
      unitRef="uref_1858178790">1344000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="cref_425078768"
      decimals="-3"
      id="ixv-14941"
      unitRef="uref_1858178790">-144455000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_412907873"
      decimals="-3"
      id="ixv-14942"
      unitRef="uref_1858178790">-18736000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_508417479"
      decimals="-3"
      id="ixv-14943"
      unitRef="uref_1858178790">-148389000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_695164559"
      decimals="-3"
      id="ixv-14944"
      unitRef="uref_1858178790">-66700000</us-gaap:NetIncomeLoss>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="cref_784097639"
      decimals="-5"
      id="ixv-14945"
      unitRef="uref_1858178790">100000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="cref_670918599"
      decimals="-5"
      id="ixv-14946"
      unitRef="uref_1858178790">100000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="cref_508417479" id="ixv-6947">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 16. RESTRUCTURING&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; Starting in July 2025, the Company implemented a corporate reorganization and other cost reduction measures to extend its cash runway. These actions included a workforce reduction, refinement of the Company&#x2019;s operating plan to focus on briquilimab clinical development programs in chronic urticaria, halting enrollment in its Phase 1b asthma study, discontinuation of other clinical and preclinical programs and cessation of vivarium operations. In 2025, the Company incurred restructuring charges related to workforce reduction of approximately $2.3 million, primarily related to severance payments, and recognized impairment charges of $1.1 million related to the abandonment of certain fixed assets and a right-of-use asset associated with vivarium operations. As of September 30, 2026 and December 31, 2025, the Company had $0.5 million and $0.4 million, respectively, of accrued severance costs related to the termination of certain employees, including the termination of an employee in connection with the restructuring, which are included in accrued expenses and other current liabilities in the condensed consolidated balance sheets. As of September 30, 2026, the related severance payments are expected to be made over a weighted-average period of approximately 10 months. &lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in;"&gt; For the nine months ended September 30, 2026 and as of September 30, 2026, the Company recognized and accrued $1.2 million and $0.7 million related to severance payments, respectively, to its former chief executive officer, whose employment was terminated in January 2026. The severance payments are expected to be made through July 2027. &lt;/p&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCosts
      contextRef="cref_251733876"
      decimals="-5"
      id="ixv-14947"
      unitRef="uref_1858178790">2300000</us-gaap:RestructuringCosts>
    <us-gaap:OtherAssetImpairmentCharges
      contextRef="cref_251733876"
      decimals="-5"
      id="ixv-14948"
      unitRef="uref_1858178790">1100000</us-gaap:OtherAssetImpairmentCharges>
    <jspr:AccruedSeveranceCosts
      contextRef="cref_508417479"
      decimals="-5"
      id="fc_166899068"
      unitRef="uref_1858178790">500000</jspr:AccruedSeveranceCosts>
    <jspr:AccruedSeveranceCosts
      contextRef="cref_251733876"
      decimals="-5"
      id="fc_251733876"
      unitRef="uref_1858178790">400000</jspr:AccruedSeveranceCosts>
    <jspr:SeveranceCostsPeriod contextRef="cref_508417479" id="ixv-14951">P10M</jspr:SeveranceCostsPeriod>
    <us-gaap:SeveranceCosts1
      contextRef="cref_508417479"
      decimals="-5"
      id="fc_508417479"
      unitRef="uref_1858178790">1200000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="cref_1858178790"
      decimals="-5"
      id="fc_1858178790"
      unitRef="uref_1858178790">700000</us-gaap:SeveranceCosts1>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="cref_425078768" id="ixv-14954">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="cref_425078768" id="ixv-14955">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="cref_425078768" id="ixv-14956">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="cref_425078768" id="ixv-14957">false</ecd:NonRule10b51ArrTrmntdFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#fc_1276532786"
          xlink:label="fc_1276532786"
          xlink:type="locator"/>
        <link:footnote id="fref_735093590" xlink:label="fref_735093590" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The fair value of common stock was determined based on the last reported                                             sale price of the Company&#x2019;s common stock of $23.22 on the Nasdaq Capital Market on                                             July 16, 2026, the date of the Acquisition, times 173,149 shares issued to Kira&#x2019;s                                             investors.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1276532786"
          xlink:to="fref_735093590"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_660020899"
          xlink:label="fc_660020899"
          xlink:type="locator"/>
        <link:footnote id="fref_1204728551" xlink:label="fref_1204728551" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The fair value of the non-voting redeemable convertible preferred stock was determined based on the price per share of $28.3528 times 4,899,439 shares issued to Kira investors. The price per share is the same as the price paid by non-related party investors that participated in the Financing and it is an equivalent of $13.9440 per share of common stock based on a conversion ratio of 2.03 shares of common stock for each share of non-voting redeemable convertible preferred stock.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_660020899"
          xlink:to="fref_1204728551"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_18519547"
          xlink:label="fc_18519547"
          xlink:type="locator"/>
        <link:footnote id="fref_1396682618" xlink:label="fref_1396682618" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Assumed options amount reflects the portion of the acquisition date fair-value                                             based measure of assumed options, that relates to the pre-Acquisition service period.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_18519547"
          xlink:to="fref_1396682618"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_2078260519"
          xlink:label="fc_2078260519"
          xlink:type="locator"/>
        <link:footnote id="fref_1402290111" xlink:label="fref_1402290111" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Legal and advisory transaction costs of $1.4 million incurred by the Company                                             in connection with the Acquisition.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_2078260519"
          xlink:to="fref_1402290111"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#fc_1412025843"
          xlink:label="fc_1412025843"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_161023939"
          xlink:label="fc_161023939"
          xlink:type="locator"/>
        <link:footnote id="fref_1618325691" xlink:label="fref_1618325691" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">The Company has 4,999,863 outstanding warrants to purchase an aggregate of&#160;16,666&#160;shares of its common stock (the &#x201c;Public Warrants&#x201d;). A holder may purchase&#160;one&#160;share of the Company&#x2019;s common stock for every&#160;ten&#160;Public Warrants at an exercise price of $3,450.00&#160;per share. The Public Warrants are publicly traded and exercisable during the exercise period, which commenced on October 24, 2021 and ended on September 24, 2026, for cash or, in certain circumstances, on a cashless basis. The Public Warrants were reclassified to equity in January 2023. The Public Warrants were fully unexercised and expired in September 2026.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_1412025843"
          xlink:to="fref_1618325691"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_161023939"
          xlink:to="fref_1618325691"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
